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Human African trypanosomiasis (HAT), commonly called African sleeping 
sickness, is caused by bloodstream form Trypanosoma brucei and has the potential to 
affect millions of people in sub-Saharan Africa. Treatments have existed for the past fifty 
years, but are characterized by severe adverse side-effects and poor efficacy. 
Trypanosomes generate ATP through glycolysis, or the metabolism of glucose, which is 
catalyzed by enzymes called hexokinases (TbHK1 and TbHK2) in trypanosomes. 
Through high-throughput screenings (HTS) and structure-activity relationships (SAR), 
both hexokinases could be targeted with small molecules to inhibit the first step in the 
glycolytic pathway of trypanosomes. Of the two hexokinases, TbHK1 has shown promise 
as a target for the development of trypanocides.  
The first half of this thesis will report the syntheses of several derivatives of 
potent TbHK1 inhibitors, ebselen and benzamidobenzoic acid (BABA). Ebselen, or 2-
phenyl-1,2-benzisoselenazol-3(2H)-one, is a drug that is currently in trials for patients 
suffering from hearing loss or bipolar disorder that has also demonstrated potency against 
trypanosomes with an IC50 of 0.05 ± 0.03 µM. BABA is a novel therapeutic derivative that 
was revealed to be a hit through SAR efforts. The final aim is the coupling of the 
inhibitors to a peptidic scaffold via solid phase peptide synthesis (SPPS). The results of 
the bioassays conducted on these conjugates will be described and presented with future 
directions to expand the role of these inhibitors toward other tropical diseases.
The Diels-Alder reaction is a carbon-carbon bond forming reaction in which a 
dienophile (e.g., alkene or alkyne) and a diene undergo a [4+2] cycloaddition to produce 
iii 
cyclohexene adducts with predictable regiochemistry. The aim of this work is to employ 
chiral boronate esters that have absolute stereocenters to propagate chiral information in 
intramolecular Diels-Alder (IMDA) reactions to establish new absolute stereocenters, 
while retaining the absolute stereocenters originally present on the original chiral 
boronate esters. The second half of this thesis will present the synthesis of a novel 
boronate ester possessing both diene and dienophile components to participate in an 
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EVALUATION OF SUBSTITUTED EBSELEN DERIVATIVES AS ANTI-
TRYPANOSOMAL DRUGS 
 
1.1  INTRODUCTION 
 
Human African Trypanosomiasis (HAT), or African Sleeping Sickness, is caused 
by the bloodstream form (BSF) of Trypanosoma brucei (i.e. trypanosomes) and is 
transmitted by a tsetse fly vector.1 Two subspecies of T. brucei exist that infect humans:  
T. b. gambiense, responsible for West African sleeping sickness, and T. b. rhodesiense, 
responsible for East African sleeping sickness.1,2,3 The disease has the potential to affect 
millions in sub-Saharan Africa, and has periodically resulted in between 50,000 to 70,000 
annual deaths  despite declining numbers of infections and fatalities more recently.4 The 
range of HAT is limited to sub-Saharan Africa as this is a suitable habitat for the tsetse 
fly.5 The disease is endemic to remote, rural regions and can be acquired through 
common daily activities that allow interaction with the fly, including farming, hunting, 
fishing, or even washing clothes.5 Between 1920 and 1940, several African nations 
invested in vector control (i.e. controlling the population of tsetse flies through the 
combination of insecticide spraying and the introduction of sterile fly specimens) and 
active surveillance of infected individuals.5 By these means, the disease was almost 
eliminated in 1960. Nonetheless, political revolution and unrest in several key nations in 
the region, such as the Democratic Republic of the Congo, Angola, southern Sudan, and 
Uganda, led to a decrease in these surveillance activities and a re-emergence of the 
disease.5  
 2 
Treatments for HAT have existed for approximately one hundred years, but are 
marked by serious adverse side-effects, such as acute toxicity, neural disorders, and in 
some cases, death.4 In other cases, the treatments are difficult to administer or are not 
well characterized in terms of their mechanism of action.6 In other cases, the therapeutics 
currently available are ineffective against the late stages of the disease once the 
trypanosomes cross the blood-brain barrier. Eflornithine, active against the late-stage T. 
b. rhodesiense disease, is air-sensitive and the dosage regime can require up to 30 days.5 
Adverse side-reactions are frequent and this drug is not used against T. b. gambiense 
where Onchocerca species, microorganisms that cause river blindness, may exist.5 The 
most widely-used therapeutic for the treatment of the later stages of disease is called 
melarsoprol and is active against T. b. gambiense, and is the only available drug for the 
later stages associated with T. b. rhodesiense.5  Due to its being an arsenical drug, 
adverse nervous system reactions are frequent and can be life-threatening.5 The only new 
molecule for treatment of the disease to arise in the clinic over the past sixty years is 
eflornithine, which is indicated for the second (meningoencephalitic) stage of the disease 
resulting from T. b. gambiense infection.  Eflornithine is preferred due to its reduced host 
toxicity as compared to melarsoprol.5 Nevertheless, this drug is not without its 
drawbacks.  The typical treatment course for a T. b. gambiense infection with eflornithine 
comprises four 2h infusions of a 400 mg/kg dose administered daily for two weeks due to 
the drug’s short half-life.  Therefore, a single patient treated with eflornithine will require 
hundreds of grams of the drug for effective treatment.5 Further, the drug is ineffective 
against T. b. rhodesiense infections, and oral administration limits its potency.1,3,5,7,8 
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As shown in Figure 1.1, the T. brucei infection cycle begins with an infected 
tsetse fly injecting metacyclic trypomastigotes into a mammalian host. The injected 
metacyclic trypomastigotes transform into BSF trypomastigotes, which multiply in the 
blood, spinal fluid, and lymph nodes of the host. The lifecycle is completed when a 
feeding tsetse fly takes a blood sample from the host. The blood sample harbors short, 
stumpy trypomastigotes, a form pre-adapted for life in the insect vector, that migrate to 
the tsetse fly’s midgut and transform into procyclic trypomastigotes. The multiplying 
procyclic trypomastigotes migrate to the salivary glands and transform into epimastigotes 
and the cycle begins anew.8,9 Newly-hatched flies are not infected with trypanosomes but 
rather must feed on an infected mammalian host to become infected.5 The parasite life 
cycle in the fly is rarely observed in the field with only 0.1% of the tsetse fly population 
carrying a fully matured infection that can be transmitted from the vector to the host.5 
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Infection with trypanosomes in a human host occurs in two stages. The first stage 
is infection of the host’s blood and lymphatic system, or the haemolymphatic stage. The 
second stage is infection and inflammation of the host’s nervous system, or the 
meningoencephalitic stage. The infection with T. b. gambiense is characterized by a 
chronic disease state that progresses rather slowly over the course of a few years, while T. 
b. rhodesiense infections induce an acute disease state that exhibits a much more rapid 
progression resulting in death within a few weeks or months in untreated cases.5 
A chancre caused by a tsetse fly bite occurs in ~19% of patients infected with T. 
b. rhodesiense but is rarely seen with T. b. gambiense. The leading signs of trypanosome 
infection include: fever, headache, pruritus (or severe itching), lymphadenopathy (or 
swelling of the lymph nodes), and hepatosplenomegaly (or swelling of the liver and/or 




spleen). Fever in infected hosts can last from a day to a week, separated by fever-free 
intervals lasting a few days and up to longer than a month. A fever is rarely observed in 
the later stages of the disease. The leading symptom of the later stages is the one that 
gives the disease its name, sleep disorder, via interruption of the circadian rhythm (or 
sleep cycle) of an infected host. Other symptoms include Parkinson-like movements due 
to muscular hypertension or even psychiatric symptoms, such as irritability, aggressive 
behavior, or psychotic reactions, occasionally leading to the incorrect admission of some 
patients into psychiatric wards.5 
The clinical diagnosis of T. b. gambiense infection relies on laboratory 
examinations, because of insufficient clinical presentations of disease associated with this 
strain of the microorganism (recall that a chancre is only produced for a small number of 
cases of T. b. rhodesiense infection). The diagnosis cycle occurs in three parts: screening, 
diagnostic confirmation, and staging. Since the late 1970s, a card agglutination test 
(CATT) has been used for the diagnosis of T. b. gambiense infections, allowing for the 
screening of hundreds of patients daily with a high degree of sensitivity and specificity. 
Other methods, including immunofluorescence or immunosorbent enzyme-linked assays, 
are used in non-endemic countries for screening of clinical features that suggest infection 
by trypanosomes. These tests are not fully accurate, therefore health professionals are 
told to search for clinical presentations in individuals with negative tests, such as the 
formation of a chancre. There is no serological screening available for the detection of T. 
b. rhodesiense infection. Inspection of a blood smear under a microscope can be used for 
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the diagnosis of T. b. gambiense infection due to the higher density of the BSF parasite in 
the host’s bloodstream.5 
With respect to emerging therapeutic strategies, the modern approach for treating 
HAT employs molecular target-based therapeutics that can be selectively directed toward 
trypanosomes.6 BSF trypanosomes generate energy, in the form of adenosine 
triphosphate (ATP), through glycolysis.3 The first step of glycolysis involves the 
phosphorylation of glucose via the transfer of a phosphoryl group from ATP to the 6’ 
hydroxyl group on glucose.3 The enzymes that catalyze this process are called 
hexokinases. In trypanosomes, the hexokinases (HKs), which are organized into 
hexamers that are called TbHK1 and TbHK2. It is important to note here that BSF, 
metacyclic, and procyclic trypomastigotes (described above) perform glycolysis in the 
glycosome, a membrane-enclosed organelle that houses the HKs along with the rest of 
their glycolysis machinery.7-9 Inhibition of trypanosomal HKs in BSF parasites is lethal 
to the microorganism.2  
RNAi-induced (RNA interference) silencing of TbHK1 was previously used 
against BSF trypanosomes to demonstrate growth inhibition of the parasite.10 The RNAi-
induced silencing of TbHK2 is also lethal to BSF parasites, confirming that both TbHK1 
and TbHK2 are essential to the parasite. TbHK1-specific RNAi was accomplished via 
targeting of a unique region in the TbHK1 3’ UTR (untranslated region). After two days 
of treatment, TbHK1 in BSF parasites was silenced and the cells began to die.2 The 
genetic validation afforded by this study demonstrated that TbHK1 can serve as a suitable 
target for therapeutic inhibition in BSF parasites.2 
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In addition, the gene sequence for TbHK1 reveals just a 30-33% amino acid 
similarity to yeast, plants, and mammalian hexokinases.2,6 Known inhibitors of 
mammalian hexokinases have demonstrated some weak inhibition of TbHK1 and exhibit 
trypanocidal effects at high concentrations.2 TbHK is also susceptible to a wide range of 
other inhibitors in vitro including fatty acids and small molecules, such as pyrophosphate. 
However, many of these compounds must be used in high concentrations to effect cell 
toxicity; a potent therapeutic should be effective in the sub-micromolar range.2,8-10 One 
such therapeutic is lonidamine (Figure 1.2), exhibiting an IC50 (half-maximal inhibitory 
concentration) of 850 µM against recombinant TbHK1 (rTbHK1; obtained from 
Escherichia coli or yeast) and 965 µM against authentic TbHK1 (obtained directly from 
T. brucei).2  TCEP (i.e. tris-(2-carboxyethyl)phosphine) (Figure 1.2) also exhibits potent 
TbHK1 inhibition as an irreversible disulfide-reactive reagent (IC50 = 6.6 ± 0.4 µM).3 
Further, a high throughput screen of 220,233 compounds resulted in ten inhibitory “hits,” 
including six structurally similar isobenzothiazolinones (Figure 1.2).3,11  
The high-throughput screening (HTS) conducted by Sharlow et al. of over 
220,233 compounds was carried out to discover potent small-molecule inhibitors of 
TbHK1.3,7,12 Three scaffolds were pursued for Strcuture-Activity Relationship (SAR) 
Analysis from the HTS endeavor: isobenzothiazolinone, isobenzoselenazolinone, and 
benzamidobenzoic acid (i.e. BABA; discussed in Chapter Two).3 Six 
isobenzoselenazolinone derivatives were initially identified in the high-throughput 
screening for TbHK1 inhibition (Figure 1.2). One of six isobenzothiazolinone candidates 
was ebselen (i.e. 2-phenyl-1,2-benzisoselenazol-3(2H)-one, or EbSe [I-1], Figure 1.2), a 
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drug that is non-toxic to humans and is currently used in clinical trials for the treatment of 
ischemic stroke.3,7 Ebselen demonstrated high potency against rTbHK1 with an IC50 of 
0.05 ± 0.03 µM.3,7 Another effective target, EbS (i.e. 2-phenyl-1,2-benzisothiazol-3(2H)-
one, [I-2]), which replaces the selenium in Ebselen with sulfur, demonstrated an IC50 of 
2.0 ± 0.5 µM against rTbHK1.3,7 One candidate, compound I-3, with a halogen 
substitution on the heterocycle aryl ring and a methyl group on the N-aryl ring, had an 
IC50 value of 4.2 ± 1.0 µM against rTbHK1.7 Another candidate, I-4, bearing a thiazole 
coupled to an ethyl ester, had a higher IC50 of 9.3 ± 0.3 µM against the enzyme, whereas 
I-5, bearing a thiazole without any substitution pattern, had an even higher IC50 of 16.9 
± 0.1 µM.7 Replacement of the N-aryl ring with an acetamido-adamantyl group, as in I-6, 
afforded a lead drug candidate with an IC50 of 2.6 ± 0.2 µM.7 Of the six lead drug 
candidates, only I-1 and I-2 were moderately potent against the BSF parasite, 
demonstrating growth inhibition of 51 ± 0.16% and 48 ± 0.15%, respectively.7 
Compounds I-3 and I-6 demonstrated a growth inhibition of 47 ± 0.15%, while the other 
two I-4 and I-5 were below 30%.7 A follow-up study by Joice et al. revealed that 
incubation of TbHK1 with EbSe and EbS inhibitors led to a five-fold decrease in 
enzymatic activity.3 This loss of HK activity remained irreversible despite a 200–fold 




One hypothesis for the efficacy of EbSe toward the inhibition of TbHK1 is the 
formation of selenyl-sulfide (Se-S) adducts with Cys residues, leading to the eventual 
oxidation of certain Cys residues in the enzyme to their corresponding sulfonic acid 
analogs. Indeed, a similar inhibition of human indoleamine 2,3-dioxygenase (IDO) with 
Figure 1.2: Three Cys-reactive compounds studied by Joice et al. are shown above: TbHK1 
inhibitors EbSe (I-1) and EbS (I-2) and reducing agent dithiothreitol (DTT). Other active 
benzisothiazolinone derivatives, I-3 to I-6, arising from the HTS are also shown. Known inhibitors 























































EbSe was accomplished by the covalent modification of several Cys residues that altered 
the enzyme’s conformation.13 A MS-MS study by Joice et al. confirmed that two Cys 
residues, C327 and C369, are critical for enzymatic structure and activity.3 This study 
demonstrated that Ebselen modifies two Cys residues by oxidizing the thiol side-chain of 
C327 and C369. Mutagenesis of the modified Cys residues revealed that only C327 was 
indispensable, indicating it is the oxidation of C327 that is detrimental toward TbHK1 
activity. A proposed mechanism for the oxidation of the Cys side-chain is depicted in 
Figure 1.3. In this pathway, a nucleophilic attack of the Cys thiol opens the heterocycle 
of EbSe, followed by a proton transfer and hydrolysis, culminating in oxidation of the 
Cys thiol. An important note regarding the proposed pathway shown in Figure 1.3 is that 
the conjugation of EbSe to Cys residues would be reversible until hydrolysis, thus 
supporting the observation that promiscuous Cys oxidation does not occur.3 











































































Further, Joice et al. demonstrated that TbHK1 could be mutated via replacement 
of key cysteine residues with either alanine or serine. Enzymatic activity was measured 
post-mutation and was compared to wild-type TbHK1 (0.60 ± 0.03 mmol min-1 µg-1). 
The results of this study are shown in Table 1.1. Cysteine residues were mutated at the 
following positions: 212; 242; 327; 386; 369; 401; 402; and 445.3 No TbHK1 activity 
was detected for the C212A, C327A, and C386A mutants. Enzymatic activity was 
slightly reduced in the C369A, C401A, and C402A mutants, and the C242A and C445A 
mutants exhibited similar activity to the wild-type enzyme. All of the active variants (i.e. 
the C242A, C369A, C401A, C402A, and C445A mutants) were effectively inhibited by 
EbSe and TCEP with no difference in sensitivity to the therapeutics as compared to wild-
type TbHK1.3 
In further experiments, the cysteine residues at positions 212, 327, and 386 were 
mutated to serine. It should be noted that C to A mutations in these positions returned 
inactive enzymes. Following the mutation, it was observed that the C212S mutant had a 
reduced enzymatic activity while the C327S and C386S mutants exhibited activity barely 
above the threshold for detection (numerical value not listed in Table 1.1). Furthermore, 
the C212S mutant remained sensitive to inhibition after EbSe treatment. This work 
provides further support for the importance of the C327 residue for enzymatic activity; 
whereas the C369 site can be modified without a significant decrease in enzymatic 




Based on the HTS endeavor by Sharlow et al., as well as the MS-MS study 
conducted by Joice et al. (described above), it was determined that cysteine residues at 
positions 327 and 369 were crucial toward the function of TbHK1.3,11,14 As such, a 
mechanism of TbHK1 inhibition by EbSe can be proposed, as is shown above in Figure 
1.3.3 It is important to take into account that a single crystalline structure of TbHK1 has 
yet to be determined as the enzyme typically exists as a hexamer held together by 
disulfide linkages.3 Nonetheless, important conclusions can be made regarding the mode 
of inhibition by EbSe with respect to TbHK1.  
If EbSe is a suicide inhibitor of TbHK1, a covalent interaction between the potent 
selenium-bearing oxidizing agent EbSe and cysteine (Cys) residues would result in the 
overall oxidation of the latter.3,11,14 Were the interaction between EbSe and Cys non-
covalent, then a dilution of the sample might result in a modest return of HK activity.3 
The lack of observable HK activity upon dilution suggests an irreversible, covalent 
Table 1.1: WT = wild-type; ND = not detected. The key residues listed are C327(A/S) and C369(A/S). 





interaction between EbSe and Cys. Following incubation of the HK with EbSe or EbS, the 
reducing agent dithiothreitol (DTT; Figure 1.2) was added to the whole cell assay.3 If the 
interaction between EbSe and Cys is reversible, then DTT would sever the interaction 
between EbSe and Cys via reduction.3 Experimentally, addition of DTT allowed for only 
a modest recovery of HK activity.3 These studies provided further evidence toward the 
hypothesis that the interaction between EbSe and Cys is covalent and essentially 
irreversible (proposed mechanism shown in Figure 1.3). As was stated previously, this 
loss in hexokinase activity is irreversible following a 200-fold dilution, suggesting that a 
covalent modification of TbHK1 occurs.3 
The HTS endeavor by Sharlow et al. lead to the discovery of potent structure-
based inhibitors of TbHK1 based on EbSe.3 The data gathered in a later work by Joice et 
al. indicates that EbSe can oxidize key cysteine residues in TbHK1, specifically C327 
and C369, to the corresponding sulfonic acid, which in turn significantly decreases 
enzymatic activity.3 In an effort to optimize the potency of EbSe against TbHK1 leading 
to trypanocidal activity, a series of novel EbSe inhibitors will be discussed below in terms 
of both their synthesis and inhibitory capabilities. To reiterate, the derivatives must meet 
certain criteria to be considered as potent inhibitors of rTbHK1. First, the inhibitor will 
be highly selective and lethal against trypanosomes, i.e. will be highly trypanocidal. 
Second, the inhibitor will exhibit low or zero host toxicity. Although the latter point was 
not validated in this work, it is a concern for the development of potent trypanocidal 
therapeutics. Both the first and second criteria will ensure that the toxic effects of the 
inhibitors will be felt by the trypanosomes, not the host. Third, the desired concentration 
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of the inhibitor will be in the single-digit micromolar range, which serves as a reflection 
of the potency of the drug candidate while minimizing host toxicity.  
Lin, et al. demonstrated that molecular cargo tagged to a fluorescent peptide 
bearing a peroxisomal targeting sequence (PTS1) could be targeted to the glycosome (this 
will be elaborated upon in greater detail in Section 1.2).15 This is crucial for the targeted 
delivery strategy that will be described later in this thesis, as the discovery of a potent 
small molecule enzyme inhibitor that meets the aforementioned criteria is rendered 
useless if it is not permeable across the cellular membrane of the trypanosome. The 
inhibitor must permeate across the cellular membrane and localize within the glycosome 
in trypanosomes to demonstrate its full potency, established by a prescreening of the 
inhibitor prior to coupling to a peptide sequence. Central to our strategy, the inhibitor, for 
example EbSe, was synthesized such that it bears a free carboxylic acid. This carboxylic 
acid was tagged with a peptide bearing a PTS1 via the routine formation of an amide 
bond using Solid Phase Peptide Synthesis (SPPS; synthetic methods described in Section 
1.2.2). The peptide-inhibitor conjugate, based on the success of the report by Lin, et al., 
can cross the cellular membrane and localize within the glycosome to demonstrate 
efficacy against both hexokinase and the whole cell organism.15  
1.2  SOLID PHASE PEPTIDE SYNTHESIS (SPPS) 
1.2.1  APPLICATIONS 
The desired peptide-drug conjugate can be broken into three sections based on 
work reported by Lin, et al.15 The three sections are the Peroxisomal Targeting Sequence 
(PTS1), the modification site, and the tether. The PTS1 is the critical region of the 
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peptide that ensures that the molecular cargo reaches the glycosome.15,16 Work by 
Subramani et al. indicated that a tripeptide (C/A/S)-(K/R/H)-(L/I)-COOH can serve as a 
PTS1 when present at the C-terminus of a protein.16 The PTS1 in this work consists of C-
LKA-N based on previous work by Lin, et al., in which this sequence was successfully 
used to deliver a sensor for determining the pH of the glycosome via fluorescence.15 The 
fluorescent probe was successfully shown to be localized within the glycosome of 
trypanosomes in the same work.15  
Ebselen, I-1, and its sulfur analogue, I-2, were determined to be potent against the 
TbHK1 enzyme. However, these two lead candidates were only moderately active against 
the BSF parasite (see discussion above).7 To enhance the potency of these drug 
candidates, we endeavored to use a peptide sequence bearing a PTS1, a tether, and an 
Ebselen derivative. We thought that incorporation of a peptidic scaffold would maintain 
the activity of the Ebselen drug candidate against the enzyme while improving its 
potency against the BSF parasite by means of the PTS1-mediated passage of the drug 
cargo across the cell membrane and into the glycosome. It was hypothesized that 
incorporation of an electron-withdrawing carboxylic acid handle onto the Ebselen 
scaffold might 1.) render the molecule more susceptible to cysteine attack by TbHK1 (i.e. 
by enhanced electrophilicity of the selenium-nitrogen or sulfur-nitrogen heterocycle via 
inductive withdrawal of electron density by the carboxylic acid functionality), and 2.) 
allow for the installation of a peptide handle by conventional solid-phase peptide 
synthesis. Because the modification site is on the N-terminus of the peptide, any amino 
acid or drug derivative with a free carboxylic acid that is amenable to side-chain 
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modification can be used as part of the peptide-drug conjugate synthesis. Therefore, the 
first aim of this thesis work was to produce a library of Ebselen derivatives bearing a 
carboxylic acid to determine the optimal positioning of the electron-withdrawing group 
as reflected by potency against the enzyme and the BSF parasite through a pre-screening 
of the carboxylic acid and corresponding methyl ester derivatives (Scheme 1.1). It was 
thought that this electron-withdrawing functional group could replace the N-aryl ring or 
be positioned on either the N-aryl or the core arene of the scaffold to produce three sets of 
Ebselen drug derivatives. Our design incorporated a tether region that was employed to 
ensure that the molecular cargo (i.e. the therapeutic) is distal to the PTS1 as per the work 
by Morris and Christensen and Subramani et al.15,16 Based on the HTS and the work by 
Lin, et al., the peptide sequence of C-LKAGG-N was selected as the desired PTS1-linker 
for the initial evaluation of our strategy.15 Two additional peptides were produced in 
which the diglycine linker was replaced with a diethylene glycol linker (Scheme 1.1). 
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1.2.2 SYNTHETIC METHODS 
The carboxylic acid functional group was necessary on the small molecule 
inhibitor as it is amenable to incorporation of a peptide sequence via formation of an 
amide bond using the highly active uronium reagent HCTU and Hünig’s base in DMF, 
standard reagents used for Solid Phase Peptide Synthesis (SPPS).15-17 SPPS involves the 
use of Fmoc amino acids with free carboxylic acids that are activated by a uronium 
reagent. The peptide on the resin, the solid phase, is an Fmoc-protected amine. Following 
addition of 20-30% 4-methylpiperidine in DMF, the Fmoc group is cleaved to reveal a 
free amine that reacts with the activated carboxylic acid. This process is repeated as 
necessary for incorporation of all desired moieties. Once the synthesis is complete, the 
Scheme 1.1: General peptide structure shown on left bearing the PTS, a tether (either diglycine or 
diethylene glycol), and the Ebselen derivative. The Ebselen derivatives generated are shown on the 
right (top to bottom) bearing an N-acetyl, N-aryl, or heterocyclic substitution with the carboxylic acid. 
First, the Ebselen derivatives were synthesized to determine the most effective position of the 
carboxylic acid (via in vitro testing of the methyl ester and carboxylic acid). Then, the Ebselen 




















peroxisomal targeting sequence (PTS) tether
N
X




























peroxisomal targeting sequence (PTS) tether Ebselen derivative
 18 
peptide can be cleaved off the resin using an acidic medium that reveals a carboxylic acid 
on the C-terminus. This approach describes a peptide synthesized in a C- to N-fashion.15-
18 Beyond SPPS, the carboxylic acid serves another important role. As part of the 
bioassays, the carboxylic acid and its ester can be screened against TbHK1 and 
trypanosomes to elucidate the influence of anionic charged species (i.e. carboxylates), or 
more broadly, the influence of electron withdrawing substituents (i.e. esters and 
carboxylic acids) on the efficacy of the drug scaffold against both the enzyme and the 
whole cell BSF parasites.  
1.3  RESULTS AND DISCUSSION 
1.3.1  COMPLETED EbSe/EbS SYNTHESES 
EbSe, or 2-phenyl-1,2-benzisoselenazol-3(2H)-one, was synthesized on a cost-
efficient, gram scale according to a protocol by Balkrishna, et al.19 EbSe was synthesized 
to evaluate the effectiveness of freshly prepared EbSe compared to expensive, 
commercial EbSe, which can cost upwards of $200 per gram (Scheme 1.2). As was 
previously discussed, EbSe (the selenium analog) has an IC50 of 0.05 ± 0.03 µM toward 
trypanosomes and EbS (the sulfur analog) has an IC50 of 2.0 ± 0.5 µM.3 Furthermore, 
oxidation of the freshly prepared EbSe was attempted with hydrogen peroxide to assess 
the utility of the corresponding selenoxide congener of EbSe as an inhibitor toward the 
trypanosomes; however, this was unsuccessful (Scheme 1.2).20 A series of derivatives 
were prepared that maintained the integral benzisoselenazol-one (EbSe) or 
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We envisioned using a carboxylic acid handle to facilitate coupling of the 
EbSe/EbS derivatives to a peptide sequence via SPPS as was discussed in Section 1.2. 
The peptide sequence that was targeted was C-LKAGG-[EbSe or EbS]-N. The first EbS 
derivative (I-12) was synthesized according to a one-pot protocol provided by Dou, et al. 
The corresponding ester I-13 was isolated by acylation of the nitrogen atom of I-9 in 
38% yield (Scheme 1.3).21 The synthesis of the first EbSe derivative (I-19) commenced 
with the diazotization of anthranilic acid (I-14) in Scheme 1.4.22-24 The diazonium salt (I-
15) was treated with disodium diselenide to provide diselenide I-16 which was then 
treated with thionyl chloride under reflux to afford compound I-17. Selenenyl chloride I-
17 was acylated with the methyl ester of glycine to afford I-18 in a modest 20% yield.22-
24 Hydrolysis of the methyl ester in I-18 with lithium hydroxide provided EbSe derivative 
I-19 in 73% yield.21 Both the EbSe and EbS derivatives were coupled to the peptide 
sequence, C-LKAGG-[EbSe or EbS]-N, as described in future sections.  
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For the other EbSe and EbS targets, the syntheses involved the formation of 
important sulfur-nitrogen or selenium-nitrogen heterocycles, respectively, based on an 
efficient copper-catalyzed method.25 The synthetic protocol for the second EbSe and EbS 
derivatives is shown in Scheme 1.5. The symmetrical, commercially available, 2-bromo-
1,3-dimethylbenzene I-20 was oxidized to the 1,3-dicarboxylic acid I-21 in 35% yield by 
action of potassium permanganate.26 Fischer esterification of I-21 with methanol and 
sulfuric acid returned the dimethyl ester I-22 in 49% yield.26 The symmetrical dimethyl 
ester was then hydrolyzed with sodium hydroxide to afford monoacid I-23.27 Monoacid 
Scheme 1.3: First EbS derivative (I-12) preparation according to protocol provided by Dou, et al.21 First 









































Scheme 1.4: First, EbSe derivative preparation beginning with diazotization of anthranilic acid, followed 
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I-23 was converted to the corresponding amide I-24 in 50% yield by a two-step process 
involving conversion of the acid chloride followed by amidation with aniline. Amide I-24 
was then cyclized by a convenient copper (I) iodide protocol in the presence of sulfur 
powder to afford I-25 in 52% yield.25 The difficulty with this EbS derivative (I-25), and 
with other derivatives reported herein, is the low yield afforded by this cyclization 
protocol. Subsequent efforts focused on the optimization of this cyclization step based on 
literature precedents.28 The EbS methyl ester was hydrolyzed with lithium hydroxide 
monohydrate to provide carboxylic acid I-27 in 77% yield.29,30 In a similar fashion, the 
EbSe methyl ester I-26 was obtained, albeit in a poor 12% yield, and was subsequently 
hydrolyzed to afford I-28 in 82% yield.29,30 
 
Further varieties of EbSe/EbS derivatives could be obtained by incorporating the 
carboxylic acid functionality onto the N-aryl ring. The synthesis of several EbSe and EbS 
analogues are shown in Schemes 1.6. Using ortho-iodobenzoic acid I-29 as a starting 
material, a variety of N-aryl functionalized Ebselen analogues were quickly obtained in 
Scheme 1.5:  Synthesis of second EbS and EbSe derivatives (I-27 and I-28) that demonstrated low cell 
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I-25, X = S, R = Me (52%)
I-26, X = Se, R = Me (12%)
I-27, X = S, R = H (77%)
I-28, X = Se, R = H (82%)
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moderate yields. Ortho-iodobenzoic acid I-29 was converted to its corresponding acid 
chloride by action of thionyl chloride followed by amidation by methyl para-amino 
benzoate affording amide I-30 in 89% yield. Similarly, addition of methyl meta-amino 
benzoate to the acid chloride of I-29 afforded amide I-31 in 62% yield. Following 
synthesis of amide I-30, it was reacted with sulfur powder in the presence of the 
aforementioned copper (I) iodide/1,10-phenanthroline catalyst to afford I-32 in 55% 
yield. Hydrolysis of methyl ester I-32 in the presence of lithium hydroxide monohydrate 
afforded I-36 in 79% yield. Amide I-31 was reacted with sulfur mediated by the same 
copper (I) iodide/1,10-phenanthroline catalyst to provide I-33 in 65% yield. The methyl 
ester was then hydrolyzed with lithium hydroxide monohydrate to give I-37 in 71% 
yield.25,29,30 
The EbSe derivatives were synthesized in a similar fashion to the EbS derivatives 
I-38 and I-39. Amide I-30 was cyclized with the copper (I) iodide/1,10-phenanthroline 
catalyst in the presence of selenium powder to afford I-34 in 46% yield. Methyl ester I-
34 was hydrolyzed by action of lithium hydroxide monohydrate to provide I-38 in 84% 
yield. Amide I-31 was cyclized using copper (I) iodide/1,10-phenanthroline with 
selenium to afford I-35 in 43% yield. Hydrolysis of the methyl ester in heterocycle I-35 
with lithium hydroxide monohydrate provided acid I-39 in 91% yield. The carboxylic 
acids (I-36, I-37, I-38, and I-39) were subsequently used for amide coupling to a peptide 
sequence. Attempts to migrate the carbonyl distal with respect to either the selenium-
carbon or sulfur-carbon bond, and meta with respect to the amide bond of the 
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heterocycle, were not successful for the EbS derivative and succeeded only once for the 
EbSe derivative in ~10% yield, afterward proving difficult to reproduce.   
 
  
1.4  COMPLETED SYNTHESES AND DEFINITION OF VARIABLES 
Two goals were accomplished as part of the efforts described in this chapter. The 
first goal was completed with the synthesis of potent TbHK1 inhibitors based on an EbSe 
and EbS scaffold. Ebselen (I-1 in Scheme 1.2 above) has three potential locations for 
substitution. The first location is substitution of the N-aryl ring with an N-carboxylmethyl 
group (Schemes 1.3 and 1.4). This allowed for the elucidation of the importance of the N-
aryl functionality in vitro. The second location is the aromatic ring of the 
benzisoselenazolinone core and the third location is the N-aryl ring. This produced three 
sets of EbSe derivatives: one set with N-carboxymethyl substitution (I-12 and I-19 in 






























I-32, X = S, p-CO2Me (55%)
I-33, X = S, m-CO2Me (65%)
I-34, X = Se, p-CO2Me (46%)
I-35, X = Se, m-CO2Me (43%)







I-36, X = S, p-CO2H (79%)
I-37, X = S, m-CO2H (71%)
I-38, X = Se, p-CO2H (84%)
I-39, X = Se, m-CO2H (91%)
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Scheme 1.3 and Scheme 1.4, respectively); a second set with substitution on the 
benzisoselenazolinone ring (I-27 and I-28 in Scheme 1.5); and a third set with N-aryl 
substitution (I-36 to I-39 in Scheme 1.6). These EbSe derivatives were coupled to a 
peptide sequence using SPPS, previously described in Section 1.2. 
The synthesized inhibitors were coupled to a peptide sequence of C-LKAGG-N or 
C-LKA(ethylene glycol)-N using SPPS. This effort produced ten peptide-drug conjugates 
which were evaluated against both TbHK1 and trypanosomes in whole-cell assays (see 
below, Section 1.4.1).  This screening yielded three results: percent TbHK1 inhibition, 
percent BSF growth inhibition, and BSF EC50. The non-conjugated drugs and peptide-
drug conjugates were screened against TbHK1 and BSF parasites at a standard 
concentration of 10 µM (the limit of detection). The rTbHK1 cultures are incubated with 
the drug or peptide-drug conjugates with the percent inhibition of the enzyme being 
recorded. BSF growth inhibition refers to the cell percentage in a trypanosome culture 
that has been affected by either the drug or the peptide-drug conjugate.  BSF EC50 refers 
to a measure of drug or peptide-drug conjugate potency against trypanosomes over a 
specified exposure time period. 
1.4.1  EBSELEN PEPTIDE-DRUG CONJUGATES 
 The synthesis of the peptide-conjugated EbSe derivatives followed the general 
method illustrated in Scheme 1.7.15-18,30 Figures 1.4 and 1.5 shows the synthesized EbSe 
and EbS peptide-drug derivatives that were screened against TbHK1 and whole cell 
trypanosomes (I-40 to I-49). The data concerning the non-conjugated EbSe/EbS 
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derivatives and the peptide-conjugated EbSe/EbS derivatives is described in detail below. 
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Scheme 1.7: General protocol for Fmoc Solid Phase Peptide Synthesis of C-LKAGG-N sequence 
(shown on top). The coupling of two glycine moieties can be replaced with the single coupling of a 
diethylene glycol unit. The Fmoc protecting group is cleaved from the second glycine for overnight 






i) DMF (3 x 5 mL), 
30% 4-methylpiperidine in DMF 
(3 x 1 mL; 1 min. each), 
DMF (3 x 5 mL)
ii) Fmoc-Lys(Boc)-OH (5 eq.; 2 x 6 min.), 
HCTU (5 eq.), 
DIPEA (5 eq.), DMF
i) DMF (3 x 5 mL), 
30% 4-methylpiperidine in DMF 
(3 x 1 mL; 1 min. each), 
DMF (3 x 5 mL)
ii) Fmoc-Ala-OH (5 eq.; 2 x 6 min.), 
HCTU (5 eq.), 
DIPEA (5 eq.), DMF
i) DMF (3 x 5 mL), 
30% 4-methylpiperidine in DMF 
(3 x 1 mL; 1 min. each), 
DMF (3 x 5 mL)
ii) Fmoc-Gly-Pfp (5 eq.; 2 x 1 hr.), 
HOBt (5 eq.), 
DIPEA (5 eq.), DMF
i) DMF (3 x 5 mL), 
30% 4-methylpiperidine in DMF 
(3 x 1 mL; 1 min. each), 
DMF (3 x 5 mL)
ii) Fmoc-Gly-OPfp (5 eq.; 2 x 1 hr.), 
HCTU (5 eq.), 





























i) DMF (3 x 5 mL), 
30% 4-methylpiperidine in DMF 
(3 x 1 mL; 1 min. each), 
DMF (3 x 5 mL)
ii) Drug (5 eq.; 1 x overnight), 
HCTU (5 eq.), 
DIPEA (5 eq.), DMF





Figure 1.4: Synthesized EbSe and EbS peptide-drug conjugates. Of the conjugates screened, I-44 and 





























































































































































As was previously stated, the data gathered from the non-conjugated drug 
derivatives and the peptide-drug conjugates was broken into three categories: percent 
TbHK1 inhibition, percent BSF growth inhibition, percent cell viability, and BSF EC50 
(Table 1.2).30 Percent TbHK1 inhibition (determined at 10 µM) refers to the amount of 
TbHK1 from the rTbHK1 culture that was inhibited. Referring to Table 1.2, only a few 
of the non-conjugated EbSe derivatives inhibited TbHK1 in preliminary trials. Both EbS 
ester I-13 and its acid I-12 were weakly active against TbHK1 showing 12.83 ± 7.45% 
and 0.87 ± 7.94% inhibition of the enzyme, respectively. EbSe I-26 (with the ester placed 
ortho to the selenium on the benzisoselenazolinone ring) demonstrated 2.67 ± 5.12% 
inhibition of TbHK1 activity. EbS ester I-32 with a para-N-aryl substitution 
demonstrated 22.78 ± 3.75% TbHK1 inhibition. EbS ester I-33 with an ester at the meta 
position on the N-aryl ring effected 1.65 ± 0.30% TbHK1 inhibition. EbSe ester I-34 
(with a para-N-aryl substitution) demonstrated 78.96 ± 2.81% TbHK1 inhibition. EbSe 
acid I-38 (with a para-N-aryl substitution) exhibited 17.18 ± 14.55% TbHK1 inhibition. 
Figure 1.5: Synthesized EbSe and EbS peptide-drug conjugates with a diethylene glycol tether in lieu 











































EbSe acid I-39 with a carboxylic acid at the meta position on the N-aryl ring 
demonstrated 18.50 ± 2.84% TbHK1 inhibition. With respect to the non-conjugated drug 
derivatives, it seems that the least potent EbSe candidates were those with substitution on 
the benzisothiazolinone and benzisoselenazolinone rings. The most potent analogues of 
EbSe were those with N-aryl substitution, as evidenced by EbS ester I-32 and EbSe ester 
I-34. Of the peptide-drug conjugates, only peptide-drug conjugate I-44 (of drug 
derivative I-32) and I-46 (of drug derivative I-12) displayed any activity against TbHK1 
(10.42 ± 0.55% for I-44 and 3.74 ± 3.79% for I-46 in Table 1.2). Conjugation to a 
peptide sequence did not increase the potency of the inactive non-conjugated EbSe/EbS 
analogues. 
The percent BSF growth inhibition (determined at 10 µM) refers to the percent of 
the trypanosomes (in a whole cell assay) that have been killed by the non-conjugated 
EbSe/EbS analogues or the peptide-drug conjugate. Of the N-carboxymethylated EbS 
derivatives, EbS methyl ester I-13 revealed a BSF growth inhibition of 98.33 ± 1.28% 
and its corresponding acid I-12 effected a BSF growth inhibition of 77.64 ± 4.26%. Of 
the substituted EbSe and EbS analogues, the esters EbS I-25 and EbSe I-26 exhibited 
52.50 ± 4.89% and 55.61 ± 7.45% BSF growth inhibition, respectively. The acid analog 
I-27 showed 10.94 ± 10.90% trypanosome growth inhibition and I-28 was ineffective 
against trypanosome growth inhibition. Of the N-aryl substituted methyl esters, EbS I-32 
exhibited 66.45 ± 10.94% BSF growth inhibition. EbS acid I-36 (of the ester I-32) was 
ineffective against trypanosome growth. Next, EbS I-33 demonstrated 8.77 ± 22.09% 
growth inhibition. EbS acid I-37 (of the ester I-33) displayed 15.84 ± 47.32% growth 
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inhibition of trypanosomes. EbSe ester I-34 (substitution at the para position on N-aryl 
ring) showed 38.6 ± 3.75% BSF growth inhibition and its acid I-38 showed a decreased 
potency against BSF growth inhibition of 11.98 ± 17.40%. EbSe ester I-35 inhibited 
18.02 ± 20.81% BSF growth inhibition and its acid I-39 was ineffective against 
trypanosomes.  
Of the non-conjugated drug derivatives, it is evident that the esters of the N-
carboxymethylated EbS derivative I-13; the core heterocycle substituted esters I-25 and 
I-27; and the N-aryl substituted EbSe and EbS analogues (specifically I-32 and I-34) 
were most potent against BSF growth inhibition. The acid I-12 of EbS derivative I-13 
also demonstrated significant BSF growth inhibition. One reason can be attributed to the 
difference in potency between a neutral compound (the ester) and an ionic compound (the 
acid) in both TbHK1 assays and BSF growth inhibition assays. This dichotomy may be 
attributed to poor passage of the compound(s) across the cellular membrane, the 
phospholipid bilayer. The exterior membrane of the bilayer is a charged region and the 
interior membrane is neutral. As a result, ionic compounds (such as carboxylic acids) will 
have more difficult passage into cells compared to neutral compounds (such as esters). 
This would help explain why the EbSe and EbS esters were more potent against 
trypanosomes as compared to their acid counterparts, the exception being EbS derivative 
I-12. To further understand the legitimacy of this supposition, it is important to look at 
the potency against BSF growth inhibition of the EbSe and EbS peptide-drug conjugates. 
Peptide-drug conjugate I-43 of EbSe I-39 demonstrated 28.44 ± 5.31% BSF growth 
inhibition. Peptide-drug conjugate I-44 of EbS I-36 showed 26.35 ± 8.20% BSF growth 
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inhibition. Peptide-drug conjugate I-45 of EbSe I-38 exhibited 44.11 ± 7.67% BSF 
growth inhibition. Peptide-drug conjugate I-47 of EbSe I-19 displayed 34.42 ± 3.12% 
BSF growth inhibition. Interestingly, the EbSe peptide-drug conjugates with N-aryl 
substitution were potent against BSF growth inhibition. EbSe peptide-drug conjugate I-45 
showed a BSF growth inhibition of 44.11 ± 7.67%.  EbS peptide-drug conjugate I-46 
showed a BSF growth inhibition of 27.95 ± 2.83%. As is evidenced by this data, the N-
carboxymethyl substituted EbSe peptide-drug conjugate I-47 was more potent against 
trypanosomes than I-44 and I-46, but not I-45. The data shows that the N-carboxylmethyl 
substituted EbSe peptide-drug conjugates were equal to or greater in potency than the N-
aryl substituted analogues. EbS peptide-drug conjugates I-40, I-41, and I-42 were 
ineffective against BSF growth inhibition. Referring to the supposition mentioned earlier 
comparing neutral and electrostatic compounds, it is important to note that the peptide-
drug conjugates described are charged species and exhibited a moderate level of growth 
inhibition against trypanosomes. These conjugates, though charged, have to pass through 
the bilayer to exhibit this moderate level of growth inhibition. It is apparent that the 
peptide (PTS1 sequence, glycine tether, and the modification site) conjugated to the EbSe 
and EbS derivatives demonstrates potency against trypanosome growth inhibition. 
Nonetheless, it is uncertain how the peptide-drug conjugates facilitate passage of the 
drugs across the bilayer (as per the work conducted by Morris and Christensen).15,30 
A desired TbHK1 inhibitor (i.e. enzyme inhibitor) will be in the single-digit 
micromolar range and will exhibit low host toxicity. The TbHK1 IC50 value represents 
the concentration of the drug necessary to reduce the enzyme’s activity by 50%. The only 
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EbSe candidate for which an IC50 was detected was derivative I-34. EbSe ester I-34 (para 
N-aryl substitution) displayed a TbHK1 IC50 of 3.16 ± 0.06 µM. On the other hand, the 
other EbS derivatives displayed an IC50 of greater than 10 µM. An IC50 could not be 
determined for any of the EbSe and EbS peptide-drug conjugates, as these values were 
over the limit of detection of 10 µM. 
As stated previously, a desired enzyme inhibitor will be in the single-digit 
micromolar range and will exhibit low host toxicity and this criterion is true for desired 
BSF inhibitors (i.e. whole cell inhibitors). Therefore, a good BSF EC50 will be an 
inhibitor that kills at least fifty percent of a trypanosome culture at the single-digit 
micromolar range. The EbS acid I-12 exhibited a high BSF EC50 of 6.27 ± 0.54 µM and 
its corresponding methyl ester I-13 demonstrated potency through a BSF EC50 of 0.28 
± 0.07 µM. EbS ester I-32 exhibited a BSF EC50 of 3.79 ± 0.06 µM. The other EbSe and 
EbS drug derivatives were past the limit of detection of 10 µM. In the future, low host 
toxicity will have to be assessed when these assays move toward in vivo trials. 
 33 
  













I-12 0.87 ± 7.94 >10 77.64 ± 4.26 7.24 ± 0.45
I-13 12.83 ± 7.45 >10 98.33 ± 1.28 0.28 ± 0.07
I-18 0 >10 0 >10
I-19 0 >10 0 >10
I-25 17.98 ± 0.36 >10 52.50 ± 4.89 ~10
I-26 2.67 ± 5.12 >10 55.61 ± 7.45 >10





I-32 22.78 ± 3.75 >10 66.45 ± 10.94 7.44 ± 1.90
I-33 1.65 ± 0.30 >10 8.77 ± 22.09 >10
I-34 78.96 ± 2.81 3.16 ± 0.06 38.60 ± 3.75 >10
I-35 0 >10 18.02 ± 20.81 >10
I-36 0 >10 0 >10
I-37 0 >10 15.84 ± 47.32 >10
I-38 17.18 ± 14.55 >10 11.98 ± 17.40 >10
I-39 18.50 ± 2.84 >10 0 >10
I-40 0 >10 0 >10
I-41 0 >10 0 >10
I-42 0 >10 0 >10
I-43 0 >10 28.44 ± 5.31 >10
I-44 10.42 ± 0.55 >10 26.35 ± 8.20 >10
I-45 0 >10 44.11 ± 7.67 >10
I-46 3.74 ± 3.79 >10 27.95 ± 2.83 >10
I-47 1.71 ± 9.51 >10 34.42 ± 3.12 >10
I-48 0 >10 35.43 ± 13.11 >10
I-49 0 >10 25.00 ± 3.62 >10
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1.5  CONCLUSIONS AND FUTURE DIRECTIONS 
In summary, a number of the EbSe and EbS acids (I-12, I-19, I-27, I-28, I-36, I-
37, I-38, and I-39) were ineffective against the TbHK1 enzyme in vitro. EbSe acids I-27 
was modestly active, demonstrating 11.77 ± 0.34% inhibition. The corresponding esters 
(I-13, I-25, I-26, I-32, and I-33) showed modest activity against TbHK1, with EbSe ester 
I-34 showing the greatest enzyme inhibition (ca. 78.96 ± 2.81%). The peptide-drug 
conjugates were mostly inactive against the enzyme, with the most detectable enzymatic 
activity (10.42 ± 0.55% inhibition) coming from peptide-drug conjugate I-44 (i.e. the 
analog of EbS ester I-32). Furthermore, conjugation to a peptide sequence did not 
increase the potency of the inactive non-conjugated EbSe analogues toward TbHK1.30  
The esters were more potent against BSF growth inhibition, with EbS ester I-13 
demonstrating almost complete inhibition of BSF growth. Note that EbS acid I-12 
bearing an N-carboxymethyl substituent showed 77.64 ± 4.26% BSF growth inhibition.30 
Installation of a methyl ester on the core aryl ring of the heterocycle (I-25 and I-26) 
afforded EbSe and EbS analogues that displayed 52.50 ± 4.89% and 55.61 ± 7.45% BSF 
growth inhibition, respectively. N-aryl substitution in the para position yielded a 
moderately active EbS derivative I-32 against BSF growth inhibition (66.45 ± 10.94%). 
Conjugation of our EbSe and EbS derivatives to a peptide conjugate bearing a 
peroxisome targeting sequence did not enhance the potency against BSF growth 
inhibition, contrary to our hypothesis that initiated this study.  In addition, the most active 
EbS derivative I-13 lost most of its efficacy when coupled to a peptide, going from 98.33 
± 1.28% to 27.95 ± 2.83% BSF growth inhibition (refer to I-46 in Table 1.2). As a result, 
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we concluded that our peptide-drug strategy did not enhance the overall potency of the 
EbSe/EbS drug class against either the TbHK1 or BSF parasites.   
At this point it is unclear whether the failure of this particular strategy was due to 
reduced potency of the peptide-modified drug at its cellular target or whether the PTS1 
was unable to facilitate transfer of the drug conjugate across the cell membrane. It is also 
unclear whether the electron withdrawing carbonyl installed on the Ebselen scaffold 
makes the therapeutic too unstable, i.e. prone to decomposition. It is interesting to note 
that I-12 and I-13 with the acetoxy substitution in lieu of the N-aryl ring were ineffective 
against the enzyme but were highly potent against the parasite. Compound I-34, on the 
other hand, was moderately effective against the enzyme with an IC50 of 3.16 ± 0.06 µM. 
Positioning of the electron-withdrawing group on the N-aryl ring enhances potency 
against the enzyme, with positioning of a carboxylmethyl group enhancing potency 
against the BSF parasite (see Figure 1.6). Perhaps, electron-donating groups could be 
incorporated on the Ebselen scaffold to offset the electron withdrawing character of the 
carbonyl moiety. Based on these results, the next candidate worth evaluating would be an 
EbS derivative bearing a N-para-carboxylmethyl substitution on the N-aryl moiety as this 
would combine both of the positive substitution patterns from the two major leads, I-13 
and I-32. This compound and its corresponding carboxylic acid should be evaluated 
against both the enzyme and the BSF parasite. 
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The key to enhancing the Ebselen drug suite, and their corresponding peptide 
conjugates, is to have a more detailed understanding of their mechanism of action (i.e. the 
biochemistry of the therapeutics). As such, the effect of the PTS1 has not yet been 
determined with respect to transport of molecular cargo across the trypanosomal 
membrane. Furthermore, we do not understand whether the most active Ebselen 
derivatives (I-12, I-13, and I-32) are directly interacting with the target enzyme, TbHK1, 
if they are interacting elsewhere in the trypanosome, or if they are rendered inactive via 
oxidation to a sulfoxide or selenoxide species within the trypanosome.  
We have found that several of our carboxylic acid and methyl ester EbSe and EbS 
derivatives are potent against the BSF parasites (see Table 1.2). Although incorporation 
of a methyl ester moiety onto the N-phenyl substituent leads to modest inhibition of BSF 
growth, it is the use of an N-carboxymethyl substituent in lieu of the N-phenyl appendage 
that leads to the greatest impact on growth inhibition. The reason for the lower activity of 
the peptide-drug conjugate has yet to be determined and could be attributed to poor 
passage of the peptide-drug conjugate across the cell membrane. Perhaps the poor 
passage of our peptide-drug conjugates is due to interactions of the conjugate with the 
surface glycoproteins on the trypanosome.5 Furthermore, our hypothesis of substituting 
the diglycine tether for the more polar diethylene glycol tether did not enhance potency of 








the Ebselen peptide-drug conjugates as evidenced by the data for I-48 and I-49 (although 
I-44 was weakly active against the enzyme, TbHK1).  
The next phase of this thesis work should be to maintain the diglycine tether as 
this tether allowed for the detection of weak enzyme and/or BSF parasite activity. The 
most effective Ebselen derivatives to use for future peptide scaffolds would be either I-13 
or I-32. The PTS1, however, should be altered with homologous amino acids. In the first 
position, leucine can be replaced with isoleucine for a different set of peptide-drug 
conjugates. The lysine is the most variable position of the PTS1 with its ability to 
accommodate a variety of amino acids bearing acidic side-chains (at neutral pH), such as 
histidine, asparagine, or glutamine. The alanine can be substituted with a similarly-sized 
amino acid bearing a non-polar side-chain, such as valine. The next phase of the work 
related to the Ebselen drug suite should focus on producing a library of peptides that vary 
at the PTS1 using the two most active Ebselen drug derivatives presented in this thesis 
work to assess whether the failed hypothesis reported here was due to a poorly selected 
PTS1. Use of an alternate PTS1 may render the Ebselen drug suite as potent against the 
trypanosomal glycolytic machinery. 
Acknowledgements 
My sincere thanks go to members of the Morris group, including Stephen Patrick, 
Jillian Milanes, and Yijian (Evan) Qiu, for obtaining all of the biological data presented 
in this dissertation.  
  
 38 
1.6  EXPERIMENTAL 
1.6.1  TRYPANOSOME GROWTH AND VIABILITY ASSAYS 
BSF 90-13 T. brucei, a 427 strain, was grown as described previously.31,32 To score 
viability, parasites (1 x 104/mL BSF) were seeded into 96-well clear-bottomed 
polystyrene plates in 200 µl HMI-9 supplemented with 10% fetal bovine serum and 10% 
Serum Plus (Sigma-Aldrich, St. Louis, MO) and grown in the presence of compound (2 
µl) or equivalently diluted carrier for 3 days in 5% CO2 at 37oC.  All assays were 
performed in triplicate.  After incubation (72 hr, at 37 °C), CellTiter-Blue (Promega) was 
added and fluorescence measured (560Ex/590Em). 
Purification of Bacterially Expressed TbHK1 and enzyme assay: 
For purification of bacterially expressed TbHK1 (rTbHK1), a starter culture of E. coli 
M15(pREP) harboring pQE30 (Qiagen, Valencia, CA) with the TbHK1 gene cloned in 
frame of a 6-His tagging sequence was grown to an OD of ~1 and then induced for 24 hr 
at room temperature with 0.25 µM isopropyl β-D-1-thiogalactopyranoside (IPTG) and 
purified as described previously.33   
HK assays were performed in triplicate as described using a coupled reaction to 
measure enzyme activity.33,34 In short, the coupled assay uses glucose-6-phosphate 
dehydrogenase (G6PDH) to convert glucose-6-phosphate (G6-P) generated by HK to 6-
phosphogluconate with coincident reduction of NADP to NADPH, which is monitored 
spectrophotometrically at 340 nm.  Note that EbSe was found to be ineffective in a 
counterscreen for inhibition of G6PDH.  Kinetic analyses were performed using 
KaleidaGraph 4.1 (Synergy Software, Reading, PA). 
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1.6.2 SYNTHESIS OF DRUGS AND PEPTIDE-DRUG CONJUGATES 
All reagents were purchased from commercial suppliers and used without further 
purification. All isolated products were purified via flash column chromatography using 
silica gel SDS 60 C.C. 40-63 µm. 1H and 13C NMR spectra were collected at ambient 
temperature on a 300 (Bruker Avance) or 500 MHz NMR spectrometer (Bruker Avance 
or JEOL Eclipse). Chemical shifts are reported in parts per million (ppm) and referenced 
to residual solvent peaks (i.e., d 7.28 ppm for 1H NMR, 77 ppm for 13C NMR in CDCl3; 
2.54 ppm for 1H NMR, 40.45 ppm for 13C NMR in DMSO-d6). Data are presented as 
follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet), 
and integration. Infrared (IR) spectra, reported in cm-1, were collected using a Fourier 
transform spectrophotometer. Compounds I-1,19 I-12,21 I-13,21 I-16,22-24 I-17,22-24 I-18,22-
24, I-21,26 I-22,27 I-23,28 and I-3225 were prepared using known methods and exhibited 
spectral data consistent with previously reported syntheses.  
 
Synthesis of I-19 
 
 To a dry, 20 mL vial was I-18 (142 mg, 0.5 mmol, 1 equiv), and 1.8 mL 1,4-
dioxane. The solution was cooled to 0 ˚C and then 1 M aq. LiOH (0.5 mL, 1.1 mmol, 2 







evaporated and then 1 mL of 10% HCl was added. The aqueous layer was extracted with 
ethyl acetate (3 x 15 mL).  The combined organics were dried over sodium sulfate, 
filtered, and concentrated by rotary evaporation to isolate I-19 as an off-white solid in 
73% yield (98 mg). 
 
Compound I-19 
1H-NMR (500 MHz, DMSO-d6): d 8.76-8.75 (1H, s), 7.51-7.39 (4H, m), 3.91-3.90 (2H, 
d, J 5 Hz); 13C-NMR (125 MHz, DMSO-d6): d 171.5, 167.2, 136.8, 131.6, 130.6, 130.3, 
129.7, 127.6, 41.1; IR (cm-1; NaCl salt plate): 3254, 3062, 2921, 2851, 1735, 1638, 1595, 
1533, 1466, 1432, 1401, 1349, 1318, 1241, 1085, 1054, 1002, 750, 725, 689; melting 
point = decomposes above 173 ˚C. 
 
Synthesis of I-24 
 
To a dry, 250 mL round-bottomed flask was added I-23 (1.4 g, 5.4 mmol, 1 
equiv), triethylamine (1.1 mL, 8.1 mmol, 1.5 equiv), and 10 mL anhydrous DCM. The 
solution was cooled to 0 ˚C. Then, thionyl chloride (1 M in DCM) (5.9 mL, 5.9 mmol, 
1.1 equiv) was added slowly by syringe. The solution was stirred at 0 ˚C for 30 min., then 
the solvent was evaporated in vacuo. The residue was then re-dissolved in 10 mL 






aniline (1.5 mL, 16.2 mmol, 3.0 equiv) was added slowly at 0 ˚C to the acid chloride and 
the solution was allowed to warm to room temperature. The solution was then refluxed 
overnight under N2, then cooled to room temperature and evaporated. The residue was 
taken up in 50 mL ethyl acetate and then washed with 50 mL aq. saturated sodium 
bicarbonate. The aqueous layer was washed with ethyl acetate (2 x 50 mL). The 
combined organics were washed with 50 mL saturated brine. The brine layer was then 
washed with ethyl acetate (2 x 25 mL). The combined organics were dried over sodium 
sulfate, filtered, and evaporated onto silica. The residue was purified via column 




1H-NMR (500 MHz, CDCl3): d 7.77-7.75 (1H, d, J 10 Hz), 7.68-7.62 (3H, m), 7.62 (s, 
1H), 7.49-7.47 (1H, t, J 5, 15 Hz), 7.42-7.39 (2H, t, J 5, 15 Hz), 7.22-7.21 (1H, s), 3.98 
(3H, s); 13C-NMR (125 MHz, CDCl3): d 166.8, 165.5, 140.5, 137.5, 134.5, 131.9, 131.5, 
129.3, 127.8, 125.2, 120.2, 117.9, 52.9; IR (cm-1; NaCl salt plate): 3282, 3134, 3061, 
2952, 1733, 1661, 1599, 1543, 1498, 1443, 1414, 1328, 1295, 1257, 1203, 1138, 1097, 
1029, 981, 907, 854, 806, 756, 725, 693; melting point = 132-133 ˚C; Rf (35% ethyl 






Synthesis of I-25 
 
To a dry, 100 mL round-bottomed flask was added 2 mL anhydrous DMF, copper 
(I) iodide (29 mg, 0.15 mmol, 0.5 equiv), and 1,10-phenanthroline (27 mg, 0.15 mmol, 
0.5 equiv). The mixture was then stirred for 15 minutes at room temperature. 
After 15 minutes, I-24 (100 mg, 0.3 mmol, 1 equiv), sulfur powder (12 mg, 3.75 
mmol, 1.25 equiv), and anhydrous potassium carbonate (50 mg, 3.6 mmol, 1.2 equiv) (i.e. 
dried in oven overnight at 140 ˚C) were added sequentially. The solution was stirred at 
room temperature for 15 minutes under nitrogen and then brought to 110 ˚C and stirred 
overnight. 
The reaction mixture was cooled to room temperature and then poured into 100 
mL saturated brine. The suspension was stirred at room temperature until a thin organic 
layer of DMF and product was detected above the aqueous layer (typically within three to 
four hours). The aqueous layer was extracted with ethyl acetate (3 x 25 mL). The 
combined organics were dried with sodium sulfate, filtered, and evaporated onto silica. 
The reaction mixture was purified via column chromatography with 0-45% ethyl acetate 










1H-NMR (300 MHz, CDCl3): d 8.34-8.32 (1H, d, J 6 Hz), 8.28-8.27 (1H, d, J 3 Hz), 
7.78-7.76 (2H, d, J 6 Hz), 7.58-7.55 (1H, t, J 6, 9 Hz), 7.52-7.49 (2H, t, J 6, 9 Hz), 7.37-
7.34 (1H, t, J 3, 9 Hz), 4.07 (3H, s); 13C-NMR (75 MHz, CDCl3): d 166.7, 163.4, 142.5, 
137.2, 132.9, 131.7, 129.4, 127.1, 126.9, 125.9, 124.5, 121.7, 53.2; IR (cm-1; NaCl salt 
plate): 2956, 2920, 2850, 1686, 1662, 1638, 1589, 1561, 1543, 1509, 1459, 1439, 1377, 
1323, 1289, 1098, 736; melting point = 185-186 ˚C; Rf (1:1 EtOAc:Hex.) = 0.58. HRMS 
(C15H11NO3S): EXPECTED: 285.3170; FOUND: 286.0552. 
 
Synthesis of I-26 
 
To a dry, 100 mL round-bottomed flask was added 3 mL anhydrous DMF, copper 
(I) iodide (100 mg, 0.53 mmol, 0.5 equiv), and 1,10-phenanthroline (95 mg, 0.53 mmol, 
0.5 equiv). The mixture was then stirred for 15 minutes at room temperature. 
After 15 minutes, I-24 (350 mg, 1.05 mmol, 1.0 equiv), selenium powder (104 
mg, 1.31 mmol, 1.25 equiv), and anhydrous potassium carbonate (174 mg, 1.26 mmol, 
1.2 equiv) (dried in oven overnight at 140 ˚C) were added sequentially. The solution was 







The reaction mixture was cooled to room temperature and then poured into 100 
mL saturated brine. The suspension was stirred at room temperature until a thin organic 
layer of DMF and product was detected above the aqueous layer (typically within three or 
four h). The aqueous layer was extracted with ethyl acetate (3 x 25 mL). The combined 
organics were dried with sodium sulfate, filtered, and evaporated onto silica. The reaction 
mixture was purified via column chromatography with 0-55% ethyl acetate in hexanes to 
afford I-26 in 12% yield (41 mg). 
 
Compound I-26 
1H-NMR (500 MHz, CDCl3): d 12.73 (1H, s), 8.56-8.52 (1H, d, J 20 Hz), 8.09-8.06 (1H, 
d, J 15 Hz), 7.75-7.72 (2H, d, J 15 Hz), 7.42-7.36 (2H, t, J 15, 30 Hz), 7.18-7.07 (2H, m), 
4.03 (3H, s); 13C-NMR (125 MHz, CDCl3): d 171.3, 159.5, 138.9, 138.3, 133.9, 129.1, 
124.4, 121.5, 120.6, 119.8, 112.9, 53.0; IR (cm-1; NaCl salt plate): 3363, 2922, 2851, 
1680, 1597, 1546, 1498, 1442, 1321, 1267, 1199, 1151, 1076, 756, 691; melting point = 
78-85 ˚C; Rf (1:1 EtOAc:Hex) = 0.64-0.55. HRMS (C15H11NO3Se): EXPECTED: 
332.9904; FOUND: 333.9983. 
 






To a dry, 20 mL vial was added I-25 (44 mg, 0.15 mmol, 1 equiv), lithium 
hydroxide monohydrate (32 mg, 0.75 mmol, 5 equiv), and 10 mL THF:methanol:H2O 
(2:1:1). The reaction mixture was stirred at room temperature for 40 hr. Saturated 
aqueous ammonium chloride (5 mL) and H2O (4 mL) were then added and the aqueous 
layer was extracted with ethyl acetate (2 x 50 mL) and chloroform/methanol (5:1; 2 x 30 
mL). The combined organics were dried with sodium sulfate, filtered, and evaporated to 
afford I-27 in 77% yield (32 mg). 
 
Compound I-27 
1H-NMR (300 MHz, CDCl3): d 8.32-8.29 (1H, d, J 9 Hz), 8.27-8.24 (1H, d, J 9 Hz), 
7.76-7.68 (3H, m), 7.57-7.52 (2H, t, J 6, 15 Hz), 7.41-7.37 (1H, t, J 6, 12 Hz); 13C-NMR 
(75 MHz, CDCl3): d 168.3, 163.1, 142.0, 137.5, 133.7, 131.2, 129.9, 127.5, 127.3, 126.4, 
124.8; IR (cm-1; KBr pellet): 3061, 2920, 2847, 2629, 1734, 1676.05, 1653, 1617, 1585, 
1560, 1507, 1490, 1479, 1438, 1421, 1349, 1326, 1267, 1243, 1199, 1162, 1112, 1052, 
1024, 908, 758, 745, 691; melting point = decomposes above 260 ˚C. HRMS 
(C14H9NO3S): EXPECTED: 271.0303 FOUND: 272.0199. 
 






To a dry, 20 mL vial was added I-26 (32 mg, 0.097 mmol, 1 equiv), lithium 
hydroxide monohydrate (20 mg, 0.49 mmol, 5 equiv), and 10 mL THF:methanol:H2O 
(2:1:1). The reaction mixture was stirred at room temperature for 40 hr. A mixture of 
saturated aqueous ammonium chloride (5 mL) and H2O (4 mL) was added and the 
aqueous layer was extracted with ethyl acetate (2 x 50 mL) and chloroform/methanol 
(5:1; 2 x 30 mL). The combined organics were dried over sodium sulfate, filtered, and 
evaporated via rotary evaporation to afford I-28 in 82% yield (25 mg). 
 
Compound I-28 
1H-NMR (500 MHz, DMSO-d6): d 10.64 (s, 1H), 7.98-7.97 (2H, d, J 5 Hz), 7.75-7.73 
(2H, d, J 10 Hz), 7.37-7.34 (2H, t, J 5, 15 Hz), 7.12-7.09 (1H, t, J 5, 15 Hz), 7.02-6.96 
(1H, t, J 10, 15 Hz); 13C-NMR (125 MHz, DMSO-d6): d 172.1, 164.3, 161.0, 139.3, 
136.0, 133.8, 129.2, 124.1, 123.6, 120.3, 118.4, 115.3; IR (cm-1; NaCl salt plate): 2923, 
2852, 1674, 1655, 1638, 1596, 1544, 1509, 1498, 1491, 1465, 1439, 1377, 1324, 1257, 
1182, 1155, 1071, 744, 685; melting point = decomposes above 213 ˚C. HRMS 
(C14H9NO3Se): EXPECTED: 318.1978; FOUND: 317.9662. 
 









To a dry, 100 mL round-bottomed flask was added a 2-iodobenzoic acid (500 mg, 
2.02 mmol, 1.0 equiv), 5 mL dry DCM, and triethylamine (0.56 mL, 4.04 mmol, 2.0 
equiv). The solution was cooled to 0 ˚C, then thionyl chloride (1 M in DCM) (2 mL, 2.2 
mmol, 1.1 equiv) was added and the solution stirred at 0 ˚C for 30 min. The solvent was 
evaporated by rotary evaporation and the residue reconstituted in 5 mL dry DCM. 
Triethylamine (0.56 mL, 4.04 mmol, 2.0 equiv) was added and the solution was cooled to 
0 ˚C after which para-amino methyl benzoate (335 mg, 2.2 mmol, 1.1 equiv) was added. 
The reaction was then refluxed overnight under N2. Then, the reaction mixture was 
cooled to room temperature and evaporated by rotary evaporation. The residue was taken 
up in 50 mL ethyl acetate and washed sequentially with 50 mL 1 M HCl, 100 mL 
saturated sodium bicarbonate, and 100 mL saturated sodium chloride. The aq. layer was 
neutralized with saturated sodium bicarbonate to pH 7 and then washed with 2 x 50 mL 
ethyl acetate. The combined organics were dried over sodium sulfate, filtered, evaporated 
onto silica gel. Product I-30 was obtained in an 89% yield (682 mg) via column 




1H-NMR (500 MHz, CDCl3): d 8.09-8.08 (2H, s), 7.95-7.94 (1H, d, J 5 Hz), 7.76-7.74 
(2H, d, J 10 Hz), 7.72 (1H, s), 7.56-7.55 (1H, s), 7.49-7.46 (1H, t, J 5, 15 Hz), 7.21-7.18 
(1H, t, J 5, 15 Hz), 3.94 (3H, s); 13C-NMR (125 MHz, CDCl3): d 167.2, 166.5, 141.7, 
141.6, 141.2, 131.8, 130.9, 128.7, 128.5, 126.3, 119.2, 92.2, 52.1; IR (cm-1; NaCl salt 
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plate): 3299, 2949, 2923, 2852, 1717, 1687, 1669, 1597, 1560, 1528, 1474, 1459, 1434, 
1407, 1364, 1323, 1311, 1281, 1255, 1191, 1176, 1107, 1039, 1016, 965, 897, 855, 769, 
742, 697, 635, 622; melting point = 170-172 ˚C; Rf (1:1 ethyl acetate:hexanes) = 0.67. 
 
Synthesis of I-31 
 
 To a dry, 100 mL round-bottomed flask was added 2-iodobenzoic acid (250 mg, 
1.01 mmol, 1.0 equiv), 5 mL dry DCM, and triethylamine (0.28 mL, 2.0 mmol, 2.0 
equiv). The solution was cooled to 0 ˚C,, then thionyl chloride (1 M in DCM) (1.1 mL, 
1.11 mmol, 1.1 equiv) was added.  The resulting solution was stirred at 0 ˚C for 30 min. 
The solvent was evaporated and the residue was reconstituted in 5 mL dry DCM. 
Triethylamine (0.28 mL, 2.0 mmol, 2.0 equiv) was added and the solution was cooled to 
0 ˚C. Next, meta-amino methyl benzoate (152 mg, 1.01 mmol, 1.1 equiv) was added, and 
the reaction refluxed overnight under N2. The reaction mixture was cooled to room 
temperature and evaporated. The residue was taken up in 50 mL ethyl acetate and washed 
sequentially with 50 mL 1 M HCl, 100 mL saturated sodium bicarbonate, and 100 mL 
saturated sodium chloride. The aq. layer was neutralized to pH 7 with saturated sodium 
bicarbonate and then was washed with 2 x 50 mL ethyl acetate. The combined organics 
were dried over sodium sulfate, filtered, and evaporated directly onto silica. Product I-31 
was obtained as an oil in a 62% yield (238 mg) via column chromatography with 0-55% 










1H-NMR (300 MHz; CDCl3): d 8.18 (s, 1H), 8.10-8.09 (2H, d, J 3 Hz), 7.89-7.88 (2H, d, 
J 3 Hz), 7.83-7.82 (2H, d, J 3 Hz), 7.51-7.45 (2H, m), 7.42-7.39 (1H, t, J 3, 9 Hz), 7.15-
7.12 (1H, t, J 3, 9 Hz), 3.83 (3H, s); 13C-NMR (75 MHz; CDCl3): d 167.5, 166.8, 141.9, 
140.1, 137.9, 131.6, 130.9, 129.3, 128.5, 128.3, 125.8, 124.7, 121.1, 92.4, 52.3; IR (cm-1; 
NaCl salt plate): 3424, 2932, 2878, 1718, 1663, 1599, 1540, 1490, 1437, 1409, 1389, 
1324, 1282, 1256, 1225, 1176, 1103, 1063, 1016, 771, 758, 698, 663; Rf (1:1 EtOAc:Hex) 
= 0.63. 
 
Synthesis of I-33 
 
To a dry, 100 mL round-bottomed flask 3 mL anhydrous DMF, copper (I) iodide 
(60 mg, 0.313 mmol, 0.5 equiv), and 1,10-phenanthroline (56 mg, 0.313 mmol, 0.5 
equiv). The mixture was stirred for 15 minutes at room temperature. 
After 15 minutes, I-31 (239 mg, 0.626 mmol, 1.0 equiv), sulfur powder (25 mg, 
0.783 mmol, 1.25 equiv), and anhydrous potassium carbonate (104 mg, 0.751 mmol, 1.2 
equiv) (i.e. dried in oven overnight at 140 ˚C) were added sequentially. The solution was 
stirred at room temperature for 15 minutes under nitrogen, and then brought to 110 ˚C 







The reaction mixture was cooled to room temperature and then poured into 100 
mL saturated brine. The suspension was stirred at room temperature until a thin organic 
layer of DMF and product was detected above the aqueous layer (typically occurs within 
three or four hours). The aqueous layer was extracted with ethyl acetate (3 x 25 mL). The 
combined organics were dried over sodium sulfate, filtered, and evaporated onto silica. 
The reaction mixture was purified via column chromatography with 0-55% ethyl acetate 
in hexanes to afford I-33 in 65% yield (117 mg). 
 
Compound I-33 
1H-NMR (300 MHz; CDCl3): d 8.18 (s, 1H), 8.12 (1H, s), 8.09-8.07 (1H, d, J 6 Hz), 
7.87-7.86 (1H, d, J 3 Hz), 7.81-7.79 (1H, d, J 6 Hz), 7 .51-7.39 (4H, m), 3.93 (3H, s); 
13C-NMR (75 MHz; CDCl3): d 166.6, 164.6, 137.8, 134.8, 131.9, 131.1, 130.6, 130.5, 
130.5, 129.3, 127.4, 125.9, 124.6, 121.0, 52.3; IR (cm-1; NaCl salt plate): 3300, 3144, 
3071, 2951, 2925, 2852, 1722, 1663, 1594, 1547, 1487, 1471, 1435, 1324, 1295, 1254, 
1222, 1190, 1167, 1128, 1083, 1051, 1035, 996, 908, 805, 755, 683, 652, 594; melting 
point = 136-139 ˚C; Rf (1:1 EtOAc:Hex)= 0.53. HRMS (C15H11NO3S): EXPECTED: 
286.0538; FOUND: 286.0572. 
 








To a dry, 100 mL round-bottomed flask was added 5 mL anhydrous DMF, copper 
(I) iodide (170 mg, 0.89 mmol, 0.5 equiv), and 1,10 phenanthroline (161 mg, 0.89 mmol, 
0.5 equiv). The mixture was stirred for 15 minutes at room temperature. 
After 15 minutes, I-30 (682 mg, 1.79 mmol, 1.0 equiv), selenium powder (177 
mg, 2.24 mmol, 1.25 equiv), and anhydrous potassium carbonate (297 mg, 2.15 mmol, 
1.2 equiv) (i.e. dried in oven overnight at 140 ˚C) were added in that order. The solution 
was stirred at room temperature for 15 minutes under nitrogen, and then brought to 110 
˚C  and stirred overnight. 
The reaction mixture was cooled to room temperature and then poured into 100 
mL saturated brine. The suspension was stirred at room temperature until a thin organic 
layer of DMF and product was detected above the aqueous layer (typically occurs within 
three or four hours). The aqueous layer was extracted with ethyl acetate (3 x 25 mL). The 
combined organics were dried over sodium sulfate, filtered, and evaporated onto silica. 
The reaction mixture was purified via column chromatography with 0-55% ethyl acetate 
in hexanes to afford I-34 in 46% yield (276 mg). 
 
Compound I-34 
1H-NMR (300 MHz, CDCl3): d 8.15-8.08 (3H, m), 7.82-7.77 (2H, d, J 15 Hz), 7.71-7.69 
(2H, m, J 6 Hz), 7.53-7.47 (1H, m), 3.95 (3H, s); 13C-NMR (75 MHz, CDCl3): d 166.3, 
165.8, 143.6, 137.2, 133.0, 130.8, 129.5, 127.5, 126.8, 124.0, 123.7, 52.2; IR (cm-1; NaCl 
salt plate): 3341, 2921, 2850, 1723, 1699, 1620, 1592, 1539, 1506, 1437, 1412, 1305, 
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1278, 1179, 1130, 1105, 1013, 958, 853, 765, 727, 695, 668; melting point = 142-145 ˚C; 
Rf (1:1 EtOAc:Hex)=0.56-0.53.  
 
Synthesis of I-35 
 
To a dry, 100 mL round-bottomed flask was added 3 mL anhydrous DMF, copper 
(I) iodide (42 mg, 0.22 mmol, 0.5 equiv), and 1,10 phenanthroline (40 mg, 0.22 mmol, 
0.5 equiv). The mixture was stirred for 15 min at room temperature. 
After 15 min, I-31 (170 mg, 0.44 mmol, 1.0 equiv), selenium powder (44 mg, 
0.56 mmol, 1.25 equiv), and anhydrous potassium carbonate (74 mg, 0.53 mmol, 1.2 
equiv) (i.e. dried in oven overnight at 140 ˚C) were added sequentially. The solution was 
stirred at room temperature for 15 min under N2 and then brought to 110 ˚C and stirred 
overnight. 
The reaction mixture was cooled to room temperature and then poured into 100 
mL of saturated brine. The suspension was stirred at room temperature until a thin 
organic layer of DMF and product was detected above the aqueous layer (typically 
occurring within three or four hours). The aqueous layer was extracted with ethyl acetate 
(3 x 25 mL). The combined organics were dried with sodium sulfate, filtered, and 
evaporated onto silica. The reaction mixture was purified via column chromatography 









1H-NMR (500 MHz; CDCl3): d 8.24 (1H, s), 8.16-8.14 (1H, d, J 10 Hz), 7.99-7.95 (2H, 
m), 7.71-7.70 (2H, m), 7.56-7.49 (2H, m), 3.96 (3H, s); 13C-NMR (125 MHz; CDCl3): d 
166.3, 165.9, 139.4, 137.5, 132.9, 131.5, 129.7, 129.5, 129.4, 127.7, 127.2, 126.74, 126.2, 
123.8, 52.4; IR (cm-1; NaCl salt plate): 3299, 3072, 2952, 2922, 2851, 1722, 1662, 1594, 
1548, 1488, 1435, 1324, 1296, 1223, 1168, 1127, 1109, 1083, 1051, 1035, 997, 908, 805, 
755, 730, 683, 652, 594; melting point = 142 ˚C; Rf (1:1 EtOAc:Hex) = 0.63-0.53. 
 
Synthesis of I-36 
 
 To a dry, 20 mL vial was added I-32 (301 mg, 1.1 mmol, 1.0 equiv), and 4 mL of 
a 2:1:1 mixture of THF:methanol:H2O. Then, lithium hydroxide monohydrate (231 mg, 
5.5 mmol, 5.0 equiv) was added. The reaction mixture was stirred at room temperature 
for 40 h. The reaction mixture was then extracted with 1 M aq. HCl (50 mL) and ethyl 
acetate (5 x 50 mL). The combined organics were washed with 50 mL saturated brine 
then dried over sodium sulfate, filtered, and evaporated. Product I-36 was obtained in a 










1H-NMR (300 MHz, DMSO-d6): d 10.81 (s, 1H), 7.92-7.89 (2H, d, J 9 Hz), 7.83-7.79 
(2H, d, J 12 Hz), 7.65-7.62 (1H, d, J 9 Hz), 7.46-7.41 (2H, m), 7.29-7.26 (1H, d, J 9 Hz); 
13C-NMR (75 MHz, DMSO-d6): d 167.4, 167.1, 143.4, 139.4, 134.6, 133.1, 131.3, 130.7, 
128.5, 127.8, 126.1, 119.5; IR (NaCl salt plate): 3423, 3283, 2923, 1719, 1701, 1685, 
1676, 1655, 1638, 1628, 1609, 1561, 1543, 1525, 1509, 1499, 1491, 1476, 1459, 1422, 
1406, 1316, 1290, 1178; melting point = decomposes above 230 ˚C. HRMS 
(C14H9NO3S): EXPECTED: 272.2978; FOUND: 272.0372. 
 
Synthesis of I-37  
 
 To a dry, 20 mL vial was added I-33 (93 mg, 0.327 mmol, 1.0 equiv), and 4 mL 
of a 2:1:1 mixture of THF:methanol:H2O. Then, lithium hydroxide monohydrate (69 mg, 
1.635 mmol, 5.0 equiv) was added. The reaction mixture was stirred at room temperature 
for 40 hours. The reaction mixture was monitored by TLC and another aliquot of lithium 
hydroxide monohydrate (69 mg, 1.635 mmol, 5.0 equiv) was added. The reaction mixture 
was stirred at room temperature for 48 hours. The solvent was evaporated and then a 
mixture of 5 mL saturated ammonium chloride and 4 mL H2O was added to the residue. 
The aqueous material was extracted with ethyl acetate (2 x 25 mL). The aqueous layer 







dried over sodium sulfate, filtered, and concentrated by rotary evaporation. Product I-37 
was obtained in a 71% yield (63 mg) and may be recrystallized from a 1:1 mixture of 
diethyl ether:ethanol, if necessary. 
 
Compound I-37 
1H-NMR (300 MHz; DMSO-d6): d 10.72 (1H, s), 8.41 (1H, s), 7.92-7.90 (1H, d, J 6 Hz), 
7.71-7.69 (1H, d, J 6 Hz), 7.63-7.58 (2H, m), 7.54-7.48 (3H, m); 13C-NMR (75 MHz; 
DMSO-d6): d 167.6, 165.6, 139.6, 137.2, 131.9, 131.7, 130.4, 130.2, 129.5, 129.4, 127.7, 
125.1, 124.2, 120.9; IR (cm-1; NaCl salt plate): 3282, 2921, 2849, 1691, 1648, 1590, 
1548, 1530, 1486, 1467, 1436, 1414, 1298, 1261, 1164, 1130, 1078, 1047, 1024, 950, 
919, 883, 755, 725; melting point = decomposes above 252 ˚C; Rf (1:1 ethyl 
acetate:hexanes) = 0.34. HRMS (C14H9NO3S): EXPECTED: 271.0303; FOUND: 
270.0217 (<3 ppm). 
 
Synthesis of I-38 
 
 To a dry, 20 mL vial was added I-34 (95 mg, 0.287 mmol, 1.0 equiv), and 4 mL 
of a 2:1:1 mixture of THF:methanol:H2O. Then, lithium hydroxide monohydrate (60 mg, 
1.435 mmol, 5.0 equiv) was added. The reaction mixture was stirred at room temperature 
for 40 h, and then concentrated by rotary evaporation. A mixture of 5 mL saturated 







suspension was extracted with ethyl acetate (2 x 25 mL). The organic layer was 
discarded, then the aqueous layer was acidified with 1 M HCl and extracted with ethyl 
acetate (25 mL). The organic layer was dried over sodium sulfate, filtered, and 
concentrated by rotary evaporation. Product I-38 was obtained in an 84% yield (77 mg) 
and may be recrystallized from a 1:1 mixture of diethyl ether:ethanol if necessary. 
 
Compound I-38 
1H-NMR (500 MHz; DMSO-d6): d 10.85 (s, 1H), 7.96-7.94 (2H, d, J 10 Hz), 7.86-7.84 
(2H, d, J 10 Hz), 7.63-7.59 (2H, m), 7.55-7.52 (1H, t, J 5, 15 Hz), 7.49-7.46 (1H, t, J 5, 
15 Hz); 13C-NMR (125 MHz; DMSO-d6): d 167.4, 165.8, 143.3, 137.1, 131.8, 130.9, 
130.4, 130.2, 129.4, 127.8, 126.3, 119.4; IR (cm-1; NaCl salt plate): 3281, 2924, 2853, 
1674, 1594, 1520, 1458, 1431, 1406, 1319, 1288, 1178, 1115, 855, 769, 686; melting 
point = decomposes above 260 ˚C; Rf (1:1 ethyl acetate:hexanes) = 0.10. 
 
Synthesis of I-39 
 
 To a dry, 20 mL vial was added I-35 (63 mg, 0.188 mmol, 1.0 equiv), and 4 mL 
of a 2:1:1 mixture of THF:methanol:H2O. Then lithium hydroxide monohydrate, (39 mg, 
0.94 mmol, 5.0 equiv) was added. The reaction mixture was stirred at room temperature 







ammonium chloride and 4 mL H2O was added to the residue. The aqueous material was 
washed with ethyl acetate (2 x 25 mL). The combined organics were dried over sodium 
sulfate, filtered, and evaporated. Product I-39 was obtained in 91% yield (54 mg) and 
may be recrystallized from a 1:1 mixture of diethyl ether:ethanol if necessary. 
 
Compound I-39 
1H-NMR (300 MHz; DMSO-d6): d 10.71 (s, 1H), 8.40 (1H, s), 7.92-7.88 (1H, d, J 12 
Hz), 7.71-7.68 (1H, d, J 9 Hz), 7.63-7.57 (2H, m), 7.55-7. 46 (3H, m); 13C-NMR (75 
MHz; DMSO-d6): d 167.6, 165.6, 139.5, 137.2, 131.9, 131.7, 130.4, 130.1, 129.5, 129.4, 
127.8, 125.1, 124.2, 120.8; IR (NaCl salt plate): 3417, 2922, 2852, 2256, 2129, 1668, 





1.6.3  GENERAL PROCEDURE FOR SOLID PHASE PEPTIDE SYNTHESIS  
  OF I-40 TO I-49 
 Peptides were assembled according to the generalized scheme presented above in 
Scheme 1.7.   
Resin Swelling:  Fmoc-Leu-Wang resin was loaded into the barrel of a fritted 10 mL 
syringe and was swelled by first washing with 3 mL DCM, followed by soaking in 
another 5 mL DCM for five minutes. The residual DCM was washed away with DMF (3 
x 5 mL). 
Fmoc Deprotection Sequences:  The Fmoc protecting group of the terminal amino acid of 
the growing peptide was removed by three sequential one-minute treatments with 5 mL 
of a 30% solution of 4-methylpiperidine in DMF. The deprotected resin was then washed 
three times with 5 mL of DMF.  
HCTU amino acid couplings:  Five equiv (relative to resin loading) of the appropriate 
Fmoc-amino acid was added to a three-dram vial, along with five equiv of HCTU.  The 
solids were dissolved in 1 mL DMF and 5 equiv of diisopropylethylamine was added.  
This mixture was then taken up into the syringe and agitated for two minutes.   The first 
treatment of the coupling mixture was then ejected from the syringe, and the resin was 
subsequently treated with a second aliquot of the same amino acid coupling mixture for 
another two minutes.  After the double coupling protocol, the resin was washed with 
DMF (3 X 5 mL).   After this coupling procedure was complete, the newly added Fmoc-
amino acid was deprotected and prepared for further coupling steps as described above.   
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Fmoc-Gly-OPfp coupling (for peptides I-40 to I-47):  The required glycine coupling 
using the more reactive Fmoc-Gly-OPfp (see Scheme 1.7 above) was achieved in the 
following manner:  five equiv of Fmoc-Gly-OPfp and five equiv of HOBt were charged 
to two sets of three-dram vials and taken up in 1 mL of DMF.  This mixture was taken up 
into the syringe containing the resin and was agitated for one hour.   The first treatment of 
the coupling mixture was then ejected from the syringe, and the resin was subsequently 
treated with a second aliquot of the same amino acid coupling mixture for another one 
hour.  After the double coupling protocol, the resin was washed with DMF (3 X 5 mL).   
After this coupling procedure was complete, the newly added Fmoc-Gly residue was 
deprotected and prepared for further coupling steps as described above. This process was 
repeated for the incorporation of each of the desired amino acids in the sequence. Fmoc-
AEEP-OH was substituted for Fmoc-Gly-OH for the installation of a diethylene glycol 
tether (for peptides II-48 and II-49) using the same protocol as that described above. 
Drug Installation:  Each peptide was capped with the appropriate EbSe/EbS drug 
candidate in the following manner:  Five equiv (relative to resin loading) of the 
appropriate EbSe/EbS carboxylic acid was added to a three-dram vial, along with five 
equiv of HCTU.  This mixture was taken up into the syringe containing the resin and was 
agitated overnight.  After the coupling protocol, the coupling solution was ejected from 
the syringe and the resin was further processed as described below.  
Peptide Cleavage and Isolation:  The resin containing the fully assembled peptide-drug 
conjugate was washed with DMF (3 x 5 mL), DCM (3 x 5 mL), and methanol (3 x 5 mL).  
Residual solvents were dried using suction and then the resin was further dried under 
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vacuum (i.e. in a 25 ˚C vacuum oven) overnight. After drying the resin was treated with 
1.5 mL of a standard peptide cleavage cocktail comprised of trifluoroacetic 
acid:H2O:methanol (95:4.5:0.5) for 1.5 h.  The resulting solution containing the liberated 
peptide was then ejected into a 1 mL Eppendorf tube and evaporated under a steady 
stream of nitrogen. The peptide was then precipitated from the resulting oil on the 
addition of ice-cold diethyl ether.  The precipitate was then localized at the bottom of the 
tube by centrifugation, the ether portion was decanted, and the precipitation procedure 
was repeated two more times to afford the desired peptide-drug conjugates.  The identity 
of the peptide-drug conjugates was then confirmed by MALDI-TOF mass spectrometry 









Expected m/z Experimental m/z
I-40 C33H43N7O8S 698.3 698.4
I-41 C33H43N7O8Se 746.2 746.3
I-42 C33H43N7O8S 698.3 698.4
I-43 C33H43N7O8Se 746.2 746.4
I-44 C33H43N7O8S 698.3 698.2
I-45 C33H43N7O8Se 746.2 746.2
I-46 C28H41N7O8S 635.7 636.3
I-47 C28H41N7O8Se 684.2 684.5
I-48 C36H50N6O9S 742.3 742.5
I-49 C36H50N6O9Se 790.8 791.6
Table 1.3: MALDI-TOF data for peptides I-40 to I-49. 
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SYNTHESIS AND EVALUATION OF POTENT TRYPANOCIDES BASED ON 
BENZAMIDOBENZOIC ACID (BABA) INHIBITOR SCAFFOLD 
 
2.1  INTRODUCTION 
As was described in Chapter One of this thesis, human African trypanosomiasis 
(HAT), or African sleeping sickness, is caused by bloodstream form (BSF) Trypanosoma 
brucei (T. brucei; trypanosomes) and is transmitted by the tsetse fly vector.1-3 The disease 
has the potential to affect millions in sub-Saharan Africa, resulting in approximately 
9,000 deaths as of 2010.4,5 Many of the treatments that are employed today are ineffective 
against the parasite once it crosses the blood-brain barrier.1,4 This portion of the thesis 
work will continue the narrative described in the first part of this thesis work. Whereas 
the discussion in the first part of this thesis focused on the use of Ebselen derivatives 
conjugated to a peptidic scaffold to ideally demonstrate increased potency against a 
hexokinase, TbHK1, and trypanosomes, this work will focus on a novel lead drug 
candidate that was evaluated as an in vitro probe, ML205 (II-1), which is part of the 
novel benzamidobenzoic acid (BABA) drug suite.6,7 Furthermore, the work reported by 
Lin, et al. that was shown to target therapeutics coupled to a peroxisomal targeting 
sequence (PTS) to the glycosome where the hexokinase is housed will be a central focus 
for our ultimate goal of focused drug delivery of the BABA drug suite.8   
As was described in Chapter One, TbHK1 was previously genetically and 
chemically validated as a suitable therapeutic target for the design and synthesis of kinase 
inhibitors.2 Three classes of inhibitors were discovered from a high-throughput screening 
campaign of over 220,000 compounds, including the isobenzothiazolinone, 
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isobenzoselenazolinone, and BABA drug suites, the latter of which will be described in 
this part of the thesis. Although the BABA scaffold is one that is relatively novel, several 
analogues were synthesized and screened through structure-activity relationship (SAR) 
assays by the Golden group that will be described here to highlight the optimal structure 
necessary to achieve high potency against both our target enzyme, TbHK1, and our target 
parasite. The BABA scaffold possesses certain features that are amenable to substitution 
to increase inhibition of enzymatic activity in trypanosomes, with the goal of preparing a 
class of highly trypanocidal therapeutics (shown in Figure 2.1).9-11 The results from the 
SAR assay demonstrated that only certain substitutions allow for high inhibition of 
enzymatic activity. Furthermore, these substitutions only served to moderately increase 
the activity of the BABA drug suite against the BSF parasite as described below. 
 
 
Compound II-1 (ML205) had a BSF percent growth inhibition of 6.9 ± 3.0% and 
a TbHK1 IC50 of 0.98 ± 0.067 µM. With respect to the single-digit IC50 displayed by II-
1, the goal was to translate the enzyme potency displayed by this inhibitor into a potent 
trypanocide by varying the substitution pattern on II-1. Substituents were chosen based 
Figure 2.1: Key features of the BABA derivatives are shown on the left; ML205 (II-1) lead drug 
candidate (IC
50




















Tetrazole tolerated (required for cellular assays)
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on changing the electronic character, steric bulk, and solubility of the II-1 lead 
candidate.10 Initially, the tert-butyl group was replaced with electron donating groups. 
Replacement with an ethyl ether moiety (II-1a in Table 2.1) led to a higher percent 
growth inhibition of BSF parasites (64.1 + 3.8% at 10 µM), but an increased IC50 value 
for TbHK1 inhibition (4.8 ± 0.38 µM). Incorporation of an ethyl group (II-1b) in place of 
the t-butyl moiety led to a similar result with a 68.7 ± 4.1% growth inhibition of the BSF 
parasite and an IC50 for TbHK1 inhibition of 4.0 ± 0.20 µM. Modulation to a propyl 
group (II-1c) at that position led to a moderately lower IC50 value against the hexokinase 
(3.6 ± 0.12 µM) and a reduced BSF growth inhibition (52.6 ± 9.5%). A derivative 
bearing an isopropyl group (II-1d) led to a TbHK1 IC50 of 7.1 ± 0.47 µM and a BSF 
percent growth inhibition of 54.9 ± 4.2%. Substitution of the tert-butyl aryl group on II-1 
with a 1,2,3,4-tetrahydronapthenyl moiety (II-1e) increased the TbHK1 IC50 to 9.9 ± 0.64 
µM with a BSF percent growth inhibition of 82.1 ± 2.3%. After this screening, it was 
determined that a tert-butyl aryl group was the most tolerable and demonstrated the 
highest potency against TbHK1.9-12 
Replacement of the carboxylic acid in II-1 with a bioisostere, such as tetrazole 
(II-1f in Table 2.1), displayed a TbHK IC50 of 5.2 ± 0.14 µM and a BSF percent growth 
inhibition of 40.7 ± 17.1%. Although the tetrazole (II-1f) was potent, the carboxylic acid 
was optimal in achieving high potency against both the enzyme and the BSF parasite. 
Substitution of the bromine in II-1 with a fluorine (II-1g) or chlorine (II-1h) lead to 
higher IC50 values of 2.79 ± 0.098 µM and 1.36 ± 0.06 µM, respectively. Although the 
bromine correlated to a good single-digit micromolar enzyme inhibition, substitution of 
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the halide with an aryl group did increase its ability as a potent BSF trypanocide as is 
evidenced by the low %BSF inhibition for II-1g of 32 ± 11% and for II-1h of 35 ± 11% 
in Table 2.1. Substitution of the bromine in II-1 with phenyl (II-1i), 2-hydroxyphenyl 
(II-1j), and 2-methoxyphenyl (II-1k) groups demonstrated 84.1 ± 0.1%, 96.2 ± 0.51%, 
and 83.3 ± 0.67% percent inhibition of rTbHK1, respectively. In addition, the phenyl 
analog II-1i exhibited an IC50 of 0.28 ± 0.002 µM against rTbHK1 (isolated from E. 
coli). Preliminary studies of the aryl-substituted analogues of II-1 showed that this 
molecular class exhibits greater than 80% inhibition of rTbHK1 at 10 µM. Furthermore, 
the phenyl (II-1i), 2-hydroxyphenyl (II-1j), and 2-methoxyphenyl (II-1k) substituted 
analogues of II-1 demonstrated 95.4 ± 0.83%, 28.4 ± 7.8%, and 90.7 ± 0.93% percent 
growth inhibition of whole cell trypanosomes, respectively.9-12 A BSF LD50 of 2.0 ± 0.22 
µM was determined for II-1k. Substitution with a 4-fluoro-phenyl (II-1l) or 4-chloro-
phenyl (II-1m) group displayed a TbHK1 percent inhibition of 27.5 ± 6.0% and 30.3 
± 2.7%, respectively, and a percent growth inhibition of the BSF parasite of 82.2 ± 13.9% 
and 76.7 ± 10.4%, respectively at 10 µM concentration. Substitution of the bromine on 
II-1 with a 4-trifluoromethyl-arene (II-1n) afforded a lower inhibition of TbHK1 (15.9 ± 
2.8%) with a high inhibition of the BSF parasite (93.6 ± 0.41%).9-12 A BSF LD50 was 
determined for II-1n of 1.3 ± 0.1 µM. Substitution of the bromine on II-1 for an electron-
withdrawing 4-nitro-arene group (II-1o) showed moderate activity against TbHK1 
(66.1 ± 8.4%) and good inhibition of the BSF parasite (83.8 ± 4.0%).9-12 This 
demonstrates that an electron-withdrawing group installed in the location of the bromine 
on II-1 serves to inhibit BSF trypanosomes to a high degree, but demonstrates low 
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inhibition of the enzyme, TbHK1, possibly due to off-target effects. Furthermore, the use 
of another electron-withdrawing group, 4-carboxyphenyl (II-1p), in place of the bromine 
in II-1 increased the TbHK1 percent inhibition to 93.6 ± 2.8% with an IC50 of 3.5 ± 0.33 
µM with a BSF parasite percent growth inhibition of 51.0 ± 14.3%.9-12 The substitution 
with a 4-carboxyarene group was of greater interest toward this thesis work as it allows 
us to incorporate a peroxisomal targeting sequence (PTS) on the BABA scaffold, which 
will now be explained in greater detail. 
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Based on the preliminary results from the SAR (described above), we endeavored 
to synthesize a novel BABA drug candidate (Scheme 2.1). The goal in this chapter was to 
synthesize a BABA derivative that demonstrated potency against TbHK1, but that also 
would demonstrable potency against the parasite. The BABA analogues described above 








II-1 (for X = Br and Y = t-Bu)
Entry X = Y = %TbHK1 inhibit. TbHK1 IC50 (µM) %BSF inhibit.
II-1a Br ethyl ether - 4.8 ± 0.38 µM 64.1 ± 3.8%
II-1b Br ethyl - 4.0 ± 0.20 µM 68.7 ± 4.1%
II-1c Br propyl - 3.6 ± 0.12 µM 52.6 ± 9.5%
II-1d Br isopropyl - 7.1 ± 0.47 µM 54.9 ± 4.2%
II-1e Br 1,2,3,4-tetrahydronapthenyl - 9.9 ± 0.64 µM 82.1 ± 2.3%
II-1g F tert-butyl - 2.79 ± 0.098 µM 32 ± 11%
II-1h Cl tert-butyl - 1.36 ± 0.06 µM 35 ± 11%
II-1i phenyl tert-butyl 84.1 ± 0.1% 0.28 ± 0.002 µM 81.4 ± 5.6%
II-1j 2-hydroxy-phenyl tert-butyl 96.2 ± 0.51% 1.2 ± 0.1 µM 28.4 ± 7.8%
II-1k 2-methoxy-phenyl tert-butyl 83.3 ± 0.67% 4.6 ± 0.32 µM 90.7 ± 0.93%
II-1l 4-F-phenyl tert-butyl 30.3 ± 2.7% - 76.7 ± 10.4%
II-1m 4-Cl-phenyl tert-butyl 27.5 ± 6.0% - 82.2 ± 13.9%
II-1n 4-CF3-phenyl tert-butyl 15.9 ± 2.8% - 93.6 ± 0.41%
II-1o 4-nitro-phenyl tert-butyl 66.1 ± 8.4% - 83.8 ± 4.0%







TbHK1 IC50 = 5.2 ± 0.14 µM





were potent enzyme inhibitors, but many were ultimately weakly active against BSF 
trypanosomes. The goal of this thesis work was to use this potency against TbHK1 and to 
translate it into a species that was equally trypanocidal. Our method for accomplishing 
this task was to incorporate a peptide-based peroxisomal targeting sequence (PTS) 
scaffold using Solid Phase Peptide Synthesis (or SPPS; described in Chapter One Section 
1.2) similar to the strategy employed for the enhancement of the Ebselen drug suite.13-15 
Previously, the Morris and Christensen groups validated the use of a PTS attached to a 
fluorescent dye (fluorescein isothiocyanate [FITC]) in carrying molecular cargo to the 
glycosomal compartment of the trypanosomes.8 We wanted to use a similar strategy to 
incorporate our BABA derivatives by first installing a PTS to a tether that was ultimately 
capped with the desired BABA drug candidate. 
Based on the results of the SAR and the data related to II-1 as indicated in Figure 
2.1, we envisioned a BABA analog that had three key components: a tert-butyl benzamide 
group, an aryl chloride, and a carboxylic acid ortho to the benzamide group.9-12 However, 
the carboxylic acid on II-1, as well as its arylated analogues, was the therapeutically 
active residue. Therefore, we referred to the SAR to develop a strategy by which we 
could install another carboxylic acid for the selective incorporation of a peptidic scaffold 
(that is, the PTS1). We envisioned that because the 4-carboxyarene substitution for 
bromine in II-1 was tolerated with respect to enzyme inhibition, we could substitute the 
bromine with a carboxyarene functionality that would possess a carboxylic acid 
(highlighted in blue in Scheme 2.1) to which a peptide sequence could be attached while 
maintaining the therapeutically relevant distal benzoic acid . The therapeutically relevant 
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carboxylic acid (highlighted in green in Scheme 2.1) would remain masked as a methyl 
ester until such time where it could be saponified to reveal the desired, active functional 
group. A more detailed synthetic outline can be found in Section 2.3. 
Furthermore, upon analyzing II-1, we discovered additional synthetic challenges 
that would provide two additional locations to which a peptide scaffold could be attached. 
First, we envisioned replacing the tert-butyl group on II-1 with a carboxylic acid to 
incorporate a peptide bond (highlighted in red in Scheme 2.1). Additionally, we could 
directly attach a peptidic scaffold to the therapeutically active carboxylic acid on II-1 
highlighted green in Scheme 2.1 to evaluate the effectiveness of II-1 when the 
therapeutically active carboxylic acid is capped with the peptidic marker. With the 
synthetic targets established, we decided to make peptidic scaffolds possessing a PTS1 to 
target the molecular cargo to the glycosomal compartment where the glycolytic 
machinery, i.e. TbHK1, is housed. As was the case with the Ebselen strategy reported in 
Chapter One, our PTS1 in this work consisted of C-LKA-N. Our tether with respect to the 
PTS1-BABA conjugates was either a diglycine or a diethylene glycol tether. 
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We hoped that conjugation to a PTS would direct the molecular cargo to the 
glycosome where the kinase (TbHK1) is housed. We also wanted to make use of a 
fluorophore, FITC, to visualize distribution of our PTS1-BABA conjugates into the 
trypanosome (Scheme 2.1). This will be described in greater detail in Section 2.3.2. This 
would allow us to accomplish two major goals. The first is synthesizing and evaluating a 
highly potent enzyme inhibitor, identified by a low, single-digit, micromolar IC50, that is 
also equally highly trypanocidal. The second is gaining a better understanding of the 
mechanism of action regarding both the PTS1 in its role in allowing passage of molecular 
cargo beyond the trypanosomal membrane toward the glycosomal machinery in the 
parasite and the BABA drug suite. Although the work by Morris and Christensen 
demonstrated uptake of a fluorophore-conjugated PTS1, it is not well understood how the 
Scheme 2.1: On the right is II-1 to which a carboxyarene could be appended in lieu of the bromine to 
allow for the incorporation of a peptide (carboxylic acid of interest is highlighted in blue). Note that the 
tert-butyl group (highlighted red) on II-1 could also be replaced with a carboxylic acid to form another 
BABA analog that would allow for incorporation of a peptide bond in that position. Although the 
carboxylic acid highlighted in green is the therapeutically active residue in II-1, as well as BABA, we 
envisioned attaching a peptidic scaffold to the carboxylic acid on II-1. On the left are two of the 
peptidic scaffolds that were envisioned for coupling to the synthesized BABA derivatives bearing either 























































TbHK1 IC50 = 0.98 ± 0.067 µM
%BSF inhibition = 6.9 ± 3.0%
BABA
%TbHK1 inhibition = 93.6 ± 2.8%
TbHK1 IC50 = 3.5 ± 0.33 µM
%BSF inhibition = 51.0 ± 14.3
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PTS1 operates nor do we understand how the BABA drug suite (without the PTS1) can 
exhibit high potency against TbHK1 and BSF trypanosomes. We also do not understand 
what role, if any, the tether plays in allowing passage of PTS-drug conjugate across the 
trypanosome membrane. Our hope was that the work reported herein would allow for the 
synthesis of a highly potent BABA analog that, when coupled to a PTS, will exhibit high 
potency against TbHK1 and will act as a potent BSF trypanocide while also allowing for 
visualization of the PTS1-BABA peptide in the trypanosome through incorporation of a 
fluorescent dye (FITC). With a positive implementation of the PTS1-BABA drug delivery 
strategy, we can begin to formulate an in vivo drug strategy that overcomes the drug 
toxicity issues reported with the use of melarsoprol and eflornithine (see Chapter One).16 
The results of our synthetic efforts are described below in detail, followed by a discussion 
of the potential to extend our work toward other neglected diseases caused by the 
Trypanosomatidae family, including Chagas disease and Leishmaniasis, mentioned in the 
Conclusions for this chapter of the thesis work.16 
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2.2  RESULTS AND DISCUSSION 
2.2.1  COMPLETED BABA SYNTHESES 
 A retrosynthetic analysis of the desired novel benzamidobenzoic acid candidate is 
shown in Figure 2.2. It was envisioned that a halogenated aniline derivative II-3 or II-4 
could be coupled to a variety of boronic acids II-2 by means of Suzuki coupling, thus 
revealing a biaryl aniline derivative II-5. Following the initial Suzuki coupling, an 
acylation with 4-tert-butyl benzoic acid II-6 would reveal a bis-ester BABA candidate II-
7. Selective cleavage of one ester in II-7 would reveal the desired BABA candidate II-8, 
primed for coupling with the requisite peptide sequence by means of conventional SPPS. 
Desired BABA candidate II-8 was conjugated to a peptidic scaffold via SPPS to afford 










































































































Scheme 2.2: In order to visualize delivery of the PTS1-BABA conjugates in the trypanosome, we 
envisioned coupling FITC to the PTS1 on two peptide conjugates shown on the right. We also envisioned 
producing a PTS1-BABA conjugate wherein the fluorescent dye was installed adjacent to the PTS1 using 
a lysine-glycine tether, rather than a diglycine tether.  
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aqueous lithium hydroxide to afford PTS-BABA acid II-9b with the therapeutically potent 
carboxylic acid revealed. PTS1-BABA-methyl ester II-9a and PTS1-BABA-acid II-9b 




Since the carboxylic acid moiety on the central tetra-substituted arene is required 
for activity against the enzyme, we desired to protect it as an ester derivative while 
leveraging the distal carboxylic acid to facilitate the incorporation of the linker-PTS1 
sequence by SPPS.13-15 As is evident in the retrosynthesis depicted in Figure 2.2, we 
ultimately employed a methyl ester to protect the pharmacologically relevant carboxylate.  
Nonetheless, we initially targeted the more readily removable t-butyl protecting group, 
Figure 2.2: Retrosynthetic analysis of successful synthetic strategy affording desired BABA methyl ester 

























Y = CO2tBu, CO2Me, CO2Bn
X = Br (II-3)



















since that moiety would cleave during the final acid-mediated resin cleavage step of the 
SPPS incorporation of the PTS1-linker peptide.12-14 
Thus, our initial forays into the synthesis of a BABA candidate of PTS 
modification targeted the t-butyl ester analog of methyl ester II-8.  These synthetic efforts 
started with the bromination of methyl 2-amino-4-chloro benzoate II-10 (Scheme 2.3).18 
Similar to brominated aniline derivative II-3, iodinated aniline derivative II-4 could be 
obtained in quantitative yield via a shorter reaction with ease of purification that could 
subsequently be used in the Suzuki couplings and acylation reactions described herein 
with great success.17 The brominated aniline derivative II-3 (isolated in 94% yield) was 
then acylated with 4-tert-butyl-benzoic acid to provide II-11 in 39% yield. Hydrolysis of 




Scheme 2.3: Bromination of 2-amino-4-chloro-methyl benzoate (II-10), followed by acylation and 
hydrolysis of II-3. The synthesis of iodinated derivative II-4 also shown. Both II-3 and II-4 were used in 
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The difficulty following this protocol was in the subsequent esterification of 
carboxylic acid II-1 to the desired tert-butyl ester II-12. Repeated attempts to effect the 
transformation failed. One possible difficulty might arise due to the potential for 
intramolecular hydrogen bonding that could activate the desired ester product toward 
facile hydrolysis after formation (Scheme 2.4, dashed box). The initial esterification 
attempt involved reaction with thionyl chloride to generate the acyl chloride intermediate 
followed by nucleophilic displacement with tert-butyl alcohol. Unfortunately, this route 
failed to provide the desired tert-butyl ester. Two different sources of the nucleophile, 
tert-butyl alcohol or potassium tert-butoxide, were investigated for this method, but the 
transformation was unsuccessful.20 Attempts at a Steglich esterification, promoted by a 
carbodiimide (e.g. EDC), and a routine Fischer esterification were also unsuccessful.21 
Ultimately, the synthesis of an acyl imidazole via reaction with carbonyl diimidazole, 
followed by nucleophilic displacement with tert-butyl alcohol was successful.22 
Nevertheless, the resultant tert-butyl ester was unstable toward standard organic 
purification methods, such as column chromatography. A column was necessary due to 
the failure of both recrystallization and extraction to separate the desired, clean tert-butyl 
ester II-12 from carboxylic acid II-1. The tert-butyl ester II-12 was sensitive to the 
relatively acidic silica gel, unless otherwise doped with eight percent triethylamine. An 
alumina column was successful; however, the change in stationary phase led to 
significant product loss. Ultimately, the product was obtained in only 17% yield after the 




Despite the difficulties encountered for its synthesis, tert-butyl ester II-12 was 
subjected to Suzuki coupling conditions. Based on our retrosynthetic analysis, the Suzuki 
coupling of II-12 would facilitate the incorporation of a third aryl ring bearing a 
carboxylic acid, thus incorporating the carboxylic acid handle that would allow us to 
couple a PTS1 peptide sequence to the BABA candidate via SPPS (refer to Figure 2.2). 
The Suzuki coupling of II-12 was first attempted under basic conditions catalyzed by 
[1,1’-bis(di-tert-butylphosphino)ferrocene] dichloropalladium (II) [PdCl2(dtbpf)] in the 
presence of 4-carboxyphenylboronic acid, either heated under conventional reflux 
conditions or by means of microwave irradiation (Scheme 2.5). Both methods led to the 
decomposition of starting material and a failure to isolate desired product II-13. The 
Scheme 2.4: Several methods for the esterification of carboxylic acid II-1 were attempted.
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decomposition was monitored via NMR in which the loss of the benzamide functional 
group was observed to afford the starting benzoic acid and tert-butyl ester II-12, which 
had been hydrolyzed to the starting acid II-1. Given the significant difficulties 
encountered in the preparation of II-12, and its failure to engage productively in the 
subsequent Suzuki coupling, our approach was altered to operate with a methyl ester 
protecting group in lieu of the problematic tert-butyl ester, as the former is also labile 




It was thought that the Suzuki coupling of II-11, conducted under the 
aforementioned conditions, with either 4-carboxyphenylboronic acid or 4-
methoxycarbonylphenylboronic acid would afford II-14 (Scheme 2.6). Nevertheless, the 
high content of water in the standard reaction protocol (~40%) led to the undesirable 
hydrolysis of the ester situated ortho to the amide, rendering the reaction intractable. 
Several examples are provided in the literature of Suzuki couplings between halogenated 
aniline derivatives and boronic acids in acetonitrile mixtures containing ~10-20% 
Scheme 2.5: Suzuki coupling of tert-butyl ester II-12 and 4-carboxyphenylboronic acid.
18
 Carboxylic 
acid highlighted red to emphasize functionality required for SPPS; ester highlighted blue to emphasize 






















water.24 The Suzuki coupling between II-11 and 4-carboxyphenylboronic acid still 
suffered significant side reactions after the amount of water was decreased according to 
literature precedents. Nonetheless, the Suzuki coupling between II-11 and 4-
methoxycarbonylphenylboronic acid was successful in the installation of the third aryl 
ring (Scheme 2.6). Unfortunately, after careful NMR studies, it was revealed that, even 
after employing decreased water content in the reaction, the ester positioned ortho to the 
amide was hydrolyzed (i.e. II-15 in Scheme 2.6 obtained in 55% yield). It is possible that 
this hydrolysis might be promoted by the internal stability afforded by the ortho 
positioning of the carboxylic acid relative to the amide analogous to the labile t-butyl 
ester depicted in dashed box of Scheme 2.4. To address this problem, the order of 
operations in the synthesis was rearranged to account for the sensitivity of the ester 




Scheme 2.6: Failed Suzuki coupling between II-11 and 4-carboxy- or 4-methoxycarbonyl-
phenylboronic acid (top). Suzuki coupling between II-11 and 4-methoxycarbonylphenyl boronic acid 










































 Accordingly, the Suzuki coupling was attempted on the brominated aniline 
derivative II-3 (Scheme 2.7). This proved to be a much more facile method for the 
incorporation of the second aryl system bearing the carboxylic acid that would be needed 
for SPPS. The aniline derivative II-3 could be coupled to either 4-carboxyphenylboronic 
acid or 4-methoxycarbonylphenylboronic acid in moderate yields affording II-16 and II-
17, respectively, albeit at prolonged reaction times. Thionyl chloride was reacted with 4-
tert-butyl benzoic acid to provide the acyl chloride that was used in the acylation of II-16 
and II-17 in the presence of triethylamine (Scheme 2.7). Aniline derivative II-16 was 
unreactive toward acylation, possibly due to the formation of a zwitterion that masks the 
nucleophilic amine as an ammonium ion that is rendered unreactive under the acylation 
conditions in Scheme 2.8. Dissolution of II-16 in pyridine, in the hopes that the base 
would reveal the nucleophilic amine, followed by acylation with 4-tert-butyl benzoyl 
chloride (Scheme 2.8) also did not provide product II-8. The acylation of methyl ester II-
17 was successful in a moderate 34% yield; however, there was no readily available 





An alternative route involving the deprotonation of II-16 with n-butyl lithium 
followed by attempted acylation with 4-tert-butyl benzoyl chloride was also unsuccessful 
(Scheme 2.9). Under these conditions, the 4-tert-butyl benzoyl group was successfully 
installed, but the methyl ester ortho to the amide also suffered alkylation as determined 
by NMR analysis. 
Scheme 2.7: Suzuki coupling of II-3 with 4-carboxyphenylboronic acid (affording II-16) and 4-


























































































The next plan was to use 4-benzyloxycarbonylphenylboronic acid in the Suzuki 
coupling, as benzyl groups are common protecting groups in organic transformations that 
can often be removed by means of hydrogenolysis under neutral conditions (Scheme 
2.10). The Suzuki coupling followed the aforementioned protocol represented in Scheme 
2.7 and afforded benzyl ester II-19 in 46% isolated yield. The acylation followed the 
same protocol depicted in Scheme 2.8, with refluxing of the reaction mixture being 
necessary, and afforded II-20 in 28% yield. Stirring of II-20 with palladium on carbon at 
ambient temperature under a hydrogen gas atmosphere yielded a product that, after 








n-BuLi, THF, -78 ˚C to rt, 30 m
Thionyl chloride (1.1 eq)
Triethylamine (1.5 eq)
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several days, had not only lost the benzyl group, but had also lost the chlorine that is a 
critical element for therapeutic activity (Figure 2.1).6,9-12 Hydrogen gas was proven to be 
an ineffective means for cleavage of the benzyl ester. Another method for cleavage of 
benzyl ester II-20 at ambient temperature with chlorotrimethylsilane and sodium iodide 
was also ineffective, but did allow for recovery of II-20.25-27 
 
  
As 4-methylcarbonylphenylboronic acid and 4-benzyloxycarbonylphenylboronic 
acid were ineffective options, another route incorporating a tert-butyl ester was 
discovered (Scheme 2.11). Using commercially available 4-tert-
butyloxycarbonylphenylboronic acid in the Suzuki coupling with iodinated aniline 
Scheme 2.10: Suzuki coupling of II-3 with 4-benzyloxycarbonylphenylboronic acid yielding II-19; 
acylation of II-19 with 4-tert-butyl benzoyl chloride (II-6); deprotection of II-20 with hydrogen gas 






















DCM, 0 ˚C to 
reflux, overnight
II-6
1 eqSOCl2 (1.1 eq)
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derivative II-4 afforded tert-butyl aniline derivative II-21 in 96% yield. The aniline 
derivative II-21 was then slowly added to an ice-cold mixture of freshly prepared 4-tert-
butylbenzoyl chloride and triethylamine. After purification, the transformation afforded 
the desired tert-butyl ester BABA candidate II-22 in 54% yield. Deprotection of the tert-
butyl ester II-22 with trifluoroacetic acid finally afforded the desired BABA drug 
candidate II-8 that was ready for SPPS. The BABA drug candidate II-8 could be 
saponified with 1 M aqueous lithium hydroxide to afford the BABA diacid II-23 in 84% 
yield (as shown in Scheme 2.12).18 
 
 
Scheme 2.11: Suzuki coupling of II-4 with 4-tert-butyloxycarbonylphenylboronic acid yielding II-
21; acylation of II-21 with 4-tert-butyl benzoyl chloride to afford bis-ester II-22; deprotection of 



















































Our synthetic strategy described above appended the peptidic scaffold to a 
carboxylic acid on the opposite terminus of the benzamide functional group. This was 
thought to be the ideal position based on the results of our SAR of the PTS1-free BABA 
derivatives that were evaluated against TbHK1 and the BSF parasite. However, we have 
not previously evaluated substitution of the tert-butyl group with an electron-withdrawing 
carboxylic acid. Furthermore, this substitution (t-Bu to COOH) merits installation of a 
peptidic scaffold, which would be on the opposite terminus when compared to PTS1-
BABA conjugates II-9a and II-9b. It was thought that this substitution would enhance the 
trypanocidal properties of the potent TbHK1 inhibitor, II-1. Using brominated aniline 
derivative II-3 in an acylation with the freshly–prepared acyl chloride of terephthalic acid 
(II-24) and thionyl chloride led to II-26, in which we installed a carboxylic acid in the 
place of a tert-butyl group on II-1 (Scheme 2.13).17,18,19 The methyl ester II-26 was 
saponified using 1 M aqueous lithium hydroxide to afford the diacid II-27. Both 
















Scheme 2.12: Hydrolysis of methyl ester II-8 to diacid II-23.18 Note that II-1p in Table 2.1 is the 




2.3 COMPLETED PEPTIDE SYNTHESES AND DEFINITION OF 
VARIABLES 
Next, BABA methyl ester II-8 was coupled to a peptide sequence of C-LKAGG-N 
or C-LKA(ethylene glycol)-N using SPPS. The methyl ester was saponified by action of 
lithium hydroxide to afford the carboxylic acid of both analogues as shown in Schemes 
2.14 (for II-28 and II-29) and 2.15 (for II-30 and II-31). Subsequently, BABA derivative 
II-26 was coupled to a PTS1 with a diglycine tether to attach the peptidic scaffold 
directly on the benzamide group (for II-32). This derivative was hydrolyzed by action of 
lithium hydroxide to afford the therapeutically active carboxylic acid (II-33 in Scheme 
2.16).  These efforts produced eight PTS1-BABA conjugates (II-28 to II-35) that were 
evaluated against both TbHK1 and trypanosomes in whole-cell assays. 
Scheme 2.13: Acylation of terephthalic acid (II-24) with brominated aniline derivative II-3 affording 
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Scheme 2.14: Hydrolysis of PTS1-BABA-diglycine methyl ester II-28 to afford PTS1-BABA-
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Scheme 2.15: Hydrolysis of PTS1-BABA-diethylene glycol methyl ester II-30 afforded PTS1-BABA-
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This screening yielded four results: percent TbHK1 inhibition, percent BSF 
growth inhibition, percent cell viability, and BSF EC50. The non-conjugated drugs and 
peptide-drug conjugates were screened against TbHK1 and BSF parasites at a standard 
concentration of 10 µM (the limit of detection). The rTbHK1 cultures were incubated 
with the drug or peptide-drug conjugates with the percent inhibition of the enzyme being 
recorded. BSF growth inhibition refers to the cell percentage in a trypanosome culture 
that has been affected by either the drug or the peptide-drug conjugate. In contrast, 
percent cell viability refers to the trypanosome percent cell survival after exposure to the 
drug or peptide-drug conjugate. BSF EC50 refers to a measure of drug or peptide-drug 
conjugate potency against trypanosomes over a specified exposure period. 
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2.3.1  EVALUATION OF PTS1-CONJUGATED BABA CONJUGATES 
The synthesis of the peptide-conjugated BABA derivatives followed the general 
method illustrated in Scheme 1.7 in Chapter One.9-15,28,29 Figure 2.3 shows the 
synthesized BABA peptide-drug derivatives that were screened against TbHK1 and whole 
cell BSF trypanosomes (II-28 to II-35). The data concerning the non-conjugated BABA 




Figure 2.3: Synthesized BABA peptide conjugates (II-28 to II-35). Of the conjugates screened, II-29 
showed mild inhibition of TbHK1. Conjugate II-30 showed high potency against whole cell 



















































































































































































The BABA diacid II-23 elicited a 93.6 ± 2.8% inhibition of TbHK1.6,9-12 In 
comparison, the diesters II-18, II-20, and II-22 did not show any TbHK1 inhibition at 10 
µM. The monoacid BABA candidate II-8 inhibited TbHK1 by 32.42 ± 17.3% at 10 µM. 
This result demonstrates that the presence of a para-carboxyphenyl moiety (required for 
peptide conjugation) does not appreciably affect the activity of the drug scaffold against 
the hexokinase; however, esterification of the carboxylic acid adjacent on the tetra-
substituted arene does have a strong effect in decreasing activity against the enzyme. 
Esterification of this carboxylic acid, as in II-18, II-20, and II-22, eliminated potency 
against the enzyme. PTS1-BABA-methyl ester II-28 was ineffective against TbHK1, 
while its acid analog II-29 displayed a 26.33 ± 3.77% TbHK1 inhibition. Replacing the 
diglycine tether with a diethylene glycol tether afforded conjugate II-30 with a 10.49 ± 
3.55% TbHK1 inhibition. Hydrolysis of ester II-30 led to conjugate II-31 with a 67.52 
± 4.60% TbHK1 inhibition. This data shows that the diethylene glycol tether in 
conjunction with the therapeutically potent carboxylic acid positioned ortho to the amide 
tert-butyl benzoyl group enhances potency against TbHK1.  
Coupling of II-1 to the PTS1 with a diglycine tether did not yield any activity 
against the enzyme (II-34). Furthermore, conjugation of the BABA scaffold directly to the 
PTS sequence without an intervening linker region (i.e. peptide-drug conjugate II-35) led 
to poor inhibition of TbHK1 at 10 µM (10.23 ± 0.27%). ML205 derivative II-26 was 
generated via substitution of the tert-butyl group with a carboxylic acid and exhibited a 
7.57 ± 3.99% TbHK1 inhibition. The diacid II-27 displayed a 29.95 ± 29.95% TbHK1 
inhibition. As expected from the SAR data, replacement of the tert-butyl group decreased 
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potency against TbHK1.6,9-12 While peptide-drug conjugate II-32 exhibited 10.97 
± 0.44% TbHK1 inhibition, conjugate II-33 exhibited a TbHK1 inhibition of 15.75 
± 12.61% TbHK1 inhibition. This reflects that positioning of the peptidic scaffold off the 
benzamide functional group (II-32 and II-33) does not appreciably enhance the activity 
of the PTS1-BABA conjugate against TbHK1 when compared to PTS1-BABA conjugate 
II-30 and II-31, bearing an ethylene glycol tether (data in Table 2.2). The inhibition of 
TbHK1 demonstrated by II-32 is interesting when compared with II-28, bearing a 
diglycine tether, which did not display any activity against the enzyme. The activity 
against TbHK1 of II-33 was slightly decreased when compared to II-29, bearing a 
diglycine tether. A TbHK1 IC50 value of 6.83 ± 0.23 µM was only realized for II-31, the 
most potent enzyme-inhibiting PTS1-BABA conjugate. 
With respect to BSF growth inhibition, and from the SAR conducted by Morris et 
al., the diacid II-23 showed 51.0 ± 14.3% BSF growth inhibition and ML205 displayed 
6.9 ± 3.0% BSF growth inhibition. BABA methyl ester II-18 and benzyl ester II-20 had 
BSF growth inhibitions of 8.91 ± 12.26% and 9.57 ± 9.73%, respectively. BABA tert-
butyl ester II-22 displayed a BSF growth inhibition of 14.81 ± 7.69%. On the other hand, 
BABA monoacid II-8 had a BSF growth inhibition of 24.50 ± 6.77%. ML205 (II-1) 
derivative II-26 revealed a 29.11 ± 6.08% BSF growth inhibition with its corresponding 
diacid II-27 demonstrating a 23.63 ± 1.31% BSF growth inhibition. It is clear based on 
this data of the non-conjugated drugs that the most potent candidate in a whole cell assay 
against trypanosomes was BABA diacid II-23. ML205 (II-1) derivative II-26 had a 
similar potency when compared to II-8 against trypanosomes, while II-27 demonstrated a 
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significantly reduced potency in comparison to both II-8 and II-23. This showed that 
more potency was achieved by substitution of the bromine on II-1 (Figure 2.1) with a 
carboxyphenyl ring, rather than replacement of the tert-butyl group with a carboxylic 
acid (data in Table 2.2). Based on these results, both the carboxyphenyl ring and the tert-
butyl group are necessary. Peptide-drug conjugates II-28 and II-29 (possessing a 
diglycine tether) and II-35 (BABA directly coupled to PTS1) showed 0% BSF growth 
inhibition. The most potent analog of all BABA conjugates was II-30 that showed 100% 
BSF growth inhibition via substitution of the diglycine tether with a diethylene glycol 
tether. The corresponding acid II-31 showed a lower BSF growth inhibition of 38.96 
± 11.14%. We hypothesize, based on this result, that PTS1-BABA methyl ester II-30 acts 
as a pro-drug (a therapeutic precursor that is metabolized into the active drug within the 
cell) that is hydrolyzed within the cell to reveal the active PTS1-BABA acid II-31 that 
inhibits TbHK1, though this hypothesis must be confirmed. Peptide-drug conjugates II-
32 and II-33, wherein PTS1 was attached to the benzamide group, displayed 0% BSF 
growth inhibition, indicating that migration of the peptide to the opposite terminus of the 
BABA scaffold did not enhance the PTS1-BABA conjugate’s potency. Peptide-drug 
conjugate II-34 in which II-1 was directly attached to C-LKAGG-N was not active 
against BSF trypanosomes demonstrating 9.97 ± 6.79% BSF growth inhibition. A BSF 
EC50 was only detected for one BABA peptide-drug conjugate (C-LKA-diethylene glycol-
BABA (methyl ester)-N) II-30 (6.76 ± 1.53 µM), with the other samples yielding values 




2.3.2 FITC-COUPLED PTS1-BABA PEPTIDE CONJUGATES 
Additional peptide conjugates were prepared bearing a fluorophore to 
demonstrate localization of our most potent peptide conjugates within the trypanosome, 
specifically into the glycosome, the organelle where the enzyme of interest, TbHK1, is 
housed.6,9-12,28,29 One conjugate (II-36 in Figure 2.4) was prepared in which a 
fluorophore, FITC, was attached to the PTS1 with a diglycine linker and II-1 (Figure 











II-8 32.42 ± 17.30 22.95 ± 11.81 24.50 ± 6.77 >10
II-18 0 >10 8.91 ± 12.26 >10
II-20 0 >10 9.57 ± 9.73 >10
II-22 0 >10 14.81 ± 7.69 >10
II-23 93.60 ± 2.80 3.50 ± 0.33 51.00 ± 14.30 -
II-26 7.57 ± 3.99 >10 29.11 ± 6.08 >10
II-27 29.95 ± 6.63 >10 23.63 ± 1.31 >10
II-28 0 >10 0 >10
II-29 26.33 ± 3.77 >10 0 >10
II-30 10.49 ± 3.55 >10 100 6.76 ± 1.53
II-31 67.52 ± 4.60 6.83 ± 0.23 38.96 ± 11.14 >10
II-32 10.97 ± 0.44 >10 0 >10
II-33 15.75 ± 12.61 >10 0 >10
II-34 0 >10 9.97 ± 6.79 >10
II-35 10.23 ± 0.27 >10 0 >10
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2.4).28,29 Another peptide conjugate (II-37 in Figure 2.4) was prepared in which the FITC 
was attached to a lysine residue via replacement of the first glycine in the tether, i.e. the 
PTS1 was free of molecular cargo. A control peptide was also synthesized bearing FITC 
on the PTS1 and a diglycine tether that was capped with an acetyl group in lieu of II-1. 
These peptide conjugates were screened against TbHK1 and BSF trypanosomes (as 
shown in Table 2.3). We discovered that greater enzyme inhibition was achieved in 
response to a PTS1-FITC-BABA conjugate that was free of molecular cargo on the PTS1 
(20.53 ± 10.19% for II-36 compared to 61.0 ± 4.23% for II-37 in Table 2.3). Installation 
of FITC adjacent to the PTS1 also demonstrated greater potency against BSF parasites 
(29.39 ± 15.9% for II-36 compared to 46.1 ± 10.86% for II-37 in Table 2.3). The control 
peptide II-38, bearing FITC on the PTS1 with a diglycine tether capped by an acetyl 
group, was ineffective against TbHK1 and BSF trypanosomes. Coupling FITC to our 
most potent PTS1-BABA conjugate (II-30) against BSF parasites resulted in a PTS1-
FITC-BABA conjugate (II-39 in Figure 2.4) that had lost its effectiveness against the 
BSF parasite and demonstrated marginal activity against TbHK1 (3.48 ± 1.15% 
inhibition). 
Use of FITC allowed for visualization of our PTS1-FITC-BABA conjugate within 
both procyclic and BSF trypanosomes. Figure 2.5 shows an image of a procyclic 
trypanosome (panel A). Panel B in Figure 2.5 shows localization of our PTS1-FITC-
BABA II-37 in the procyclic trypanosome. Panel C in Figure 2.5 shows the expression of 
PTS2-mCherry in the glycosomal compartment of the procyclic trypanosome. mCherry is 
expressed as a transgene introduced by electroporation.12 The fusion protein, a PTS-2 
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bearing mCherry protein, is targeted, post-synthesis, to the glycosome via assistance from 
chaperone proteins.12 Finally, Panel D in Figure 2.5 is a composite image that 
demonstrates that our peptide co-localizes with the glycosomal compartment of the 
trypanosome where TbHK1 is housed.  
As is shown in Figure 2.6, the peptide conjugate II-37 did indeed localize within 
the glycosomal compartment of the BSF trypanosomes. The expression of PTS2-
mCherry in the glycosomal compartment of trypanosomes is evidenced in panel B of 
Figure 2.6. The expression of our FITC-conjugated peptide derivative II-37 is shown to 
localize within the trypanosomes in panel C in Figure 2.6. Composite images (panels D 
and E) demonstrate that our peptide conjugate does in fact localize within the glycosome 
of trypanosomes. Although functionalization of the PTS1 with FITC did not hinder entry 
of the peptide conjugate within the trypanosome, it was more effective against TbHK1 
and the BSF parasite to conjugate the fluorophore adjacent to the PTS1 rather than place 
the molecular cargo directly onto the PTS1 (as evidenced by the data presented in Table 
2.3).  
Conjugation of FITC to our most potent PTS1-BABA conjugate (II-30) afforded 
PTS1-FITC-BABA conjugate II-39, which showed a complete loss of activity toward the 
inhibition of BSF trypanosomes (Figure 2.7). The expression of PTS2-mCherry in the 
glycosome of procyclic and BSF trypanosomes is evidenced in panels B and F, 
respectively. The expression of our FITC-conjugated peptide derivative II-39 is shown to 
localize within the trypanosomes in panel C (procyclic trypanosomes) and panel G (BSF 
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trypanosomes). Composite images (panels D and H) demonstrate that our peptide 



















































































































Table 2.3: Biological data for FITC-tagged peptide conjugates. 
Structure TbHK1% inhibition (10 µM)
TbHK1 IC50 (10 
µM)




II-36 20.53 ± 10.19 >10 29.39 ± 15.9 >10
II-37 61.0 ± 4.2 4.26 ± 0.77 46.1 ± 10.86 >10
II-38 0 >10 0 >10
II-39 3.48 ± 1.15 >10 0 >10
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Figure 2.5:  Localization of conjugate II-37 into the glycosome of procyclic T. brucei.  (A) DIC image of 
procyclic T. brucei. (B) Green fluorescent PTS1-FITC-BABA conjugate II-37 localized into glycosomes. 





















 TbHK1 IC50 = 4.26 ± 0.77 µM
% growth inhibiton (BSF T. brucei) = 46.1 ± 10.9%
FITC
II-37
A B C D
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Figure 2.6:  Localization of conjugate II-37 into the glycosome of BSF T. brucei.  (A) DIC image of 
live BSF T. brucei. (B) PTS2-mCherry localized into glycosomes. (C) Green fluorescent PTS1-FITC-






















 TbHK1 IC50 = 4.26 ± 0.77 µM






2.4  CONCLUSIONS AND FUTURE DIRECTIONS 
Trypanosomes are highly virulent parasites that are responsible for HAT, a 
disease that has the potential to affect a large population of people in sub-Saharan Africa.  
BABA is a novel therapeutic scaffold that has been shown to be potent against TbHK1 
and trypanosomes through a SAR by Sharlow, et al.6,9-12 This portion of the thesis work 
detailed the synthesis of a variety of novel, esterified BABA derivatives (II-18, II-20, and 
II-22), as well as a novel BABA derivative II-8, followed by a discussion of a library of 
novel PTS1-BABA conjugates that were screened against both TbHK1 and BSF 
PF 
BSF 























%TbHK1 inhibition = 3.48 ± 1.15%
% growth inhibition (BSF T. brucei) = 0%
II-39
B A C D 
E F G H 
Figure 2.7: Localization of conjugate II-39 into the glycosome of procyclic and BSF T. brucei. (A) 
DIC image of procyclic T. brucei. (B) PTS2-mCherry localized into glycosomes. (C) Green fluorescent 
PTS1-FITC-BABA conjugate II-39 localized into glycosomes. (D) Merged images of B and C. (E) DIC 
image of BSF T. brucei. (F) PTS2-mCherry localized into glycosomes. (G) Green fluorescent PTS1-
FITC-BABA conjugate II-39 localized into glycosomes. (H) Merged images of F and G. 
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trypanosomes. In contrast to our work with the Ebselen drug suite as discussed in Chapter 
One, our results with the BABA drug suite indicate a positive result with respect to our 
hypothesis for the targeted delivery of our therapeutic across the trypanosome membrane 
toward the glycosome where the TbHK1 is house via utilization of PTS1. We conjugated 
our BABA derivative to the PTS1 using a diglycine tether and were not able to detect 
marginal activity against the enzyme (II-28 in Table 2.2) and we did not detect any 
activity against the BSF parasite (II-29 in Table 2.2). Appending the peptidic scaffold to 
the benzamide group did not improve this result (II-32 and II-33 in Table 2.2). 
Amazingly, substitution of the tether with the more polar diethylene glycol species 
enhanced the potency of the PTS1-BABA conjugate through complete inhibition of the 
BSF parasites (II-30 in Table 2.2). The conjugate acid of this PTS1-BABA conjugate (II-
31 in Table 2.2) demonstrated a high degree of TbHK1 inhibition. It is hypothesized that 
PTS1-BABA methyl ester II-30 acts as a pro-drug and is metabolized by the trypanosome 
into the active PTS1-BABA acid II-31 within the cell. It is also thought that perhaps the 
PTS1-BABA peptide is metabolized as soon as it crosses the trypanosome membrane to 
release the BABA therapeutic in the trypanosome. The PTS1 in this scenario merely acts 
as a carrier to facilitate passage of BABA across the trypanosome membrane. A 
combination of FITC on the PTS1 and Alexa Fluor 647 positioned on either the tether or 
the BABA drug candidate may allow us to validate this claim and allow for the 
visualization of the decomposition of the peptide within the parasite, if that is the mode 
by which the drug is being introduced to the BSF trypanosome. If the whole PTS1-BABA 
conjugate is being delivered to the glycosomal compartment of the trypanosome, no 
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fluorescence would be observed due to quenching of the two fluorescent markers. If the 
PTS1 is being cleaved from the BABA therapeutic, fluorescence of either one or both 
fluorescent markers would be observed. The most important result from this thesis work 
is the demonstration of a drug-delivery strategy based on tagging potent enzyme 
inhibitors with a PTS1 sequence that can localize the drug in the appropriate cellular 
compartment that may signal the beginning of a novel treatment strategy for patients 
suffering from African sleeping sickness.  
Another route for modification of this drug suite is use of a different PTS1. The 
PTS1 used in the work reported herein is C-LKA-N; however, homologous modifications 
might lead to more potent peptide-drug conjugates.13-15 For instance, the leucine can be 
replaced with an isoleucine; the lysine can be replaced with an amino acid bearing a basic 
side-chain (or acidic at neutral pH), such as asparagine, glutamine, or histidine; and the 
alanine can be replaced with a similarly-sized or nonpolar amino acid, such as valine, 
cysteine, or serine.13-15 In order to determine the most effective PTS1, a standard tether 
(such as diglycine or diethylene glycol) would need to be used to ensure that any change 
in potency of the peptide-drug conjugate can be attributed solely to a change in the PTS1.  
Our advantageous	 result with respect to PTS1-BABA conjugates II-30 and II-31 
alerts us to the role the tether plays in delivering molecular cargo across the trypanosomal 
membrane. The tether could be just as important as the PTS1 and the drug itself; 
however, this must be further evaluated with modifications to the tether. Once a potent 
PTS1 is determined, then a variety of tethers can be screened to further increase potency 
of the peptide-drug conjugate. Two tethers that would make for an interesting study are 
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lysine-glycine (used with respect to our PTS1-FITC-BABA conjugates) and triethylene 
glycol, a longer version of the successful diethylene glycol tether that was employed with 
II-30. Furthermore, one can envision that unnatural amino acids (ones that are not 
coded), such as formylmethionine or pyrrolysine, could also be incorporated into the 
tether. As fluorine derivatives are prevalent throughout the medicinal chemistry literature, 
use of fluorinated amino acids in the tether, such as a trifluoromethylated analog of 
alanine, would make for an interesting case study with respect to the novel BABA drug 
suite reported herein. 
Additionally, the value of the most active BABA-peptide conjugate II-30 with 
respect to mouse modeling and cell imaging studies will be critical as this conjugate 
transitions from an in vitro to in vivo therapeutic. In order to circumvent the degradation 
of the peptide scaffold in living organisms and to ensure that the molecular cargo reaches 
its destination, it will be important to test more stable peptide-like backbones. Two such 
scaffolds that would be interesting from a biological perspective and for assays would be 
peptoids and peptidines. Peptoids have been well-characterized for their stability in 
aqueous environments, but work related to the applicability of peptidines is in its 
infancy.30 Whereas a peptoid has a peptide bond in which the nitrogen of the amide is 
functionalized with the R group of an amino acid, peptidines possess di-substituted 
glycine-derived amidines (Figure 2.8). The use of peptidines with respect to our potent 
BABA analog would lead to an interesting case study with respect to the marketability of 
these derivatives as potent therapeutics against BSF trypanosomes.30 
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With the results reported in hand, the medicinal relevance of the BABA drug suite 
can be extended to other infectious diseases, such as leishmaniasis. Leishmaniasis is 
prevalent in 98 countries with over 100 million people at risk for infection in East Asia, 
East Africa, and Brazil.16 Leishmania protozoa belong to the Trypanosomatidae family, 
with over 20 species showing pathogenicity in mammals.16 The disease is transmitted by 
hematophagous sand flies, in contrast to the tsetse fly responsible for the transmission of 
HAT, with the same mode of transmission as that depicted in Figure 1.1 in Chapter One. 
Similar to HAT, kinase targets in both humans and mammals are useful for the 
development of therapeutic inhibitors of kinetoplastid parasites, such as Leishmania sp. 
Another disease that may be of greater interest to residents of the United States is Chagas 
disease, also called American Trypanosomiasis, caused by Trypanosoma cruzi.31 Unlike 
HAT, which is caused by the transmission of trypanosomes via a tsetse fly vector, Chagas 
disease is caused by the transmission of T. cruzi via blood-sucking triatomine bugs.31 As 
both diseases are caused by a parasite within the Trypanosomatidae family, future work 
related to the extension of the BABA drug suite toward the inhibition of other 
trypanosomal species responsible for infectious diseases will allow for the development 
of novel BABA therapeutics that will highlight the potential of this novel drug 
scaffold.16,31 













One of the difficulties associated with our study of the BABA drug suite is that we 
do not fully understand the biochemistry (or the mechanism of action) of the PTS, the 
tether, nor the BABA drug itself. Although this is a topic available for further evaluation, 
we endeavored to obtain some preliminary understanding of whether our peptide-drug 
conjugates were targeting the hexokinase TbHK1 (the desired target) via conjugation of 
FITC to our PTS1, followed by attachment of the diglycine tether capped by (+)-biotin 
(II-40 in Figure 2.9). The trypanosomes will be exposed to the PTS1-FITC-(+)-biotin 
conjugate, followed by lysing of the cells. The cell lysate will then be passed through a 
streptavidin column that will ideally bind to the PTS1-FITC-(+)-biotin conjugate bound 
to TbHK1. It is expected that the PTS1-FITC-(+)-biotin conjugate will bind to other 
transport and chaperone proteins on its way to the glycosomal compartment of the 
trypanosome. Following isolation of the PTS1-FITC-(+)-biotin-protein complexes, mass 
spectrometry can be used to determine which proteins have bound to the PTS1-FITC-(+)-
biotin conjugate. Our preliminary results with II-40 suggest weak enzyme inhibition 
(%TbHK1 inhibition is equal to 6.984 ± 0.182%) as would be expected with this peptide 
conjugate, as (+)-biotin is not a potent TbHK1 inhibitor compared to BABA. With this 
data in hand, the next phase with respect to this investigation will be to utilize II-40 as a 
preliminary molecular probe to investigate the cellular machinery that is responsible for 
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2.5  EXPERIMENTAL 
2.5.1  TRYPANOSOME GROWTH AND VIABILITY ASSAYS  
BSF 90-13 T. brucei, a 427 strain, was grown as described previously.33,34 To score 
viability, parasites (1 x 104/mL BSF) were seeded into 96-well clear-bottomed 
polystyrene plates in 200 µL HMI-9 supplemented with 10% fetal bovine serum and 10% 
Serum Plus (Sigma-Aldrich, St. Louis, MO) and grown in the presence of compound (2 
µL) or equivalently diluted carrier for 3 days in 5% CO2 at 37 ˚C.  All assays were 
performed in triplicate.  After incubation (72 hr, at 37 °C), CellTiter-Blue (Promega) was 
added and fluorescence measured (560Ex/590Em). 
Purification of Bacterially Expressed TbHK1 and enzyme assay: 
For purification of bacterially expressed TbHK1 (rTbHK1), a starter culture of E. coli 
M15(pREP) harboring pQE30 (Qiagen, Valencia, CA) with the TbHK1 gene cloned in 
frame of a 6-His tagging sequence was grown to an OD of ~1 and then induced for 24 h 
at room temperature with 0.25 µM isopropyl β-D-1-thiogalactopyranoside (IPTG) and 
purified as described previously.35   
HK assays were performed in triplicate as described using a coupled reaction to 
measure enzyme activity.35,36 In short, the coupled assay uses glucose-6-phosphate 
dehydrogenase (G6PDH) to convert glucose-6-phosphate (G6-P) generated by HK to 6-
phosphogluconate with coincident reduction of NADP to NADPH, which is monitored 
spectrophotometrically at 340 nm.  Note that the drugs were found to be ineffective in a 
counterscreen for inhibition of G6PDH.  Kinetic analyses were performed using 
KaleidaGraph 4.1 (Synergy Software, Reading, PA). 
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2.5.2  SYNTHESIS OF DRUGS AND PEPTIDE-DRUG CONJUGATES 
All reagents were purchased from commercial suppliers and used without further 
purification. All isolated products were purified via flash column chromatography using 
silica gel SDS 60 C.C. 40-63 µm. 1H and 13C NMR spectra were collected at ambient 
temperature on a 300 (Bruker Avance) or 500 MHz NMR spectrometer (Bruker Avance 
or JEOL Eclipse). Chemical shifts are reported in parts per million (ppm) and referenced 
to residual solvent peaks (i.e., d 7.28 ppm for 1H NMR, 77 ppm for 13C NMR in CDCl3; 
2.54 ppm for 1H NMR, 40.45 ppm for 13C NMR in DMSO-d6). Data are presented as 
follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet), 
and integration. Infrared (IR) spectra, reported in cm-1, were collected using a Fourier 
transform spectrophotometer. Compounds II-1,18 II-3,18 II-4,17 II-1118, and II-2318 were 
prepared using known methods and exhibited spectral data consistent with previously 
reported syntheses.  
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Synthesis of 4-chloro-5-[4-carboxyphenyl]-[2-tert-butylbenzamido]-methyl benzoate (II-
8) 
 
 To a dry, 100 mL round-bottomed flask was added a stirbar, II-22 (411.9 mg, 
0.789 mmol, 1 equiv), and 0.1 M anhydrous DCM. To the round-bottomed flask was 
added trifluoroacetic acid (2.6 mL, 37.5 mmol, 44.1 equiv). The reaction mixture was 
stirred overnight under N2 at room temperature. The solvent was evaporated the 
following day. Ice-cold diethyl ether (10 mL) was added to the mixture and evaporated. 
This procedure was repeated twice more. The residue was dissolved in 25 mL ethyl 
acetate and washed with 25 mL 1 M aq. HCl and 25 mL saturated sodium chloride. The 
combined aqueous layers were washed with ethyl acetate (2 x 25 mL). The combined 
organics were dried with sodium sulfate, filtered, and evaporated onto silica. Product II-8 
was obtained in 97% yield (356.1 mg) after column chromatography with hexanes:ethyl 











1H-NMR (500 MHz, DMSO-d6): d 12.99 (s, 1H), 11.71 (s, 1H), 8.87 (s, 1H), 
8.04-8.02 (d, 2H), 7.93 (s, 1H), 7.87-7.85 (d, 2H), 7.61-7.59 (d, 2H), 7.55-7.54 (d, 
2H), 3.89 (s, 3H), 1.312 (s, 9H); 13C-NMR (125 MHz, DMSO-d6): d 167.7, 167.4, 
165.3, 156.1, 142.0, 141.3, 137.5, 133.7, 133.4, 131.4, 130.8, 129.9, 129.8, 127.4, 
126.4, 121.4, 115.8, 53.4, 35.3, 31.3. IR (cm-1; NaCl salt plate): 2958, 2923, 2853, 
1732, 1685, 1653, 1636, 1608, 1579, 1559, 1541, 1519, 1507, 1491, 1457, 1437, 
1419, 1377, 1312, 1268, 1233; Rf (1:1 ethyl acetate:hexanes with 3% acetic 
acid)= 0.43; melting point = decomposed above 260 ˚C; HRMS: EXPECTED 
466.9378; FOUND: 466.1248. 
 
Synthesis of II-1118 
 
 To a dry, 250 mL round-bottomed flask was added a stirbar, II-3 (3.34 g, 12.6 
mmol, 1 equiv), triethylamine (3.52 mL, 25.2 mmol, 2.0 equiv), and 50 mL anhydrous 
DCM. Then, 4-tert-butyl-benzoyl chloride (5.85 mL, 13.9 mmol, 1.1 equiv) was added 






nitrogen. The reaction mixture was cooled and the precipitate that formed was filtered. 
The filtrate was then evaporated and the residue was taken up in 50 mL ethyl acetate. The 
reaction mixture was washed sequentially with saturated aq. sodium bicarbonate (100 
mL) and saturated aq. brine (100 mL). The combined aqueous layers were washed with 
ethyl acetate (1 x 75 mL). The combined organics were dried with sodium sulfate, 
filtered, and evaporated onto silica. Product II-11 was obtained by column 
chromatography with hexanes:ethyl acetate (0 to 20%) in 39% yield (2.07 g). 
 
Compound II-1118 
1H-NMR (500 MHz, CDCl3): d 11.89 (s, 1H), 9.14 (s, 1H), 8.18 (s, 1H), 7.94-7.89 
(d, 2H), 7.55-7.51 (d, 2H), 3.94 (s, 3H), 1.37 (s, 9H); 13C-NMR (125 MHz, 
CDCl3): d 167.4, 165.6, 162.5, 158.5, 156.0, 141.5, 141.2, 135.3, 131.3, 130.6, 
127.2, 126.2, 125.9, 121.8, 114.9, 114.7, 53.2, 35.31, 35.1, 31.3; IR (cm-1; NaCl 
salt plate): 3421, 2961, 2868, 1699, 1683, 1596, 1573, 1493, 1437, 1371, 1305, 
1271, 1253, 1228, 1123, 1088, 1105, 1023, 932, 899, 850, 788, 766, 697, 657; Rf 













Synthesis of 4-chloro-5-bromo-[2-tert-butylbenzamido]-tert-butyl benzoate (II-12) 
 
 
 To a dry, 500 mL round-bottomed flask was added a stirbar, II-11 (5.81 g, 9.1 
mmol, 1 equiv), and 65 mL DMF. Then, N,N-carbonyldiimidazole (1.47 g, 1 mmol, 1 
equiv) was added the solution stirred at 80 ˚C for 22 hours under nitrogen (monitored by 
TLC). N,N-carbonyldiimidazole (1.47 g, 1 mmol, 1 equiv) was added again and the 
solution was stirred at 80 ˚C for 1 h. Next, tert-butyl alcohol (1.79 mL, 18.2 mmol, 2 
equiv) and DBU (1.36 mL, 9.1 mmol, 1.0 equiv) were added and the solution stirred at 80 
˚C overnight. The reaction mixture was cooled to RT and diluted with 100 mL diethyl 
ether. The reaction mixture was washed sequentially with 10% aq. HCl (40 mL), 
saturated aq. brine (50 mL), and saturated aq. sodium bicarbonate (50 mL). The 
neutralized aqueous layer was washed with diethyl ether (100 mL). The combined 
organics were dried with sodium sulfate, filtered, and then evaporated onto silica. Product 
II-12 was obtained via column chromatography using hexanes and ethyl acetate as eluent 









Rf (4% triethylamine/ethyl acetate) = 1.0 
1H-NMR (500 MHz, CDCl3): d 9.19 (s, 1H), 8.19 (s, 1H), 7.98-7.96 (d, 2H), 
7.563-7.55 (d, 2H), 1.66-1.65 (s, 9H), 1.37-1.34 (s, 9H); 13C-NMR (125 MHz, 
CDCl3): d 166.4, 165.5, 155.8, 141.6, 140.3, 135.37, 131.5, 129.4, 127.3, 127.2, 
125.8, 125.3, 121.8, 116.5, 114.6, 83.7, 35.0, 31.18, 28.2; IR (cm-1; NaCl salt 
plate): 3293, 3246, 3112, 2964, 2869, 1720, 1682, 1637, 1655, 1647, 1593, 1572, 
1491, 1394, 1371, 1314, 1272, 1251.86, 1199.26, 1157, 1122, 1106, 1087, 1016, 
906, 850, 789, 767, 697, 659; Rf (4% triethylamine/ethyl acetate) = 1.0; melting 
point = 149–152 ˚C. 
 
Synthesis of 4-chloro-5-[4-methoxycarbonylphenyl]-[2-tert-butylbenzamido]-benzoic 
acid (II-15) 
 
 To a dry, 100 mL round-bottomed flask was added a stirbar, II-11 (0.100 g, 0.153 








equiv), Pd(dtbpf)Cl2 (1.99 mg, 0.003 mmol, 0.02 equiv), K2CO3 (32.0 mg, 0.23 mmol, 
1.5 equiv), and 30 mL of a 3:2 mixture of acetonitrile:water. The solution was refluxed 
overnight under nitrogen. The reaction mixture was cooled to room temperature and 
evaporated. The residue was dissolved in 50 mL DCM. The reaction mixture was washed 
with 50 mL saturated aq. sodium bicarbonate and 50 mL saturated aq. brine. The 
combined aqueous layers were washed with 10 mL DCM. The combined organics were 
dried with sodium sulfate, filtered, and evaporated onto silica. The monoester II-15 was 
obtained in 55% yield (62.4 mg) via column chromatography with dichloromethane:(0-
10%) methanol. 
 
 Compound II-15 
Rf (10% methanol/DCM) = 0.4 
1H-NMR (500 MHz, DMSO-d6): d 8.94 (s, 1H), 8.16 (s, 1H), 8.02-8.00 (d, 2H), 
7.98-7.96 (d, 2H), 7.58-7.53 (m, 4H), 3.87 (s, 3H), 1.30 (s, 12H); 13C-NMR (75 
MHz, DMSO-d6): d 170.1, 166.9, 165.3, 155.4, 143.9, 142.1, 141.5, 136.4, 132.4, 
132.2, 130.2, 129.6, 129.1, 127.8, 125.9, 123.5, 120.3, 119.7, 52.5, 35.3, 31.4; IR 
(cm-1; NaCl salt plate): 3113, 2963, 2869, 2586, 2499, 1720, 1679, 1608, 1581, 
1519, 1493, 1462, 1436, 1411, 1367, 1276, 1235, 1205, 1107, 1021, 996, 938, 
918, 907, 858, 847, 827, 795, 771, 730, 715, 701; Rf (10% methanol/DCM) = 0.4; 







Synthesis of 4-chloro-5-[4-carboxyphenyl]-[2-amino]-methyl benzoate 
 (II-16) 
 
 To a dry, 100 mL round-bottomed flask was added a stirbar, II-3 (0.250 g, 0.945 
mmol, 1 equiv), 4-carboxyphenylboronic acid (0.188 g, 1.134 mmol, 1.2 equiv), 
anhydrous potassium carbonate (0.198 g, 1.418 mmol, 0.53 equiv), and [1,1’-bis(di-tert-
butylphosphino)ferrocene]dichloropalladium(II) (0.012 g, 0.019 mmol, 0.02 equiv). The 
solids were taken up in a 9:1 mixture of acetonitrile:H2O and refluxed under N2 for 48 h. 
The reaction mixture was cooled to room temperature and filtered through a plug of 
Celite. The Celite cake was rinsed with ethyl acetate (100 mL), DCM (100 mL), and 
MeOH (100 mL). The filtrate was then dried with sodium sulfate, filtered, and evaporated 
onto silica. The reaction mixture was isolated in 43% yield (124.3 mg) after purification 
via column chromatography with dichloromethane:(0-10%) methanol to obtain the 
desired aniline derivative. 
 
Compound II-16 
1H-NMR (500 MHz, DMSO-d6): d 8.01-7.99 (d, 2H), 7.71 (s, 1H), 7.47-7.46 (d, 







d 167.6, 167.4, 151.9, 143.1, 137.2, 133.8, 129.9, 129.6, 129.0, 125.8, 117.3, 
108.8, 52.2; IR (cm-1; NaCl salt plate): 2919, 2850, 1693, 1652, 1605, 1574, 1557, 
1506.47, 1489, 1456, 1433, 1373, 1234, 1184, 1102, 1018, 924, 773.32, 710.90; 
Rf (10% methanol/DCM) = 0.56-0.54; melting point = decomposes above 244 ˚C. 
 
Synthesis of 4-chloro-5-[4-methoxycarbonylphenyl]-[2-amino]-methyl benzoate 
(II-17) 
 
 To a dry, 100 mL round-bottomed flask was added a stirbar, II-3 (0.250 g, 0.945 
mmol, 1 equiv), 4-methoxycarbonylphenylboronic acid (204 mg, 1.134 mmol, 1.2 equiv), 
anhydrous potassium carbonate (0.198 g, 1.418 mmol, 1.5 equiv), and [1,1’-bis(di-tert-
butylphosphino)ferrocene]dichloropalladium(II) (0.012 g, 0.019 mmol, 0.02 equiv). The 
solids were taken up in a 9:1 mixture of acetonitrile:H2O and refluxed under N2 for 48 
hours. The reaction mixture was cooled to room temperature and filtered through a plug 
of Celite. The Celite cake was rinsed with ethyl acetate (100 mL), DCM (100 mL), and 
MeOH (100 mL). The filtrate was then dried with sodium sulfate, filtered, and evaporated 
onto silica. The reaction mixture was purified via column chromatography with 










1H-NMR (500 MHz, CDCl3): d 8.11-8.09 (d, 2H), 7.89 (s, 1H), 7.53-7.51 (d, 2H), 
6.84 (s, 1H), 5.89 (s, 2H), 3.97 (s, 3H), 3.89 (s, 3H); 13C-NMR (125 MHz, 
CDCl3): d 167.8, 166.9, 150.4, 143.4, 138.1, 133.8, 129.7, 129.3, 128.9, 127.8, 
117.2, 109.8, 52.1, 51.8; IR (cm-1; NaCl salt plate): 2917, 2848, 1706, 1653, 1625, 
1608, 1590, 1545, 1521, 1507, 1489, 1474, 1457, 1434, 1419, 1396, 1374, 1335, 
1289, 1253, 1234, 1189, 1094, 1019, 967, 924, 848, 835, 785, 772, 746, 731, 713, 
700; Rf (10% methanol/DCM) = 0.97; melting point = 162–164 ˚C. 
 
Synthesis of 4-chloro-5-[4-methoxycarbonylphenyl]-[2-tert-butylbenzamido]-methyl 
benzoate (II-18) 
 
 To a dry, 100 mL round-bottomed flask was added a stirbar, 4-tert-butyl benzoic 
acid (21 mg, 0.118 mmol, 1 equiv), and 5 mL anhydrous DCM. To this solution was 








0 ˚C in an ice/water bath, then thionyl chloride (1 M in DCM) (0.130 mL, 0.130 mmol, 
1.1 equiv) were added. The solution was stirred at 0 ˚C for 30 min. and the solvent was 
evaporated. The residue was re-dissolved in 5 mL anhydrous dichloromethane and 
triethylamine (0.025 mL, 0.177 mmol, 1.5 equiv). The solution was cooled to 0 ˚C, then 
II-17 (37.6 mg, 0.118 mmol, 1 equiv) in 5 mL anhydrous DCM and triethylamine (0.025 
mL, 0.177 mmol, 1.5 equiv) was added to the acyl chloride slowly. The reaction mixture 
was stirred at 0 ˚C for 30 min., then brought to room temperature under nitrogen for 48 
hours. The reaction mixture was then evaporated directly onto silica and purified via 
column chromatography with DCM:(0-5%) methanol to afford II-18 in 34% (19.4 mg). 
 
Compound II-18 
1H-NMR (500 MHz, CDCl3): d 12.079 (s, 1H), 9.24 (s, 1H), 8.15-8.14 (d, 2H), 
8.09 (s, 1H), 8.03-8.02 (d, 2H), 7.60-7.59 (d, 2H), 7.57-7.55 (d, 2H), 3.997 (s, 
3H), 3.98 (s, 3H), 1.39 (s, 9H); 13C-NMR (125 MHz, CDCl3): d 168.3, 166.8, 
165.7, 155.9, 142.8, 142.1, 139.2, 133.7, 133.1, 131.5, 129.6, 129.5, 127.3, 125.9, 
121.7, 113.8, 52.7, 52.2, 35.1, 31.2; IR (cm-1; NaCl salt plate): 2955, 2925, 2869, 
1723, 1696, 1682, 1653, 1608, 1581, 1540, 1518, 1492, 1456, 1435.75, 1408, 
1397, 1379, 1311, 1275, 1233, 1192, 1182, 1111, 1019, 967, 932, 899, 850, 829, 
791, 775, 754, 717, 699, 626, 603; Rf (1:1 ethyl acetate:hexanes) = 0.79-0.70; 







Synthesis of 4-chloro-5-[4-benzyloxycarbonylphenyl]-[2-amino]-methyl benzoate (II-19) 
 
 
 To a dry, 100 mL round-bottomed flask was added a stirbar, II-3 (0.250 g, 0.945 
mmol, 1 equiv), 4-benzyloxycarbonylphenylboronic acid (0.259 g, 1.134 mmol, 1.2 
equiv), anhydrous potassium carbonate (0.198 g, 1.418 mmol, 1.5 equiv), and [1,1’-
bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (0.012 g, 0.019 mmol, 0.02 
equiv). The solids were taken up in a 9:1 mixture of acetonitrile:H2O and refluxed under 
N2 for 48 hours. The reaction mixture was cooled to room temperature and filtered 
through a plug of Celite. The Celite cake was rinsed with ethyl acetate (100 mL), DCM 
(100 mL), and MeOH (100 mL). The filtrate was then dried with sodium sulfate, filtered, 
and evaporated onto silica. The reaction mixture was purified via column 













1H-NMR (500 MHz, CDCl3): d 7.88 (s, 1H), 7.52-7.50 (d, 2H), 7.47-7.44 (d, 2H), 
7.40-7.37 (m, 3H), 7.07-7.06 (d, 2H), 6.83 (s, 1H), 5.82 (s, 2H), 5.15 (s, 2H), 3.89 
(s, 3H); 13C-NMR (125 MHz, CDCl3): d 168.0, 158.1, 149.8, 138.6, 137.0, 133.8, 
131.6, 130.8, 128.7, 128.5, 128.1, 127.8, 127.6, 117.1, 114.4, 109.8, 70.1, 51.7; 
IR (cm-1; NaCl salt plate): 2922, 2851, 1684, 1653, 1623, 1609, 1576, 1554, 1517, 
1482, 1466, 1453, 1438, 1420, 1396, 1384, 1331, 1309, 1282, 1256, 1231, 1191, 
1181, 1099, 1018, 977, 924, 845, 832, 787, 753, 736, 700; Rf (10% 
methanol/DCM) = 1.0; melting point = 135–137 ˚C. 
 
Synthesis of 4-chloro-5-[4-benzyloxycarbonylphenyl]-[2-tert-butylbenzamido]-methyl 
benzoate (II-20) 
 
 To a dry, 100 mL round-bottomed flask was added a stirbar, 4-tert-butyl benzoic 
acid (35.2 mg, 0.197 mmol, 1 equiv), and 5 mL anhydrous DCM. To this solution was 









0 ˚C in an ice-water bath, then thionyl chloride (1 M in DCM) (0.220 mL, 0.215 mmol, 
1.1 equiv) were added. The solution was stirred at 0 ˚C for 30 min., then the solvent was 
evaporated. The residue was re-dissolved in 5 mL anhydrous dichloromethane and 
triethylamine (0.038 mL, 0.269 mmol, 1.5 equiv). The solution was cooled to 0 ˚C, then 
II-19 (71 mg, 0.179 mmol, 1 equiv) was added to the acyl chloride slowly. The reaction 
mixture was stirred at 0 ˚C for 30 min., then the solution was refluxed under nitrogen 
overnight. The reaction mixture was cooled to room temperature and the residue was 
dissolved in 150 mL diethyl ether. The organic layer was washed with 100 mL saturated 
sodium bicarbonate. The bicarbonate layer was washed with diethyl ether (2 x 25 mL). 
The combined organics were washed with 100 mL saturated brine. The brine layer was 
washed with diethyl ether (2 x 25 mL). The combined organics were dried with sodium 
sulfate, filtered, and evaporated onto silica. Purification via column chromatography 
afforded II-20 in 28% yield (28.3 mg) using hexanes:(0-50%) ethyl acetate. 
 
Compound II-20 
1H-NMR (500 MHz, CDCl3): d 12.04 (s, 1H), 9.19 (s, 1H), 8.08 (s, 1H), 8.03-8.02 
(d, 2H), 7.60-7.58 (d, 2H), 7.51-7.49 (d, 2H), 7.46-7.41 (m, 4H), 7.41-7.38 (t, 
1H), 7.09-7.07 (d, 2H), 5.15 (s, 2H), 3.98 (s, 3H), 1.39 (s, 9H); 13C-NMR (125 
MHz, CDCl3): d 168.5, 165.7, 158.6, 158.0, 155.9, 141.2, 139.5, 137.1, 136.9, 
134.5, 133.8, 133.2, 131.7, 130.9, 130.7, 128.6, 128.6, 128.0, 127.9, 127.8, 127.5, 
127.5, 127.3, 125.9, 121.5, 115.2, 114.6, 113.7, 70.1, 52.6, 35.0, 31.2; IR (cm-1; 
NaCl salt plate): 3297, 3256, 3114, 3034, 2958, 2925, 2868, 1693, 1680, 1652, 
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1609, 1582, 1492, 1456, 1437, 1418, 1380, 1310, 1285, 1267, 1234, 1178, 1122, 
1107, 1093, 1016, 970, 931, 916, 900, 885, 851, 834, 790, 767, 736, 697, 647, 
623, 604; Rf (1:1 ethyl acetate:hexanes) = 0.77-0.74; melting point = decomposed 
above 145 ˚C. 
 
Synthesis of 4-chloro-5-[4-tert-butyloxycarbonylphenyl]-[2-amino]-methyl benzoate (II-
21) 
 
 To a dry, 100 mL round-bottomed flask was added a stirbar, II-4 (250 mg, 0.802 
mmol, 1 equiv), tert-butylcarbonylbenzeneboronic acid (214 mg, 0.962 mmol, 1.2 equiv), 
PdCl2(dtbpf) (10.5 mg, 0.016 mmol, 0.02 equiv), and potassium carbonate (168 mg, 
1.203 mmol, 1.5 equiv) (ground and dried in an oven overnight at 140 ˚C). Added 9.5 mL 
acetonitrile:0.5 mL water and refluxed 48 hours under N2. Cooled to room temperature 
and filtered through Celite cake. The Celite cake was rinsed with 100 mL ethyl acetate, 
100 mL DCM, and 100 mL methanol. The filtrate was dried with sodium sulfate, filtered, 
and evaporated onto silica gel doped with 1% triethylamine. Product II-21 was obtained 
as a waxy solid in 96% yield (262 mg) after column chromatography with DCM doped 









1H-NMR (500 MHz, CDCl3): d 8.05-8.03 (d, 2H), 7.87 (s, 1H), 7.49-7.47 (d, 2H), 
6.83 (s, 1H), 5.88 (s, 2H), 3.89 (s, 3H), 1.64-1.63 (s, 9H); 13C-NMR (125 MHz, 
CDCl3): d 167.9, 165.7, 150.4, 142.9, 138.2, 133.9, 130.8, 129.6, 129.2, 127.9, 
117.3, 109.8, 81.1, 51.9, 28.3; IR (cm-1; NaCl salt plate): 3473, 3364, 2977, 1698, 
1616, 1580, 1548, 1477, 1437, 1394, 1368, 1297, 1252, 1232, 1165, 1119, 1100, 
1019, 926, 848, 777, 761, 713; Rf (DCM:1% NEt3): 0.633; melting point = waxy 
solid. Melting point not possible to ascertain; HRMS: EXPECTED 362.8298; 
FOUND: 362.1179. 
 
Synthesis of 4-chloro-5-[4-tert-butyloxycarbonylphenyl]-[2-tert-butylbenzamido]-methyl 
benzoate (II-22) 
 
 To a dry, 100 mL round-bottomed flask was added a stirbar, 4-tert-butyl benzoic 
acid (193 mg, 1.084 mmol, 1.1 equiv), and 5 mL anhydrous DCM. To this solution was 








to 0 ˚C in an ice/water bath, then thionyl chloride (1 M in DCM) (1.2 mL, 1.192 mmol, 
1.21 equiv) were added. The solution was stirred at 0 ˚C for 30 min., then the solvent was 
evaporated. The residue was re-dissolved in 5 mL anhydrous dichloromethane and 
triethylamine (0.227 mL, 1.626 mmol, 1.65 equiv). The solution was cooled to 0 ˚C, then 
II-21 (356 mg, 0.986 mmol, 1 equiv) in 5 mL anhydrous DCM and triethylamine (0.227 
mL, 1.626 mmol, 1.65 equiv) was added to the acyl chloride slowly. The reaction mixture 
was stirred at 0 ˚C for 30 min., then the solution was refluxed under nitrogen overnight. 
The reaction mixture was cooled to room temperature and evaporated. The residue was 
taken up in 50 mL and washed with saturated sodium bicarbonate (3 x 50 mL) and 
saturated brine (50 mL). The aq. layer was washed with ethyl acetate (50 mL). The 
combined organics were dried with sodium sulfate, filtered, and evaporated onto silica. 
Product II-22 was obtained in 54% yield (338 mg) via column chromatography with 
hexanes:(0-75%) ethyl acetate with 1% triethylamine. 
 
Compound II-22 
1H-NMR (500 MHz, CDCl3): d 12.05 (s, 1H), 9.2 (s, 1H), 8.09 (s, 1H), 8.07-8.06 
(d, 2H), 8.01-7.99 (d, 2H), 7.58-7.56 (d, 2H), 7.52-7.50 (d, 2H), 3.97 (s, 3H), 
1.63-1.62 (s, 9H), 1.38 (s, 9H); 13C-NMR (125 MHz, CDCl3): d 168.4, 165.7, 
165.5, 156.0, 142.3, 141.9, 139.2, 133.9, 133.2, 131.5, 131.4, 129.5, 129.4, 127.4, 
125.9, 121.6, 113.8, 81.3, 52.8, 35.1, 31.2, 28.3; IR (cm-1; NaCl salt plate): 3299, 
3261, 2966, 2931, 1711, 1686, 1656, 1638, 1608, 1580, 1545, 1516, 1492, 1459, 
1438, 1409, 1392, 1367, 1294, 1269, 1234, 1166, 1117, 1019, 932, 899, 849, 790, 
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777, 761, 699; Rf (1:1 ethyl acetate:hexanes with 1% triethylamine) = 0.83; 
melting point = 140–142 ˚C; HRMS: EXPECTED: 523.0458; FOUND: 522.2051. 
 
Synthesis of 4-chloro-5-bromo-2-[4-carboxybenzamido]-methyl benzoate (II-26) 
 
 To a dry, 100 mL round-bottomed flask was added a stirbar, terephthalic acid (II-
24) (69.1 mg, 0.416 mmol, 1.1 equiv), 4 mL anhydrous DCM, and triethylamine (0.232 
mL, 1.664 mmol, 4 equiv). The reaction mixture was cooled to 0 ˚C in an ice/water bath. 
Slowly added thionyl chloride (1 M in DCM) (0.998 mL, 0.998 mmol, 2.4 equiv) and 
stirred at 0 ˚C under N2 for 30 minutes. The solvent was evaporated and the residue was 
dissolved in 3 mL anhydrous DCM and triethylamine (0.232 mL, 1.664 mmol, 4 equiv) at 
0 ˚C. A solution of II-3 (100 mg, 0.378 mmol, 1 equiv) in 1 mL anhydrous DCM and 
triethylamine (0.232 mL, 1.664 mmol, 4 equiv) at 0 ˚C was added slowly to the acyl 
chloride. Stirred at 0 ˚C for 1 hour, then refluxed overnight under N2. The reaction 
mixture was cooled to room temperature and then evaporated. The residue was dissolved 
in 25 mL ethyl acetate and washed sequentially with 50 mL 1 M HCl, 100 mL saturated 
sodium bicarbonate, and 50 mL saturated sodium chloride. The neutral aq. layer with 
ethyl acetate (2 x 50 mL) and DCM (2 x 25 mL). The combined organics were dried 










column chromatography using a gradient of hexanes:(0-55%, then 40-45% with 1% 
acetic acid) ethyl acetate in 25% yield (38.3 mg). 
 
Compound II-26 
1H-NMR (300 MHz; DMSO-d6): d 13.32 (s, 1H), 11.57 (s, 1H), 8.74 (s, 1H), 
8.23 (s, 1H), 8.15-8.12 (d, 2H), 8.04-8.01 (d, 2H), 3.90 (s, 3H); 13C-NMR (75 
MHz; DMSO-d6): d 167.0, 166.6, 164.8, 140.2, 139.2, 137.8, 135.5, 134.7, 130.4, 
129.9, 127.9, 122.8, 118.8, 115.7, 53.6; IR (cm-1; NaCl salt plate): 2915, 2847, 
1686, 1569, 1508, 1490, 1421, 1259, 1211, 1107, 1014, 937, 900, 866, 751, 695; 
Rf (1:1 ethyl acetate:hexanes)=0.45; melting point = decomposed above 260 ˚C. 
 
Synthesis of 4-chloro-5-bromo-2-[4-carboxybenzamido]-benzoic acid (II-27) 
 
 To a dry, 20 mL vial was added a stirbar, II-26 (37.3 mg, 0.090 mmol, 1 equiv), 
and 2 mL anhydrous THF. Added 1 M aq. LiOH (0.452 mL, 0.452 mmol, 5 equiv) and 
stirred under N2 overnight for 48 hours at room temperature, then the solvent was 
evaporated. The residue was dissolved in 25 mL ethyl acetate and washed with 10 mL 1 
M aq. HCl. The organic layer was separated and then the acidic aq. layer was washed 










with sodium sulfate, filtered, and evaporated. Product II-27 was obtained as an off-white 
solid in >99% yield (39.8 mg). 
 
Compound II-27 
1H-NMR (300 MHz; DMSO-d6): d 13.29 (s, 1H), 12.49 (s, 1H), 8.92 (s, 1H), 
8.26 (s, 1H), 8.13-8.10 (d, 2H), 8.04-8.01 (d, 2H); 13C-NMR (75 MHz; DMSO-
d6): d 167.1, 166.9, 164.6, 141.1, 138.6, 137.9, 135.9, 134.9, 130.4, 129.9, 127.8, 
121.6, 114.9; IR (cm-1; NaCl salt plate): 3252, 2955, 2921, 2850, 2671, 2548, 
1688, 1597, 1576, 1512, 1498, 1458, 1432, 1374, 1308, 1267, 1129, 1107, 1087, 
1016, 933, 913, 874, 786, 712, 685, 665, 610; Rf (1:1 ethyl acetate:hexanes) = 
0.364-0; melting point = decomposed above 260 ˚C. 
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2.5.3  GENERAL PROCEDURE FOR SOLID PHASE PEPTIDE SYNTHESIS  
  OF II-28 TO II-40 
Peptides were assembled according to the generalized schemes presented above (i.e. 
Scheme 1.7 in Chapter One).   
Resin Swelling:  Fmoc-Leu-Wang resin was loaded into the barrel of a fritted 10 mL 
syringe and was swelled by first washing with 3 mL DCM, followed by soaking in 
another 5 mL DCM for five minutes. The residual DCM was washed away with DMF (3 
x 5 mL). 
Fmoc Deprotection Sequences:  The Fmoc protecting group of the terminal amino acid of 
the growing peptide was removed by three sequential one-minute treatments with 5 mL 
of a 30% solution of 4-methylpiperidine in DMF. The deprotected resin was then washed 
three times with 5 mL of DMF.  
HCTU amino acid couplings:  Five equiv (relative to resin loading) of the appropriate 
Fmoc-amino acid was added to a three-dram vial, along with five equiv of HCTU.  The 
solids were dissolved in 1 mL DMF and 5 equiv of diisopropylethylamine was added.  
This mixture was then taken up into the syringe and agitated for two minutes.   The first 
treatment of the coupling mixture was then ejected from the syringe, and the resin was 
subsequently treated with a second aliquot of the same amino acid coupling mixture for 
another two minutes.  After the double coupling protocol, the resin was washed with 
DMF (3 X 5 mL).   After this coupling procedure was complete, the newly added Fmoc-
amino acid was deprotected and prepared for further coupling steps as described above.   
 132 
Fmoc-Gly-OPfp coupling (for peptides II-28 to II-29 and II-32 to II-35):  The required 
glycine coupling using the more reactive Fmoc-Gly-OPfp (see Scheme 1.7 in Chapter 
One) was achieved in the following manner:  five equiv of Fmoc-Gly-OPfp and five 
equiv of HOBt were charged to two sets of three-dram vials and taken up in 1 mL of 
DMF.  This mixture was taken up into the syringe containing the resin and was agitated 
for one hour.   The first treatment of the coupling mixture was then ejected from the 
syringe, and the resin was subsequently treated with a second aliquot of the same amino 
acid coupling mixture for another one hour.  After the double coupling protocol, the resin 
was washed with DMF (3 X 5 mL).   After this coupling procedure was complete, the 
newly added Fmoc-Gly residue was deprotected and prepared for further coupling steps 
as described above. This process was repeated for the incorporation of each of the desired 
amino acids in the sequence. Fmoc-AEEP-OH was substituted for Fmoc-Gly-OH for the 
installation of a diethylene glycol tether (for peptides II-30 and II-31) using the same 
protocol as that described above. 
Drug Installation:  Each peptide was capped with the appropriate BABA drug candidate in 
the following manner:  Five equiv (relative to resin loading) of the appropriate BABA 
carboxylic acid was added to a three-dram vial, along with five equiv of HCTU.  This 
mixture was taken up into the syringe containing the resin and was agitated overnight.  
After the coupling protocol, the coupling solution was ejected from the syringe and the 
resin was further processed as described below.  
Fluorophore Installation (for peptides II-36 to II-40):  Each peptide was capped with 
FITC in the following manner:  Five equiv (relative to resin loading) of FITC was added 
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to a three-dram vial in a minimal amount of 0.12:0.07:0.05 pyridine:DMF:DCM.  This 
mixture was taken up into a syringe wrapped in aluminum foil containing the resin and 
was agitated overnight. A second coupling was applied for 72 hours and a third coupling 
was applied for 48 hours.  After the coupling protocol, the coupling solution was ejected 
from the syringe and the resin was further processed as described below.  
Peptide Cleavage and Isolation:  The resin containing the fully assembled peptide-drug 
conjugate was washed with DMF (3 x 5 mL), DCM (3 x 5 mL), and methanol (3 x 5 mL).  
Residual solvents were dried using suction and then the resin was further dried under 
vacuum (i.e. in a 25 ˚C vacuum oven) overnight. After drying the resin was treated with 
1.5 mL of a standard peptide cleavage cocktail comprised of trifluoroacetic 
acid:H2O:methanol (95:4.5:0.5) for 1.5 h.  The resulting solution containing the liberated 
peptide was then ejected into a 1 mL Eppendorf tube and evaporated under a steady 
stream of nitrogen. The peptide was then precipitated from the resulting oil on the 
addition of ice-cold diethyl ether.  The precipitate was then localized at the bottom of the 
tube by centrifugation, the ether portion was decanted, and the precipitation procedure 
was repeated two more times to afford the desired peptide-drug conjugates.  The identity 






Peptide Number Condensed Molecular Formula Expected m/z Experimental m/z
II-28 C45H58ClN7O10 892.4 892.5
II-29 C44H56ClN7O10 878.4 878.5
II-30 C48H65ClN6O11 937.5 937.5
II-31 C47H63ClN6O11 924.5 924.2
II-32 C35H45BrClN7O10 840.2 840.5
II-33 C34H43BrClN7O10 826.0 826.3
II-34 C37H51BrClN7O8 838.2 838.2
II-35 C40H50BrClN5O8 765.3 765.4
II-36 C58H62BrClN8O13S 1225.4 1225.4
II-37 C62H71BrClN9O13S 1297.7 1296.9
II-38 C42H49N7O12S 875.9 877.4
II-39 C69H76ClN7O16S 1326.9 1326.6
II-40 C50H61ClN9O13S2 693.8 693.4
Table 2.4: MALDI-TOF data for peptides II-28 to II-40. Please note that the [M]+ m/z is shown for 
peptides II-28 to II-39 while the [M+Na]
+
 m/z is shown for peptide II-40. 
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SYNTHESIS AND UTILITY OF A NOVEL CHIRAL BORONATE ESTER IN THE 
INTRAMOLECULAR DIELS-ALDER REACTION 
3.1  INTRODUCTION 
 The Diels-Alder (DA) reaction is a well-known example of a carbon-carbon bond 
forming reaction in organic chemistry. The DA reaction consists of a [4+2] cycloaddition 
between a dienophile, e.g. alkene or alkyne, and a diene leading to a cyclohexene 
cycloadduct that is often formed with predictable regio- and diastereoselectivity.1 
Traditionally, the reaction consists of a mixture of the dienophile and diene in an aprotic 
solvent under thermal or Lewis acid (LA) activation.1 The reaction can occur in both 
inter- and intra-molecular fashions; the variation in DA adducts (i.e. products) arises from 
the substituents present on the dienophile and/or diene. 
In a traditional intermolecular Diels-Alder cycloaddition, an electron-rich diene, 
such as 1-methoxybutadiene, can be utilized in conjunction with an electron-poor 
dienophile, such as ethyl acrylate (Figure 3.1).1-3 In general, the better the donor 
substituents on the diene and the stronger the acceptor substituents on the dienophile, the 
faster the cycloaddition proceeds.1 Maleic anhydride, quinones, and nitroalkenes are other 
well-known dienophiles that can participate in the DA reaction.1 Chiral catalysts (or 
auxiliaries), such as oxazolidinone, can be appended onto dienophiles to increase the 
enantio- and diastereo-selectivity of the cycloaddition reactions.1,2 In addition, vinyl 
esters and vinyl ethers bearing chiral auxiliaries (see Figure 3.2) have been used to exert 
stereochemical control in the DA reaction; however, they may require the use of 
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additional synthetic operations or purification protocols.1-3 Vinyl silanes have also 
received attention in the intermolecular Diels-Alder cycloaddition for their role as 
acetylene equivalents.4 Although highly reactive vinyl silanes do exist, they are hindered 
by their low preparative yields and harsh reaction conditions (see Figure 3.2).1,3,4 
In contrast, an inverse electron demand Diels-Alder cycloaddition reverses the 
roles of the reactants where an electron-rich dienophile, such as a vinyl silyl ether, will 
react with an electron-poor diene, such as 2,4-pentadienoic acid ethyl ester (Figure 3.1). 
In an inverse electron demand Diels-Alder cycloaddition, the highest occupied molecular 
orbital (HOMO) of an electron-rich dienophile interacts strongly with the lowest 
unoccupied molecular orbital (LUMO) of an electron-poor diene. This contrasts with a 
traditional Diels-Alder cycloaddition, in which the HOMO of an electron-rich diene 
interacts strongly with the LUMO of an electron-poor dienophile. In either reaction (i.e. 
traditional or inverse electron demand Diels-Alder cycloaddition), it is expected that a 
mixture of endo:exo products would be observed. 
 
 
Figure 3.1: General schemes shown for traditional Diels-Alder (top) and an inverse electron demand 















Recently, boronates have gained attention in the literature as substrates in the 
Diels-Alder cycloaddition due to the ease of their preparation and their ability to act as a 
Lewis acid.1-3,5,6 Additional Lewis acids, such as EtAlCl2, can be added to promote a 
traditional Diels-Alder cycloaddition through the activation of a dienophile species that 
can readily accept the boronate diene.1,2 Furthermore, boronate esters can be tailored with 
a variety of groups, including small alkyl moieties, such as ethyl or 1,3-butadienyl 
substitutions, or even large hydrocarbons, such as anthracene, that can be incorporated 
onto either the diene or dienophile to impart greater reactivity and/or stereocontrol to the 
substrate.1 One of the major drawbacks in using boronate esters as dienes, such as 1-
boronobutadienes (described in greater detail below), arises from the steric and electronic 
deactivating effect exerted by the boronate substituent which necessitates the need for 
highly-activated dienophiles in the Diels-Alder cycloaddition (e.g. maleic anhydride) and, 
potentially, Lewis acid activation.2 Nonetheless, vinyl boronate esters participating as 
dienophiles have shown remarkable results (see Figure 3.2). In an investigation authored 
by Bonk and Avery, the use of a dioxygenated boronate as a dienophile was successful in 
the synthesis of a norbornenyl alcohol III-3 through a Diels-Alder cycloaddition with 
cyclopentadiene III-1 and boronate tartrate ester III-2 (Scheme 3.1). In this reaction, 
Figure 3.2: Examples of vinyl derivatives that can participate in the Diels-Alder cycloaddition.
1-6 


















cyclopentadiene was heated at 200 ˚C in benzene in a sealed tube with 1% phenothiazine 
(as a stabilizer) followed by oxidation of the boronate with hydrogen peroxide and 
sodium hydroxide to afford the desired norbornenyl alcohol III-1 (endo:exo 37:35) as 
shown in Scheme 3.1. Although this method was successful in employing the Diels-
Alder cycloaddition to a vinyl boronate ester, additional investigations will now be 
presented in which boronate esters (participating as either the diene or dienophile) were 
used to exert stereocontrol in the Diels-Alder cycloaddition to enhance the selectivity for 
either the endo or exo products. This introduction will be followed by an explanation of a 
major aim for this thesis chapter followed by a discussion of the successful synthetic 
route implemented thus far in the synthesis of a novel, chiral boronate ester that can 
participate in the intramolecular Diels-Alder cycloaddition (IMDA). 
 
Matteson and Waldbillig investigated the use of ethylene boronic esters as 
dienophiles for their electron-withdrawing power in the Diels-Alder cycloaddition.6 As is 
shown in Table 3.1, the use of dibutyl ethylene boronate (Entry 3 where R = t-butyl) and 
excess cyclopentadiene heated to reflux gave a good mixture of the dibutyl endo- and 
exo-5-norbornene-2-boronates. Based on the results in Table 3.1, a less bulky boronic 
ester lead to a higher proportion of the endo adduct than the bulkier ester. Entry 1 in 
Scheme 3.1: Diels-Alder cycloaddition between cyclopentadiene (3 eq) and diethyl boronotartrate (1 
















Table 3.1, where R = H, shows a higher endo:exo ratio (1.70) than that obtained with 
Entries 2 and 3 (for R = n-butyl and t-butyl the values are 0.64 and 0.37, respectively). 
This result was obtained after heating the boronic acid with cyclopentadiene in benzene 
at 80 ˚C for 4.5 hours, versus the boronate esters that were heated neat for longer time 
periods (in excess of 7.5 hours) at higher temperatures (in excess of 100 ˚C). 
Furthermore, use of a boronic acid gave a higher amount of the endo product (Entry 1 in 
Table 3.1), whereas use of a boronate ester gave the opposite result with a higher 
population of the exo product (Entries 2 and 3 in Table 3.1).6 Furthermore, refluxing the 
dibutyl ethylene boronate with isoprene in benzene or diglyme did not result in the Diels-
Alder adduct; however, heating the two samples in a sealed tube at 140 ˚C afforded the 
Diels-Alder adduct in 85% yield (Scheme 3.2; no endo:exo ratio provided by the 
authors).6 Kinetic control in the isomerization of the endo:exo products (see Entries 1, 2, 
and 3 in Table 3.1) was observed through the failure of the dibutyl endo- or exo-5-
norbornene-2-boronate to isomerize at 120 ˚C (no change in endo:exo ratio).6 This 
investigation demonstrated that the dialkoxyboryl group has a moderate activating effect 
with the potent diene, cyclopentadiene, in the Diels-Alder cycloaddition through the 






In a later work, Vaultier and co-workers demonstrated the use of 1,3-substituted 
dienes in the Diels-Alder cycloaddition, as this would install allylboronates in the 
cyclohexenyl product in a stereodefined way for further reactions as part of a tandem, or 
multi-component, reaction (Scheme 3.3).7 In this investigation, Vaultier heated methyl 
acrylate with 2-methyl-1,3-butadienylboropinacolate (III-2) in toluene at 100 ˚C for 100 
hours to afford the cyclohexenyl adduct in 69% yield (Scheme 3.3; endo:exo ratio 
observed was 1:1.8).7 The resultant cyclohexenyl product was then oxidized by action of 
trimethylamine-N-oxide to give the ß-hydroxyester which allowed the investigators to 
Table 3.1: Several examples of a DA reaction between cyclopentadiene (III-1) and a vinyl boronate 
acid or ester (shown above), used as a chiral auxiliary, are displayed.
6 
Entry R endo:exo Temp (˚C)
Time 
(h) Solvent Yield (%)
1 H 1.7 80 4.5 Benzene 62
2 butyl 0.64 100 4 neat 83
3 tert-butyl 0.37 100 7.5 neat 83
B(OR)2
Δ, 













Scheme 3.2: Diels-Alder cycloaddition between isoprene and dibutyl ethylene boronate.6 
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establish the regiochemistry of the final product by X-ray crystallography (no yield 
provided by the authors).  
 
Based on the precedent set by Vaultier and co-workers (described above), Gao 
and Hall reported the use of 1-boronobutadienes as substrates in the Diels-Alder 
cycloaddition.2 They demonstrated the cycloaddition of these versatile dienes with a good 
dienophile, followed by allylboration with an aldehyde component to provide a final 
hydroxyalkyl-substituted cyclohexene product with high diastereoselectivity. In their 
investigation, Gao and Hall demonstrated the use of ether-substituted 1-
boronopinacolates in the Vaultier tandem reaction (Scheme 3.4).2 As is evidenced in 
Table 3.2, diene III-5 reacted with maleimides (III-6) and methyl acrylate to provide 
Diels-Alder cycloadducts III-7 at relatively high temperature (in toluene at 80 ˚C), but 
the allylboration product III-8 was not observed even after the mixture was heated at 
higher temperatures (up to 120 ˚C, after which decomposition of the product was 
observed) possibly due to steric hindrance by the methoxy group on III-5.2 Use of diene 
III-7 afforded the desired allylboration product after diene III-7 and the desired 
maleimide (III-6) were heated in toluene between 80 ˚C for 16-24 hours (endo-selectivity 
though the authors did not provide the endo:exo ratio), followed by the addition of the 
Scheme 3.3: Diels-Alder between 2-methyl-1,3-butadienylboropinacolate (III-4) and methyl acrylate, 

















desired aldehyde (descriptions for maleimide and aldehyde are shown in Table 3.2).2 The 
doubly-activated dienophiles, such as N-phenyl and N-methyl maleimide, participated 
efficiently in the Diels-Alder cycloaddition, followed by addition of either aliphatic or 
aromatic aldehydes that afforded the desired b-hydroxy-cyclohexenyl product III-12 
(Scheme 3.4). When N-phenyl-maleimide was used, higher yields for the tandem reaction 
product were obtained with the use of 4-nitrophenyl-, 4-methoxyphenyl-, or 4-
bromophenyl-substituted aldehyde (92% for Entry 2, 82% for Entry 3, and 93% for Entry 
4) than with benzaldehyde (76% for Entry 1). Using N-methyl-maleimide, yields for the 
tandem reaction product were lower than those obtained with N-phenyl-maleimide when 
the same aldehydes were screened (89% for Entry 5, 67% for Entry 6, 78% for Entry 7).2 
 





































1 eq 1.1 eq
R2CHO (1.1 eq)
















The cycloaddition between diene III-3 and oxazolidinone III-13 followed by a 
tandem reaction with 4-nitro-benzaldehyde afforded the cyclohexenyl product (III-14) as 
shown in Scheme 3.5 with high exo selectivity after heating in toluene for 18 hours at 
110 ˚C.2 This investigation into the Vaultier tandem reaction showed the potential of 1-
boronobutadienes towards a diastereoselective synthesis of hydroxyalkylated 
cyclohexenyl products.7 Although use of methyl acrylate did not afford the desired 
tandem reaction product when used with diene III-5, the use of activated dienophiles, 
maleimides, in the reaction sequence with dienes III-5 and III-9 provided a new 
approach toward the diastereoselective synthesis of cyclohexenyl derivatives that could 
potentially be incorporated in natural product synthesis (Scheme 3.4).2 
Entry Dienophile (R1) Aldehyde (R2) Temperature (˚C) Time (h) Yield (%)
1 Ph C6H5 80 16 76
2 Ph 4-NO2-C6H4 80 24 92
3 Ph 4-MeO-C6H4 100 16 82
4 Ph 4-Br-C6H4 80 16 93
5 Me 4-NO2-C6H4 80 24 89
6 Me 4-MeO-C6H4 100 16 67
7 Me 4-Br-C6H4 80 16 78
Table 3.2: Cycloaddition (see Scheme 3.4) of diene III-9 with maleimides (R
1
 = Ph or Me) followed by 





 Boronate esters have been used to activate and influence the regioselectivity of 
phenoxy-derivatized quinones as dienophiles in Diels-Alder [4+2] cycloadditions.8 
Employing chiral diols as boronate substituents is a synthetic advantage in using boronate 
esters as Lewis acids for cycloadditions and subsequent transformations.8 Kennedy and 
Hall investigated the effect of the boronate substituent by subjecting acrylanilide 
dienophiles III-15 and III-16 (Scheme 3.6) with the highly-reactive diene 
cyclopentadiene to afford cycloadducts III-17 and III-18.8 Based on the results of their 
assay, dienophile III-15 reacted with greater preference for the endo product as shown in 
Table 3.3.8 This is possibly due to a small self-activation effect via internal coordination 
of the boronate ester and the carbonyl of the acrylanilide in III-15 (Scheme 3.7).8 To 
demonstrate the effect of this self-activation of the acrylanilide, a competitive kinetic 
experiment was conducted between a simultaneous reaction between III-15 and III-19 
with excess cyclopentadiene in deuterated benzene at room temperature (Scheme 3.7).8 
These results indicated that the consumption of III-15 was faster than III-19 to provide a 
larger percentage of the ortho adducts (III-20) compared to the para adducts (III-21) to 
Scheme 3.5: Cycloaddition between diene III-9 and oxazolidinone dienophile III-13 followed by 
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toluene

















further corroborate the self-activation by internal coordination of the ortho-substituted 










Scheme 3.6: Endo:exo ratios afforded by the Diels-Alder between excess cyclopentadiene and 
acrylanilide III-15 or III-16. Highlighted in the box is the internal coordination of the boronate ester 

































Table 3.3: Endo:exo ratios (see Scheme 3.6) afforded by the Diels-Alder cycloaddition between III-15 
or III-16 and excess cyclopentadienone.
8 
Time (h) Acrylanilide III-15 Acrylanilide III-15 Acrylanilide III-16 Acrylanilide III-16
S.M./adduct endo:exo S.M./adduct endo:exo
1 3.8:1 - No rxn 2.7:1
6 1.2:1 3.8:1 1:0.4 2.5:1






Kennedy and Hall then investigated the possibility of using internal coordination 
to impart stereocontrol in a long-range fashion. In this investigation, 1,8-stereoinduction 
could be harnessed via internal coordination of the carbonyl of the acrylanilide to the 
boron atom to form a tetrahedral stereogenic boronate complex.8 The resulting tetrahedral 
boronate would be rendered stereogenic at the boron after  temporary 1,4-stereoinduction 
in the formation of the Diels-Alder cyclohexenyl adduct.8 Chiral 2-boronoacrylanilides 
(III-22 to III-25 shown in Figure 3.3) were reacted with cyclopentadiene III-1 in the 
presence of BHT (butylated hydroxytoluene) in refluxing toluene (see Entries 1 to 4 in 
Table 3.5).8 The endo:exo ratio showed low selectivity (maximum endo:exo ratio 
observed 3.7:1 for III-24) from Entries 1 to 4, although the greatest diastereomeric 
Scheme 3.7: Competitive kinetic experiment between acrylanilide derivative III-15 and III-19 and 


























Time para s.m. ortho s.m. para adducts ortho adducts
Start point 55 45 0 0
After 17 d 43 11 10 36
Table 3.4: Data for competitive kinetic experiment (see Scheme 3.7) between III-15, III-19, and 
excess cyclopentadiene III-1 showing preference for ortho product.8 
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excess of 28% was observed with acrylanilide dienophile III-24.8 Based on the low 
endo:exo selectivity observed, it can be said that the chiral information resident in the 
chiral diol ligands may be positioned too far away from the dienophile to allow for 
effective transmission of stereochemical information.8 
 
 
Figure 3.3: Chiral 2-boronoacrylanilide derivatives prepared by Kennedy and Hall. Numbering for 



































Table 3.5: Remote 1,8-stereoinduction (numbering shown in Figure 3.3) reflected in the Diels-Alder 
cycloaddition between III-22 to III-25 and excess cyclopentadienone. Reaction with III-24 was 




Dienophile Yield endo:exo De (endo, %) De (exo, %)
III-22 94 2.0:1 8 6
III-23 56 1.5:1 5 9
III-24 72 3.7:1 0 28
III-25 85 2.4:1 -6 22
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Using molecular modeling approaches, Kennedy and Hall determined that the 
chiral boronate auxiliaries drawn in Figure 3.3 are far removed from the reaction center 
on the acrylamide unit to induce high levels of selectivity.8 This investigation 
demonstrated that non-activated dialkoxyboronic esters can participate in the Diels-Alder 
cycloaddition as weak, internal Lewis acids and thus activate carbonyl-containing 
functionalities intramolecularly toward accepting a diene, such as cyclopentadiene III-1.8 
Kennedy and Hall also demonstrated the effects of the internal coordination between the 
carbonyl and boronate center as well as the 1,8-stereoinduction transmitted through a 
tetrahedral stereogenic boronate center.8 Of interest from this investigation was the 
observation of a weak activating effect (through the isolation of products with low 
diastereoselectivies) despite the distance of the auxiliary (the boronate center) from the 
reaction center (the dienophile, acrylanilide).8 
Although the intermolecular Diels-Alder reaction is a powerful method for the 
selective formation of cyclohexenyl derivatives, it is contingent upon effective matching 
of the diene and dienophile reaction partners to ensure good regiocontrol and 
diastereoselectivity.9 One solution is to couple the diene and dienophile together to 
undergo an intramolecular Diels-Alder (IMDA). The constraining effects of the tether can 
have a large effect on the overall regiochemistry and diastereoselectivity of the 
cycloaddition products.9 Roush and Gillis demonstrated the effects of a Lewis acid 
activated cyclization and thermally activated cyclization on trienes III-26a and III-26b 
that were subjected to an IMDA (Scheme 3.8).10 Trans-triene III-26a was heated at 160 
˚C for 48 hours neat to afford a 50:50 mixture of endo:exo products in 69% yield.10 
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Similarly, cis-triene III-26b was heated at 180 ˚C for 3 hours to afford the endo:exo 
products (55:45 mixture) in Scheme 3.8 in 71% yield.10 Trans-triene III-26a was also 
exposed to the Lewis acid, ethyl aluminum dichloride (Scheme 3.9), to afford an 88:12 
(endo:exo) mixture of products (III-27 and III-28) in 69% yield.10 The cis-triene III-26b 
was reacted in a similar fashion to afford the opposite preference (<8:92 endo:exo  in 
products III-29 and III-30) in 77% yield.10  
 
 
















III-27;  endo III-28; exo
CO2CH3CO2CH3
III-29;  endo III-30; exo
Scheme 3.9: Intramolecular Diels-Alder cycloaddition on trienes III-26a and III-26b in the 











III-27;  endo III-28; exo
CO2CH3CO2CH3






Batey and co-workers accomplished another example of an IMDA using a boron-
tethered substrate (Scheme 3.10).9 In this case, the boronic acid III-31 was first 
transesterified to a boronate ester (III-33) with alcohol III-32 and then heated to form the 
desired Diels-Alder cycloadduct (III-34) that was hydrolyzed at the boronate ester center 
to reveal a free hydroxyl group (III-35).9 This was a curious investigation as this is 
directly applicable to one of the major aims of this thesis work. Although a more detailed 
synthetic application will be provided in Section 3.2 of this chapter, it can briefly be 
stated here that the goal with this thesis work was to take a chiral diol that could be 
transesterified with a boronic acid (in a similar strategy as that employed by Batey and 
co-workers to synthesize III-33 in Scheme 3.10).9 Following this transesterification, we 
hope to carry out an IMDA with good diastereoselectivity as that achieved by Batey and 
co-workers (see Scheme 3.10 for product III-35).9 
 
Scheme 3.10: Intramolecular Diels-Alder cycloaddition following transesterification between boronic 


















80 ˚C, 24 h,









3.1.1 A BRIEF BACKGROUND OF SELECTIVE DIHYDROXYLATION OF 
DIENES AND TRIENES 
The chiral diol that we intended to use for our investigations was prepared 
according to a strategy employed by Zhang and O’Doherty.11 Previously, Sharpless 
studied the asymmetric dihydroxylation of polyenes using osmium quinuclidine ligand 
systems that reacted preferentially at the more electron-rich double bond of a polyene π-
system. Zhang and O’Doherty used the Sharpless asymmetric dihydroxylation (SAD) 
protocol to assess the selective dihydroxylation of two conjugated dienes (III-36a and 
III-36b) as shown in Schemes 3.11 (see Tables 3.6 and 3.7 for data). In general, 
dihydroxylation of III-36a favored the diol product where the more electron-rich alkene 
was preferentially reacted (III-37a and b) over the electron-deficient alkene (III-38a and 
b) adjacent to either an ester, thioester, Weinreb amide, or ketone.11  





R1 = Me (III-36a)








R1 = Me (III-37a)




R1 = Me (III-38a)








With respect to the dihydroxylation of conjugated diene III-36a, greater 
selectivity (>20:1) was exhibited for the more electron-rich alkene when an ethyl ester 
(Entry 1 in Table 3.6 resulting in 78% yield), Weinreb amide (Entry 4 in Table 3.6 
resulting in 82% yield), ketone (Entry 5 in Table 3.6 resulting in 68% yield), or a 
thioester (Entry 1 in Table 3.6 resulting in 38% yield) were used.11 The highest 
enantioselectivity (92% ee) was observed for both R = OEt and R = SMe (Entries 1 and 
6, respectively).11 Use of branched esters, such as isopropyl or tert-butyl esters (Entries 2 
and 3 in Table 3.6), afforded more of the dihydroxylation product where the more 
Table 3.6: Dihydroxylation results for conjugated diene III-36a.
11 
Entry (for III-36a) R Yield (%) Ratio (III-37a/III-38a) %ee III-37a %ee III-38a
1 OEt 78 >20:1 92 n.a.
2 Oi-Pr 45 9:2 72 96
3 Ot-Bu 76 6:1 76 n.a.
4 N(OMe)Me 82 >20:1 75 n.a.
5 Me 68 >20:1 69 n.a.
6 SMe 38 >20:1 92 n.a.
Table 3.7: Dihydroxylation results for conjugated diene III-36b.
11 
Entry (for III-36b) R Yield (%) Ratio (III-37b/III-38b) %ee III-37b %ee III-38b
1 OEt 76 5:1 99 n.a.
2 Oi-Pr 50 7:3 91 98
3 Ot-Bu 62 5:3 91 99
4 N(OMe)Me 85 >20:1 99 n.a.
5 Me 68 ~10:1 98 n.a.
6 SMe 31 3.7:1 99 99
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electron-deficient alkene had been dihydroxylated (ratio of III-37a/III-38a 9:2 and 6:1, 
respectively).11  
Yields for the dihydroxylation of III-36b were comparable to those achieved for 
III-36a.11 Nonetheless, the selectivity for the electron-rich alkene was significantly 
reduced for the dihydroxylation of substrate III-36b.11 The highest selectivities were 
observed for the Weinreb amide (>20:1 for Entry 4 in Table 3.7 resulting in 85% yield) 
and ketone (~10:1 for Entry 5 in Table 3.7 resulting in 68% yield).11 The ethyl, 
isopropyl, and tert-butyl esters (Entries 1 to 3 in Table 3.7) afforded less selectivity (ratio 
of III-37b/III-38b 5:1, 7:3, and 5:3, respectively).11 In contrast to diene III-36a, 
conjugated diene III-36b afforded the highest ee’s for the dihydroxylation of the 
electron-rich alkene.11 Based on this data, it is thought that dihydroxylation is less 
favorable on the electron-rich alkene when R = Ph (III-36b) due to disruption of 
conjugation in the diene (between the Ph, a,b-alkene, and g,d-alkene) compared to III-
36a (R = Me).11 Furthermore, a clear trend can be observed with III-36a where an 
increase in steric bulk of the ester (i.e. branched esters) coincided with a decrease in 
regioselectivity (Entries 2 and 3 in Table 3.6), possibly due to steric interactions between 
the branched ester and the ligand used, (DHQD)2PHAL.11 
Dihydroxylation of triene III-39 also exemplified the regiocontrol of the 
Sharpless protocol (Scheme 3.12).11 As is observed in Table 3.8, higher yields were 
obtained for the unbranched esters (R = Me in 82% yield and Et 96% yield) as compared 
to the use of branched esters (R = tert-butyl in 78% yield).11 Higher ee’s were observed 
for the unbranched esters (>96% ee for Entry 1 and 2 in Table 3.8) compared to the 
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branched ester that was screened.11 In all three Entries in Table 3.8, the favorability of 
the electron-rich alkene was >20:1 for the dihydroxylation as compared to the electron-
deficient alkene.11 In summary, this study demonstrated that the dihydroxylation of 
phenyl-substituted diene III-36b afforded diol products with higher enantiomeric 
excess.11 The unbranched ethyl ester III-36a (Entry 1 in Table 3.6) gave diol product 




3.2  RESULTS AND DISCUSSION 
3.2.1  SYNTHETIC AIMS 
With the results of the investigation by Zhang and O’Doherty in mind, we set out 
to synthesize a diene that possessed both an electron-rich and electron-poor diene for a 
subsequent dihydroxylation.11 Based on the results of Zhang and O’Doherty’s 
investigation, we sought fit to synthesize a diene in which the electron-rich alkene was an 














Table 3.8: Data for dihydroxylation (see Scheme 3.12) of triene III-39 showing preference for 
unbranched esters.
11 
Entry R Yield (%) Ratio %ee III-40
1 Me 82 >20:1 96
2 Et 96 >20:1 99
3 t-Bu 78 >20:1 96
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a,b-unsaturated aryl group and the electron-poor diene was an a,b-unsaturated ethyl 
ester, as unbranched esters afforded greater regioselectivity and enantioselectivity.11 The 
aim of this molecule, alluded to earlier in Section 3.1.1, was to synthesize a diol with 
good regiocontrol and enantioselectivity that could be transesterified for installation of a 
boronate ester species that could participate in an IMDA (Scheme 3.13). In this scenario, 
the electron-poor diene (a,b-unsaturated ethyl ester) would serve as our intramolecular 
dienophile and the boronate ester would be our diene. Of interest from the investigation 
by Zhang and O’Doherty was triene III-39 in Scheme 3.12, which indicated to us that 
distance could be introduced between the electron-rich diene and the electron-deficient 
diene for greater control over the regiochemistry and stereochemistry in the resulting diol 
product.11 Nonetheless, because the resultant diol we endeavored to synthesize would be 
used in an IMDA (after further transformations), the presence of the extra alkene between 
the electron-rich and electron-deficient alkene in III-39 in Scheme 3.12 poses a major 
geometrical constraint. We decided to synthesize an alternative diene, III-41, in Scheme 
3.13 where the functional group that links our electron-rich and electron-deficient alkene 
was selected to be either an ethylene linker (n = 2) or butylene linker (n = 4). It was 
thought that the regiocontrol and stereocontrol afforded to the dienes produced in the 
work by Zhang and O’Doherty would be transmitted in our model substrate despite the 
presence of a saturated, rather than an unsaturated, linker between our two alkenes.11 We 
then envisioned a Sharpless Asymmetric Dihydroxylation occurring preferentially on the 
electron-rich alkene (a,b-unsaturated aryl group) in both high regiocontrol and 
enantiocontrol (III-42). Following this dihydroxylation, we will have set two 
 160 
stereocenters along with two diols that can be transesterified with several unique boronic 
acids (III-4 is used in Scheme 3.13). Our overall strategy hinged on the hope that easily 
installed diol stereocenters resident on the boronate ester (III-43) would effectively 
influence the diastereoselectivity in the subsequent IMDA cycloaddition according to the 
investigations conducted by Hall and Batey (described above).2,9  The net result of this 
approach would realize the facile relay of simply installed stereochemical information in 
the substrate into much more complex chiral molecular scaffolds via the IMDA.  The 
boronate ester (III-43) that is generated can be subjected to a variety of Diels-Alder 
conditions (Lewis acid activated and thermally activated methods) in an effort to produce 
substrate (III-44, most likely as diastereomers) in accordance with the previously 
described work by Batey and Roush.9,10 
 
Initially, diene III-47 was produced in moderate yield according to an olefin 
cross-metathesis of styrene, 1,5-hexadiene, and methyl acrylate catalyzed by a Grubbs 
second generation catalyst using a method reported by Chatterjee et al. (Scheme 3.14).12 
Scheme 3.13: Proposed synthetic route for novel chiral boronate ester that can participate in IMDA 
cycloaddition. 
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Due to the low yield of the reaction, an alternative synthetic strategy was determined for 
generating the diene. 
 
 
First, 6-bromo-1-hexanol (III-48) was oxidized using pyridinium chlorochromate 
to an aldehyde (III-49) that was used without further purification and reacted via a Wittig 
reaction to install an a,ß-unsaturated ester (III-50) in 78% yield (Scheme 3.15).13 It 
should be noted that this reaction is operable with 4-bromo-1-butanol with similar 
results.13 The brominated ester was then heated neat in the presence of 
triphenylphosphine to afford the phosphonium bromide (III-51) in 97% yield.13 We next 
sought to deprotonate the phosphonium bromide with a suitable base followed by 
addition of benzaldehyde to install the styrenyl portion of the diene. Unfortunately, the 
investigation of several bases including sodium hexamethyldisilazide (NaHMDS), 
sodium hydride, potassium tert-butoxide, n-butyl lithium, while also calibrating the 
temperature (e.g. room temperature, 0 ˚C, or -78 ˚C), did not facilitate the installation of 
this key alkene functionality (III-52).13 A similar protocol was used (Scheme 3.16) with 
both bromo-valeric acid and bromo-butyric acid (III-53), wherein the phosphonium 




i) Grubbs 2nd catalyst 
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bromide (III-54) was deprotonated with NaHMDS followed by addition of benzaldehyde 
at -60 ˚C, to no great effect.14 Another failed experiment (Scheme 3.17) was attempted in 
which we hoped to deprotonate diethyl malonate (III-56) followed by alkylation with 
cinnamyl chloride (III-57), followed by Krapcho decarboxylation, as a potential route to 




A successful route to an appropriate diene for our strategy was initiated with the 
addition of vinyl magnesium bromide to benzaldehyde affording allyl alcohol (III-60) in 
quantitative yield, which was followed by a Johnson-Claisen rearrangement to afford the 
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styrenyl ester (III-58) in 99% yield shown in Scheme 3.18.16 The ethyl ester was reduced 
in the presence of lithium aluminum hydride to afford a primary alcohol (III-61) in 89% 
yield that was oxidized to an aldehyde (III-62) via the Doering-Parikh protocol in 67% 
yield.16,17 The aldehyde was reacted with triphenylcarbethoxymethylenephosphorane to 
afford the desired diene in 82% yield (III-63). Product III-63 was then dihydroxylated by 
the Sharpless Asymmetric Dihydroxylation (SAD) protocol to afford diol III-64 in 89% 
yield.18 It should be noted that the diol was used after a basic work-up without further 
purification, as it proved unstable to silica gel column chromatography, whereby the diol 
product suffered decomposition to an unsaturated hydrocarbon species as judged by both 
proton and carbon NMR. Following the basic work-up, diol III-64 was condensed with a 
series of boronic acids to provide a suite of three boronic esters (III-65, III-66, and III-
67) using a room temperature mixture of the diol, the desired boronic ester, and 4 Å 
molecular sieves in chloroform overnight.19 Products III-65, III-66, and III-67 represent 
substrates ready for an IMDA cycloaddition, possessing both the diene and the dienophile 
(Scheme 3.18). 
The synthesis of the 2-methyl-1,3-butadienylboronic acid III-69 is represented in 
Scheme 3.19.20,21 Hydroboration of 2-methyl-1-buten-3-yne (III-68) with pinacolborane 
and the Schwartz reagent afforded the pinacol ester III-4 in 50% yield.20 Oxidative 
hydrolysis of the pinacol ester was achieved in 87% yield (III-69) in the presence of 
sodium metaperiodate and ammonium acetate.20,21 The boronic acid can be produced well 




Several methods were explored in an attempt to execute the desired IMDA 
cycloaddition utilizing precursors III-65, III-66, and III-67.22-25 The substrates were 
heated for up to three days at 160 ˚C, both neat and in toluene, resulting in isolation of 
starting material. Heating the substrates neat in temperatures up to 260 ˚C resulted in 
decomposition of the substrate. Stirring the compounds at room temperature for up to 
four days in the presence of a Lewis acid (EtAlCl2, SnCl4, or ZnCl2) afforded starting 
material. Heating these Lewis acid catalyzed reactions may be advantageous for 
performing the Diels-Alder cycloaddition of our substrate; however, this was not 
Scheme 3.18: Retooled synthesis of diene for higher mass yield. Synthesis was further retooled upon 
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4 Å molecular sieves
Scheme 3.19: Hydroboration and hydrolysis of 2-methyl-1-buten-3-yne affording desired boronic acid 
III-69.
20,21 


















attempted as part of this thesis work. Use of lanthanide Lewis acids, such as Eu[fod]3 or 
Yb[fod]3, also resulted in isolation of starting material. Several of these failed attempts 
are highlighted in Scheme 3.20.22-25 All of the methods represented in Scheme 3.20 were 
evaluated with III-65, III-66, and III-67, respectively. 
 
 
Due to the failure of the IMDA cycloaddition under a number of conditions, as 
evidenced in Scheme 3.20, it was thought the ethylene linker was too geometrically 
restrictive to allow for the cycloaddition to occur. Therefore, another diene was 
synthesized via repeating previously reported protocols to install a longer butylene linker 
that would hopefully overcome this issue (Scheme 3.21).26,27 This route began with the 
mono-protection of 1,6-hexanediol (III-70) with a THP group in 66% yield (III-71). 
Swern oxidation of the alcohol was achieved in 77% yield (III-72) followed by a Wittig 
reaction that could be carried out on a gram-scale to install the desired, unsaturated ester 
in 96% yield (III-73). The THP group was cleaved via stirring the protected alcohol in 
ethanol with a few drops of concentrated hydrochloric acid to afford a free alcohol in 
quantitative yield (III-74). Swern oxidation of the free alcohol revealed an aldehyde in 
72% yield (III-75).  This synthetic route hit a roadblock when aldehyde III-75 failed to 
engage in the requisite olefination necessary to install the styrenyl portion of the desired 











R= 2-methyl-butadien-3-yl; 2-furanyl; 3-furanyl
n = 1 or 3 n = 1 or 3
(i) EtAlCl2 (0.9 eq), DCM:toluene (1:1), rt, 4 d
(ii) toluene (0.02 M), 160 ˚C, 65-72 h
(iii) SnCl4 (1 eq), DCM, rt, 4 d
(iv) ZnCl2 (1 eq), DCM, rt, o/n
(v) Eu(fod)3, (0.1 eq), TFE, rt, 48 h
(vi) Yb(fod)3, (0.1 eq), TFE, rt, 48 h
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diene III-52, despite evaluating several olefination conditions (see Scheme 3.21). 
Ultimately, this route was abandoned in favor of a more tractable route to the same target 
(vide infra, Scheme 3.24).  
A few other unsuccessful routes are highlighted below for posterity. First, we 
envisioned accessing an appropriate aldehyde intermediate (i.e. III-75) en route to a 
diene with a longer methylene tether via an alkylation strategy employing an appropriate 
alkyl iodide and enamine (Scheme 3.22). The enamine was generated by one of two 
methods: a.) reflux of pyrrolidine and acetaldehyde in toluene under Dean-Stark 
conditions for 48 hours, and b.) allowing a solution of pyrrolidine, acetaldehyde, and 
sodium sulfate to stand in the freezer overnight.28,29 The alkyl iodide III-78 was 
generated via a Mitsunobu reaction of alcohol III-61. Nonetheless, the successful 
alkylation of III-78 with the enamine was never realized, so this route was abandoned.30   
 
Scheme 3.21: Alternative route that was repeated involving THP protection, Swern, and Wittig 
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In a second unsuccessful approach, we sought to incorporate a heteroatom in the 
linker region separating the two alkenes of the target diene. Therefore, we attempted to 
alkylate the alkoxide of alcohol III-61 with 4-bromocrotonate utilizing several basic 
conditions as highlighted in Scheme 3.23. The desired alkylation event was never 
realized. 
 
Ultimately, a diene bearing a longer, 4-carbon linker was successfully prepared by 
a convenient route that is depicted in Scheme 3.24. Sonogashira coupling of iodobenzene 
Scheme 3.22: Attempted alkylation of alkyl iodide III-78 with enamine III-77.
28-31 
I2 (1.5 eq.), 
PPh3 (1.5 eq.), 
imidazole (1.5 eq.)
DCM (0.3 M), 
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(ii) LiHMDS (1.1 eq), THF, 0˚C or -78 ˚C
ethyl bromocrotonate (1.1 eq), THF, rt
(i) n-BuLi (1.1 eq), THF, 78 ˚C
ethyl bromocrotonate (1.1 eq), THF, rt
III-80
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(III-81) and 6-heptyn-1-ol (III-82) resulted in clean arylation of the alkynyl alcohol 
producing III-83 in 86% yield.32 Reduction of the alkyne to the alkene was performed in 
the presence of refluxing lithium aluminum hydride to afford III-84 in quantitative 
yield.33-35 The alcohol was then oxidized according to the Doering-Parikh protocol to 
afford aldehyde III-79 in 69% yield.17,36,37 Wittig olefination of the aldehyde resulted in 
isolation of diene III-52 in 84% yield, which was then dihydroxylated according to the 
Sharpless Asymmetric Dihydroxylation (SAD) protocol using AD-mix-ß to afford diol 
III-85 in 95% yield.18 Diol III-85 was then converted to the desired boronic ester III-86 
in 84% yield through a room temperature reaction of the diol and boronic acid III-69 in 
chloroform with 4 Å molecular sieves.19 Product III-86 represents an analog of IMDA-
precursor III-65 bearing a longer, more flexible 4-C linker separating the boronate ester 
diene from the a,b-unsaturated ester dienophile. Unfortunately, substrate III-86 was 





3.3  CONCLUSIONS AND FUTURE DIRECTIONS 
The synthesis of a novel chiral boronate ester (III-86) for participation in the 
IMDA cycloaddition was accomplished in the third part of this thesis work. The potential 
beauty of the proposed IMDA to generate product III-87 in Scheme 3.24 is: 1.) the 
potential to set several stereocenters with high diastereoselectivity as a result of the 
IMDA cyclization governed by the easily installed diol stereochemistry embedded in the 
boronate ester diene, and 2.) the potential to effect further transformations of the boronate 
ester moiety resident in the Diels-Alder product III-87. For example, oxidative removal 
of the boronate ester would reveal an alcohol that could then engage in several 
transformations including etherifications, esterifications, and acylations, etc. Another 
option is an allylboration, discussed previously in the work by Gao and Hall.2 
Scheme 3.24: Synthesis of boronate ester III-86 for use in the IMDA cycloaddition. Asterisks used to 
emphasize absolute stereocenters set as a result of this methodology.





































































Organometallic transformations, such as Suzuki couplings, might also be possible from 
cycloadduct III-87.   
In addition, an alternate synthetic route can be envisioned that allows for the 
positioning of the boronate ester diene in an “exo” fashion (i.e. not part of the longest 
chain on the molecule) relative to the a,b-unsaturated ester dienophile as presented in 
Scheme 3.25. A 1,2-addition of phenyl lithium to caprolactone (III-88) will afford a 
keto-alcohol (III-89) that can be protected as a silyl ether using conventional methods 
(III-90) to accommodate for a selective Wittig olefination at the ketone carbonyl (III-
91).38 The silyl group can then be deprotected to reveal the starting alcohol (III-92) that 
can then be oxidized to an aldehyde using the Doering-Parikh oxidation (III-93), 
followed by a Wittig olefination to afford our desired unsaturated ester (III-94). The exo 
alkene can then be dihydroxylated via the Sharpless protocol reported in this document to 
afford a diol (with one stereocenter installed instead of the two incorporated onto III-85) 
that can be transesterified to the desired boronate ester (III-96 resulting from the use of 
boronic acid III-69 for the purposes of this illustration). The rationale behind this method 
is that the exo positioning of the boronate ester diene may facilitate an easier 
intramolecular Diels-Alder reaction with the a,b-unsaturated ester dienophile via reduced 
geometrical constraint of the aliphatic tether.  
 171 
 
In addition, we can take advantage of the gem-dimethyl effect through the 
incorporation of two methyl groups alpha to the carbonyl center on molecule III-79. 
Performing the Wittig olefination, dihydroxylation, and transesterification described 
above in Scheme 3.25 will produce a chiral boronate ester that will have the diene and 
dienophile in closer proximity through steric repulsion caused by the two interfering 
methyl groups (Scheme 3.26). As a result, this may facilitate a more facile intramolecular 
Diels-Alder cycloaddition.  
 
Although the reaction shown in Scheme 3.24 depicts one type of styrenyl, a,b-
unsaturated ester, and alkyl functionality. Multiple derivatives can be targeted through 
variations of the three aforementioned functionalities. The aromatic ring could be 
functionalized with electron-donating groups so that an electron-rich alkene participates 
Scheme 3.25: Alternate synthetic strategy appending boronate ester diene in exo fashion to a,b-









































Scheme 3.26: Addition of two methyl groups on III-79 to facilitate gem-dimethyl effect for IMDA. 








in the SAD. Various derivatives of III-86 can be prepared by tailoring the length of the 
aliphatic tether or via the introduction of a heteroatom. Although the latter idea was as yet 
unsuccessful (as described above), perhaps an amine or amide linker could be useful in 
enhancing the scope of this synthetic methodology toward highly-substituted organic 
molecules. Furthermore, variations in tether length will help establish a maximum 
distance before the IMDA cycloaddition will no longer be feasible. The source of diene 
might be varied even further via migration of the boronate ester from a 1,4-position, e.g. 
2-methyl-1-butadien-3-yl, as shown in Scheme 3.24, to a 1,2- or 1,3-position. These 
sources for variation will supplement the utility of the projected novel, stereo-enriched 





3.4  EXPERIMENTAL 
3.4.1 COMPLETED SYNTHESES 
All reagents were purchased from commercial suppliers and used without further 
purification. All isolated products were purified via flash column chromatography using 
silica gel SDS 60 C.C. 40-63 µm. 1H and 13C NMR spectra were collected at ambient 
temperature on a 300 (Bruker Avance) or 500 MHz NMR spectrometer (Bruker Avance 
or JEOL Eclipse). Chemical shifts are reported in parts per million (ppm) and referenced 
to residual solvent peaks (i.e., d 7.28 ppm for 1H NMR, 77 ppm for 13C NMR in CDCl3; 
2.54 ppm for 1H NMR, 40.45 ppm for 13C NMR in DMSO-d6). Data are presented as 
follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet), 
and integration. Infrared (IR) spectra, reported in cm-1, were collected using a Fourier 
transform spectrophotometer. Compounds III-49 to III-51,13 III-54,14 III-57,15 III-71 to 
III-75,26,27 III-77,28,29 and III-7830 were prepared using known methods and exhibited 
spectral data consistent with previously reported syntheses. 
 
Synthesis of [(1E)-3-methylbuta-1,3-dien-1-yl] boronic acid pinacol ester (III-4) 
 
To a dry, 100 mL roundbottomed flask were added 13 mg Cp2ZrHCl (0.05 mmol; 0.05 





pinacolborane (1.1 mmol; 1.1 eq) was added dropwise followed by 95 µL 3-methyl-but-
3-en-1-yne III-68 (1 mmol; 1 eq). The reaction mixture was stirred at room temperature 
for 48 hours and then loaded directly onto a column. After washing the column with (0 to 
25%) ethyl acetate:hexanes, III-4 was obtained in 50% yield (40.2 mg; 0.207 mmol). 
 
Compound III-4 
1H-NMR (500 MHz; CDCl3): d 7.13-7.09 (d, 1H, J = 20 Hz), 5.58-5.55 (d, 1H, J = 15 
Hz), 5.17 (s, 2H), 1.86 (s, 3H), 1.29 (s, 12H); 13C-NMR (125 MHz; CDCl3): d 152.3, 
143.1, 120.2, 83.3, 24.9, 24.6, 17.8; IR (NaCl salt plate): 3064, 3030, 2965, 2932, 1718, 
1682, 1625, 1572, 1535, 1506, 1472, 1393, 1370, 1344, 1313, 1280, 1226, 1152, 1137, 
1120, 1105, 1069, 1043, 1002, 968, 939, 909, 878, 858, 833, 814, 780, 755, 740, 699, 
683.7,20,21 
 
Synthesis of 2-[6-phenyl-hex-5-enyl]-ethyl acrylate (III-52) 
 
To a three-dram vial were added a stirbar, 25 mg III-79 (0.133 mmol; 1 eq), 1 mL 




Four total reactions were set up (used 100 mg; 0.568 mmol III-79). The solutions were 
stirred at room temperature overnight. The next day, the solutions were evaporated onto 
silica and the column was washed with ethyl acetate (1% to 5%):hexanes to isolate diene 
III-52 (0.1149 g; 0.470 mmol) in 87% yield. 
 
Compound III-52 
1H-NMR (500 MHz; CDCl3): d 7.37-7.35 (d, 2H, J = 10 Hz), 7.33-7.29 (t, 2H, J = 10, 20 
Hz), 7.23-7.20 (t, 1H, J = 5, 15 Hz), 7.02-6.96 (m, 1H), 6.42-6.39 (d, 1H, J = 15 Hz), 
6.25-6.19 (m, 1H), 5.86-5.83 (d, 1H, J = 15 Hz), 4.23-4.18 (q, 2H, J = 10, 25 Hz), 2.25 
(m, 4H), 1.54-1.53 (m, 4H), 1.32-1.29 (t, 3H, J = 5, 15 Hz); 13C-NMR (125 MHz; 
CDCl3): d 166.8, 149.2, 137.8, 131.6, 130.5, 130.2, 128.6, 128.3, 126.9, 126.0, 121.5, 
60.2, 32.8, 32.1, 28.9, 27.6, 14.4; IR (NaCl salt plate): 3080, 3057, 3024, 2979, 2929, 
2855, 1719, 1654, 1598, 1577, 1560, 1542, 1492, 1459, 1447, 1390, 1367, 1307, 1264, 
1182, 1145, 1096, 1071, 1042, 980, 965, 913, 853, 799, 745, 693. 
 
Synthesis of (4E)-ethyl-5-phenylpent-4-enoate (III-58) 
 
To a high-pressure glass tube was added 670.9 mg III-60 (5 mmol; 1 eq), 7.5 mL triethyl 
orthoacetate (1.5 mL/mmol), and 26 µL propionic acid (0.347 mmol; 0.07 eq). The 




cooled to room temperature and diluted with 5 mL ethyl acetate. The organic layer was 
washed sequentially with 5 mL 1 M HCl, 5 mL water, and 5 mL saturated brine. The 
organic layer was dried with sodium sulfate, filtered, and concentrated to afford III-58 in 
99% yield (1.0214 g; 5 mmol). 
 
Compound III-58 
1H-NMR (300 MHz; CDCl3): d 7.40-7.29 (m, 4H), 7.25-7.20 (m, 1H), 6.48-6.43 (d, 1H, 
J = 15 Hz), 6.28-6.18 (m, 1H), 4.21-4.14 (q, 2H, J = 6, 21 Hz), 2.57-2.50 (m, 4H), 1.31-
1.26 (t, 3H, J = 9 Hz); 13C-NMR (75 MHz; CDCl2): d 172.9, 137.5, 130.9, 128.6, 127.2, 
126.9, 126.1, 60.4, 34.1, 28.4, 14.2; IR (neat): 1735, 1596, 1489, 1444, 1372, 1252, 1189, 
1161, 965, 742, 691.39 
 
Synthesis of 1-hydroxy-1-phenyl-prop-2-ene (III-60) 
 
To a dry, 100 mL roundbottomed flask were added benzaldehyde III-59 (0.510 mL; 5.0 
mmol; 1.0 eq) and 25 mL THF (0.2 M). The solution was cooled to 0 ˚C in an ice-water 
bath followed by the dropwise addition of vinylmagnesium bromide (1 M in THF; 5 mL; 
5 mmol; 1 eq). The solution was stirred at 0 ˚C for 15 minutes, then at room temperature 
for 4 hours. After that time, the solution was re-cooled to 0 ˚C, then quenched with the 
addition of 20 mL saturated ammonium chloride. The reaction mixture was extracted 
OH
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with diethyl ether (3 x 50 mL). The combined organics were washed with 50 mL 
saturated brine, then dried with sodium sulfate, filtered, and concentrated to afford III-60 
in quantitative yield (0.8433 g; 6.28 mmol).  
 
Compound III-60 
1H-NMR (500 MHz; CDCl3): d 7.29-7.27 (m, 5H), 5.98-5.93 (m, 1H), 5.28-5.25 (d, 1H, 
J = 15 Hz), 5.12-5.11 (d, 1H, J = 5 Hz); 13C-NMR (125 MHz; CDCl2): d 140.4, 128.7, 
127.8, 127.1, 126.4, 115.2, 75.4, 68.0; IR (neat): 3370, 1025, 990, 930, 760, 700.40 
 
Synthesis of (E)-5-phenylpent-4-en-1-ol (III-61) 
 
To a dry, 100 mL roundbottomed flask were added 87 mg lithium aluminum hydride (2.3 
mmol; 0.5 eq) using a dry bag. The roundbottomed flask was cooled in an ice-water bath 
at 0 ˚C followed by the dropwise addition of 1 M diethyl ether (10 mL; 0.23 M). To this 
suspension was added 0.931 g III-58 (4.6 mmol; 1 eq) in 1 M diethyl ether (4.6 mL). The 
reaction mixture was stirred at 0 ˚C for 2 hours, then at room temperature overnight. The 
following day, the reaction mixture was cooled to 0 ˚C in an ice-water bath. To the 
suspension was SLOWLY added 1 mL water, 1 mL 3.75 M NaOH, and 3 mL water. The 
suspension was filtered through a funnel and the white precipitated salts rinsed copiously 
with diethyl ether (approx. 300 mL). The filtrate was evaporated to afford III-61 in 88% 





1H-NMR (500 MHz; CDCl3): d 7.40-7.27 (m, 4H), 7.21 (m, 1H), 6.46-6.43 (d, 1H, J = 
15 Hz), 6.29-6.24 (m, 1H), 3.73-3.70 (5, 2H, J = 6.5, 15 Hz), 2.36-2.33 (m, 2H), 1.79-
1.76 (m, 2H); 13C-NMR (125 MHz; CDCl2): d 130.2, 128.7, 128.6, 127.1, 127.1, 126.1, 
62.5, 32.3, 29.4; IR (neat): 3347, 3024, 2935, 1597, 1494, 1447, 1057, 965, 914, 741, 
692.41 
 
Synthesis of Synthesis of (E)-5-phenylpent-4-en-1-al (III-62) 
 
To a dry, 100 mL roundbottomed flask were added 559 mg III-61 (3.45 mmol; 1 eq), 3.5 
mL anhydrous DMSO, 3.5 mL anhydrous DCM, and 2.4 mL trimethylamine (17.25 
mmol; 5 eq). The solution was cooled to 0 ˚C in an ice-water bath followed by addition of 
1.65 g sulfur trioxide-pyridine complex (10.35 mmol; 3 eq). The reaction mixture was 
stirred at 0 ˚C for 2 hours, and then quenched using phosphate buffer solution (10 mL; 
20X; pH = 7.9). The aqueous layer was extracted with ethyl acetate (3 x 25 mL). The 
combined organic layer was washed combined organics with saturated brine (35 mL), 
then dried with sodium sulfate, filtered, and concentrated. The residue was loaded onto a 
column and III-62 was obtained after washing with hexanes:ethyl acetate (0 to 20%) in 






1H-NMR (500 MHz; CDCl3): d 9.85 (m, 1H), 7.37-7.35 (d, 2H, J = 10 Hz ), 7.34-7.31 
(t, 2H, J = 10, 15 Hz), 7.25-7.22 (t, 1H, J = 5, 15 Hz), 6.48-6.44 (d, 1H, J = 20 Hz), 6.26-
6.22 (m, 1H), 2.66-2.65 (m, 2H), 2.49-2.47 (m, 2H); 13C-NMR (125 MHz; CDCl2): d 
201.9, 137.3, 131.2, 128.6, 128.2, 127.3, 126.1, 43.4, 25.6; IR (neat): 3080, 3050, 3020, 
2920, 2830, 2730, 1720, 1600, 1495, 1450, 970, 755, 700.27 
 
Synthesis of 2-[4-phenyl-but-3-enyl]-ethyl acrylate (III-63) 
 
To a dry, 3 mL vial were added 25 mg III-62 (0.156 mmol; 1 eq), 1.0 mL anhydrous 
THF, and 25 mg triphenylcarbethoxymethylenephosphorane (0.218 mmol; 1.4 eq). Set up 
three vials (used 75 mg; 0.326 mmol III-62). The reaction mixture was stirred overnight 
at room temperature. The following day the reaction mixture was evaporated onto silica 
and loaded onto a column. Product III-63 was isolated after washing with hexanes:ethyl 
acetate (0 to 5%) in 82% yield (88.5 mg; 0.384 mmol). 
 
Compound III-63  
1H-NMR (500 MHz; CDCl3): d 7.37-7.35 (d, 2H, J = 10 Hz), 7.33-7.30 (t, 2H, J = 5, 15 




6.23-6.20 (m, 1H), 5.91-5.88 (d, 1H, J = 15 Hz), 4.23-4.19 (q, 2H, J = 5, 20 Hz), 2.42-
2.40 (m, 4H), 1.33-1.29 (t, 3H, J = 10, 20 Hz); 13C-NMR (125 MHz; CDCl2): d 166.7, 
148.2, 137.5, 131.0, 128.9, 128.6, 127.2, 126.1, 121.9, 60.3, 32.1, 31.5, 14.37; IR (NaCl 
salt plate): 2957, 2924, 2853, 1719, 1687, 1677, 1655, 1638, 1474, 1458, 1450, 1421, 
1397, 1368, 1311, 1264, 1201, 1177, 1095, 1041, 980, 701. 
 
Synthesis of 2-[4-phenyl-3,4-butanediol]-ethyl acrylate (III-64) 
 
To a dry, 100 mL roundbottomed flask were added a stirbar, 4 mL tert-butyl alcohol, 4 
mL water, 166 mg (1.75 mmol; 0.49 eq) methanesulfonamide, and 5.66 g AD-mix-beta. 
The solution was stirred at room temperature for 30 minutes, then brought to 0 ˚C in an 
ethylene glycol bath using an immersion cooler. Once the solution had reached the 
appropriate temperature, 820.9 mg (3.56 mmol; 1 eq) of III-63 in 2 mL (1:1) tert-butyl 
alcohol:water was added all at once. The solution was stirred at 0 ˚C for 18 hours. After 
that time, solution as quenched with 20 mL saturated sodium sulfite, then extracted with 
ethyl acetate (3 x 25 mL). The combined organics were then washed with 5 mL 2 M 
KOH, dried with sodium sulfate, filtered, and evaporated. Diol III-64 (942 mg; 3.56 









1H-NMR (500 MHz; CDCl3): d 7.38-7.32 (m, 5H), 6.93-6.87 (m, 1H), 5.79-5.75 (d, 1H, 
J = 20 Hz), 4.45-4.44 (d, 1H, J = 5 Hz), 4.19-4.15 (q, 2H, J = 10, 20 Hz), 3.73-3.69 (m, 
1H), 2.1-2.78 (broad s, 2H), 2.42-2.40 (m, 2H), 2.23-2.21 (m, 1H), 1.57-1.52 (m, 1H), 
1.47-1.43 (m, 1H), 1.30-1.27 (t, 3H, J = 5, 15 Hz); 13C-NMR (125 MHz; CDCl2): d 166.7, 
148.5, 140.9, 128.7, 128.3, 126.8, 121.6, 78.0, 75.1, 60.2, 30.9, 28.4, 14.3; IR (NaCl salt 
plate): 3083, 3061, 3028, 2981, 2934, 1717, 1652, 1602, 1554, 1508, 1494, 1451, 1393, 
1368, 1311, 1271, 1196, 1157, 1096, 1041, 981, 920, 852, 763, 702, 667, 638, 622. 
 
Synthesis of 2-[4-phenyl-3,4-[2-methyl-1-buten-3-yl-borono]-butanediol]-ethyl acrylate 
(III-65) 
 
To a dry, 100 mL roundbottomed flask were added a stirbar, III-64 (95.7 mg; 0.362 
mmol; 1 eq), 0.02 M chloroform, 4 Å molecular sieves, and 2-methyl-1-buten-3-yl-
boronic acid (41 mg; 1 eq; 0.362 mmol). The solution was stirred at room temperature 






with DCM (3 x 10 mL). The combined organics were then dried with sodium sulfate, 




1H-NMR (500 MHz; CDCl3): d 7.42-7.31 (m, 5H), 7.26-7.23 (d, 1H, J = 20 Hz), 7.02-
6.97 (m, 1H), 5.88-5.85 (d, 1H), (5.69-5.65 (d, 1H, J = 20 Hz), 5.23-5.22 (d, 2H, J = 5 
Hz), 4.98-4.97 (d, 1H, J = 5 Hz), 4.22-4.18 (m, 3H), 2.51-2.49 (m, 1H), 2.41-2.35(m, 
2H), 1.92 (s, 3H), 1.31-1.28 (t, 3H, J = 5, 15 Hz)13C-NMR (125 MHz; CDCl3): d 166.6, 
153.5, 147.7, 143.1, 140.7, 128.9, 128.5, 126.1, 125.8, 122.2, 120.8, 84.2, 84.2, 60.34, 
34.1, 28.2, 17.8, 14.3; IR (NaCl salt plate): 3082, 3062, 3028, 2978, 2929, 2855, 1716, 
1652, 1624, 1600, 1495, 1451, 1368, 1342, 1294, 1181, 1096, 1041, 997, 906, 851, 804, 
759, 700, 640. 
 
Synthesis of 2-[4-phenyl-3,4-[2-furanylborono]-butanediol]-ethyl acrylate (III-66) 
 
To a dry, 100 mL roundbottomed flask were added a stirbar, diol III-64 (26 mg; 0.1 







mg; 1 eq; 0.1 mmol). The solution was stirred at room temperature overnight. The 
solution was then filtered and diluted with 5 mL water before extraction with DCM (3 x 
10 mL). The combined organics were then dried with sodium sulfate, filtered and 
evaporated to afford boronate ester III-66 in 91% yield (31.1 mg; 0.09 mmol). 
 
Compound III-66 
1H-NMR (500 MHz; CDCl3): d 7.74 (s, 1H), 7.44-7.41 (m, 4H), 7.39-7.32 (m, 1H), 7.21-
7.20 (d, 1H, J = 5 Hz), 7.02-6.96 (m, 1H), 6.52 (d, 1H), 5.88-5.85 (d, 1H, J = 15 Hz), 
5.10-5.09 (d, 1H, J = 5 Hz), 4.41-4.37 (m, 1H), 4.24-4.20 (q, 2H, J = 10, 20 Hz), 2.42-
2.41 (m, 2H), 1.99-1.95 (m, 2H), 1.32-1.29 (t, 3H, J = 5, 15 Hz); 13C-NMR (125 MHz; 
CDCl3): d 166.5, 147.8, 147.4, 139.9, 128.9, 128.6, 128.5, 126.0, 125.9, 124.3, 122.2, 
121.9, 110.5, 84.7, 84.7, 60.27, 33.8, 28.0, 14.3; IR (NaCl salt plate): 3063, 3030, 2930, 
1717, 1653, 1624, 1577, 1507, 1485, 1456, 1390, 1369, 1341, 1316, 1279, 1228, 1203, 
1160, 1096, 1076, 1042, 981, 910, 886, 833, 782, 757, 699. 
 








To a dry, 100 mL roundbottomed flask were added a stirbar, III-64 (100 mg; 0.378 
mmol; 1 eq), 0.02 M chloroform, 4 Å molecular sieves, and 3-furanylboronic acid (42.3 
mg; 1 eq; 0.378 mmol). The solution was stirred at room temperature overnight. The 
solution was then filtered and diluted with 5 mL water before extraction with DCM (3 x 
10 mL). The combined organics were then dried with sodium sulfate, filtered and 
evaporated to afford boronate ester III-67 in 91% yield (142.7 mg; 0.419 mmol). 
 
Compound III-67 
1H-NMR (500 MHz; CDCl3): d 7.89 (s, 1H), 7.53 (s, 1H), 7.42-7.33 (m, 5H), 7.02-6.99 
(m, 1H), 6.68 (s, 1H), 4.33-4.32 (m, 1H), 4.22-4.19 (m, 2H), 2.53-2.51 (m, 1H), 2.41-
2.38 (m, 2H), 1.95-1.94 (m, 2H), 1.30-1.29 (m, 3H); 13C-NMR (125 MHz; CDCl3): d 
166.6, 151.8, 147.6, 143.3, 140.4, 128.9, 128.6, 126.1, 125.9, 122.2, 113.2, 84.4, 84.4, 
60.4, 34.1, 28.2, 14.3; IR (NaCl salt plate): 3064, 3030, 2965, 2932, 1718, 1682, 1625, 
1572, 1535, 1506, 1472, 1393, 1370, 1344, 1313, 1280, 1226, 1152, 1137, 1120, 1105, 
1069, 1043, 1002, 968, 939, 909, 878, 858, 833, 814, 780, 755, 740, 699, 683. 
 
Synthesis of [(1E)-3-methylbuta-1,3-dien-1-yl] boronic acid (III-69) 
 
To a dry, 100 mL roundbottomed flask were added 100 mg III-4 (0.515 mmol; 1.0 eq), 





sodium metaperiodate (1.54 mmol; 3 eq). The reaction mixture was stirred overnight at 
room temperature. The solution was evaporated to remove the acetone, then 5 mL 2 M 
sodium hydroxide was added. The aqueous layer was washed with ethyl acetate:hexanes 
(2:8; 2 x 15 mL). The aqueous layer was acidified to pH = 3 with 2 M HCl. The aqueous 
layer was washed with ethyl acetate (2 x 15 mL). The organic layer was dried with 




1H-NMR (300 MHz; CDCl3): d 7.47-7.41 (d, 1H, J = 18 Hz), 5.73-5.67 (d, 1H, J = 18 
Hz), 5.32-5.29 (s, 2H), 1.94 (s, 3H); 13C-NMR (75 MHz; CDCl3): d 154.8, 143.1, 121.4, 
17.9; IR (NaCl salt plate): 3214, 2974, 1623, 1595, 1340, 1273, 993.20 
 
Synthesis of (E)-7-phenyl-hept-6-en-1-al (III-79) 
 
To a dry, 100 mL roundbottomed flask were added 509.3 mg III-84 (2.68 mmol; 1 eq), 
2.7 mL anhydrous DMSO, 2.7 mL anhydrous DCM, and 1.9 mL triethylamine (13.4 
mmol; 5 eq). The reaction mixture was cooled to 0 ˚C in an ice-water bath, then 1.28 g 
sulfur trioxide-pyridine complex (8.04 mmol; 3 eq) was added. The reaction mixture was 




(20X; pH = 7.9). The reaction mixture was extracted with ethyl acetate (3 x 25 mL). The 
combined organics were washed with saturated brine (20 mL). The organics were dried 
with sodium sulfate, filtered, and concentrated under reduced pressure. The residue was 
loaded onto a column and was washed with hexanes:ethyl acetate (0 to 5%) to afford III-
79 in 69% yield (347.7 mg; 1.85 mmol). 
 
Compound III-79 
1H-NMR (500 MHz; CDCl3): d 9.80 (m, 1H), 7.38-7.36 (d, 2H, J = 10 Hz), 7.35-7.30 (t, 
2H, J = 7, 25 Hz), 7.24-7.21 (t, 1H, J = 7.5, 14.5 Hz), 6.43-6.40 (d, 1H, J = 16 Hz), 6.25-
6.20 (m, 1H), 2.50-2.43 (t, 2H, J = 10, 35 Hz), 2.28-2.24 (q, 2H, J = 10, 20 Hz), 1.75-
1.69 (m, 2H), 1.58-1.52 (m, 2H); 13C-NMR (125 MHz; CDCl3): d 202.7, 137.8, 130.4, 
130.2, 128.6, 127.0, 126.0, 43.9, 32.8, 28.9, 21.7; IR (NaCl salt plate): 3425, 3080, 3058, 
3025, 2931, 2859, 2720, 1722, 1598, 1493, 1450, 1409, 1390, 1350, 1308, 1261, 1204, 
1156, 1073, 1024, 966, 878, 800, 748, 696, 614.36,37 
 
Synthesis of 7-phenyl-hept-6-yn-1-ol (III-83) 
 
To a dry, 100 mL roundbottomed flask were added 58 mg Ph(Ph3)4 (0.05 mmol; 0.005 
eq) and 20 mg copper (I) iodide (0.105 mmol; 0.0105 eq) in a dry bag. Then were added 
1.12 mL iodobenzene III-81 (10 mmol; 1 eq) and 0.628 mL 6-heptyn-1-ol III-82 (5 
mmol; 0.5 eq). The reaction mixture was stirred overnight at room temperature. The 
OH
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reaction mixture was filtered through filter paper and the filtrate evaporated onto silica. 
The column was washed with hexanes:diethyl ether (0 to 45%) to afford III-83 in 86% 
yield (0.8064 g; 4.28 mmol). 
 
Compound III-83 
1H-NMR (500 MHz; CDCl3): d 7.42-7.40 (m, 2H), 7.31-7.27 (m, 3H), 3.69-3.67 (t, 2H, J  
= 5, 10 Hz), 2.46-2.43 (t, 2H, J = 5, 15 Hz), 1.66-1.62 (m, 4H), 1.58-1.55 (m, 2H); 13C-
NMR (125 MHz; CDCl3): d 131.6, 128.3, 127.6, 124.1, 90.2, 80.9, 62.9, 32.4, 28.6, 25.2, 
19.5; IR (NaCl salt plate): 3332, 3056, 2936, 2860, 2234, 1598, 1571, 1490, 1460, 1441, 
1331, 1156, 1070, 1052, 961, 914, 756, 692.42 
 
Synthesis of (E)-7-phenyl-hept-6-en-1-ol (III-84) 
 
To a dry, 100 mL roundbottomed flask was added 757 mg lithium aluminum hydride 
(19.95 mmol; 7.5 eq) in a dry bag. A reflux condenser was fitted to the roundbottomed 
flask and the solid was cooled to 0 ˚C in an ice-water bath. Anhydrous THF (17 mL) was 
added slowly. Then, 500 mg of III-83 dissolved in 8 mL anhydrous THF was added to 
the roundbottomed flask. The suspension was then heated to reflux for 96 hours. The 
reaction mixture was cooled to room temperature and then cooled to 0 ˚C in an ice-water 
bath. The reaction mixture was SLOWLY quenched with 1 mL water, 1 mL 3.75 M 
sodium hydroxide, and 3 mL water. Diethyl ether (30 mL) and 1 M HCl (30 mL) was 
OH
 188 
added to the white suspension and the layers were separated. The acidic layer was 
washed with diethyl ether (2 x 30 mL). The combined organics were dried with sodium 
sulfate, filtered, and concentrated to afford III-84 in >99% yield (509.3 mg, 1.01 mmol). 
 
Compound III-84 
1H-NMR (500 MHz; CDCl3): d 7.37-7.35 (d, 2H, J = 10 Hz), 7.33-7.31 (t, 2H, J = 5, 10 
Hz), 7.22-7.20 (t, 1H, J = 5, 10 Hz), 6.42-6.39 (d, 1H, J = 15 Hz), 6.26-6.23 (m, 1H), 
3.66-3.63 (t, 2H, J = 6.9, 15 Hz), 2.26-2.23 (m, 2H), 1.61-1.44 (m, 6H); 13C-NMR (125 
MHz; CDCl3): d 137.9, 130.9, 130.0, 128.6, 126.9, 126.0, 62.9, 33.1, 32.7, 29.3, 25.5; IR 
(NaCl salt plate): 3337, 3102, 3080, 3058, 3024, 2931, 2856, 1598, 1494, 1448, 1375, 
1350, 1071, 1054, 1031, 964, 744, 713, 693, 606.35 
 
Synthesis of 2-[6-phenyl-5,6-hexanediol]-ethyl acrylate (III-85) 
 
To a dry, 100 mL roundbottomed flask were added a stirbar, 4 mL tert-butyl alcohol, 4 
mL water, 118.1 mg (1.24 mmol; 0.49 eq) methanesulfonamide, and 2.505 g AD-mix-






using an immersion cooler. Once the solution had reached the appropriate temperature, 
320.8 mg (1.242 mmol; 1 eq) III-52 in 2 mL (1:1) tert-butyl alcohol:water were added all 
at once. The solution was stirred at 0 ˚C for 48 hours. After that time, solution as 
quenched with 20 mL saturated sodium sulfite, then extracted with ethyl acetate (3 x 15 
mL). The combined organics were then washed with 7.5 mL 2 M KOH, dried with 
sodium sulfate, filtered, and evaporated. Diol III-85 (346.1 mg; 1.18 mmol) was isolated 
in 95% yield. 
 
Compound III-85 
1H-NMR (500 MHz; CDCl3): d 7.34-7.31 (m, 5H), 6.91-6.88 (m, 1H), 5.77-5.74 (d, 1H, J 
= 15 Hz), 4.40-4.39 (d, 1H, J = 5 Hz), 4.19-4.15 (m, 3H), 3.67-3.63 (m, 1H), 3.03 (broad 
s, 2H),  2.14-2.10 (q, 2H, J = 5, 20 Hz), 1.66-1.64 (m, 1H), 1.50-1.32 (m, 6H), 1.29-1.26 
(m, 5H); 13C-NMR (125 MHz; CDCl3): d 166.9, 149.2, 131.4, 131.6, 128.6, 128.3, 128.1, 
126.9, 124.4, 78.0, 75.8, 60.3, 32.4, 32.1, 31.2, 27.9, 25.3, 14.3; IR (NaCl salt plate): 
3419, 3024, 2980, 2930, 2856, 1719, 1653, 1599, 1493, 1448, 1367, 1308, 1266, 1182, 







Synthesis of 2-[6-phenyl-5,6-[2-methyl-1-buten-3-yl-borono]-hexanediol]-ethyl acrylate 
(III-86) 
 
To a dry, 100 mL roundbottomed flask were added a stirbar, III-85 (95.3 mg; 0.326 
mmol; 1 eq), 0.02 M chloroform, 4 Å molecular sieves, and 2-methyl-1-buten-3-yl-
boronic acid (36.5 mg; 1 eq; 0.326 mmol). The solution was stirred at room temperature 
overnight. The solution was then filtered and diluted with 5 mL water before extraction 
with DCM (2 x 5 mL). The combined organics were then dried with sodium sulfate, 




1H-NMR (500 MHz; CDCl3): d 7.41-7.38 (m, 2H), 7.34-7.32 (m, 3H), 7.26-7.22 (d, 1H, J 
= 20 Hz), 6.98-6.93 (m, 1H), 5.84-5.81 (d, 1H, J = 15 Hz), 5.69-5.66 (d, 1H, J = 15 Hz), 
5.22-5.21 (m, 2H), 4.96-4.95 (d, 1H, J = 5 Hz), 4.23-4.18 (m, 3H), 2.25-2.21 (m, 2H), 







NMR (125 MHz; CDCl3): d 166.8, 153.2, 148.9, 143.1, 141.0, 131.6, 128.8, 128.3, 125.8, 
121.6, 120.6, 84.9, 84.2, 60.3, 35.6, 32.1, 27.9, 24.9, 17.8, 14.4; IR (NaCl salt plate): 
3082, 3063, 3029, 2979, 2935, 2860, 1718, 1653, 1624, 1600, 1495, 1454, 1435, 1342, 
1369, 1319, 1295, 1233, 1183, 1093, 1039, 997, 902, 850, 761, 701, 640. 
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NMR Spectra for Chapter One 
 





















































































































































NMR Spectra for Chapter Two 
 
























































































































4-chloro-5-bromo-2-[4-carboxybenzamido]-benzoic acid (II-27) 
 











NMR Spectra for Chapter Three 
 


























































































































2-[6-phenyl-5,6-[2-methyl-1-buten-3-yl-borono]-hexanediol]-ethyl acrylate (III-86) 
 
Ph
O
O
B
EtO2C
